Committee for medicinal products for human use (CHMP)

Minutes of the meeting on 17-20 July 2017
Chair: Tomas Salmonson – Vice-Chair: Harald Enzmann

Health and safety information
In accordance with the Agency’s health and safety policy, delegates are to be briefed on health, safety and emergency information and procedures prior to the start of the meeting.

Disclaimers
Some of the information contained in this agenda is considered commercially confidential or sensitive and therefore not disclosed. With regard to intended therapeutic indications or procedure scopes listed against products, it must be noted that these may not reflect the full wording proposed by applicants and may also vary during the course of the review. Additional details on some of these procedures will be published in the CHMP meeting highlights once the procedures are finalised and start of referrals will also be available.

Of note, this agenda is a working document primarily designed for CHMP members and the work the Committee undertakes.

Note on access to documents
Some documents mentioned in the agenda cannot be released at present following a request for access to documents within the framework of Regulation (EC) No 1049/2001 as they are subject to ongoing procedures for which a final decision has not yet been adopted. They will become public when adopted or considered public according to the principles stated in the Agency policy on access to documents (EMA/127362/2006).
# Table of contents

1. **Introduction** ................................................................. 8
    1.1. Welcome and declarations of interest of members, alternates and experts .......... 8
    1.2. Adoption of agenda .......................................................... 8
    1.3. Adoption of the minutes ...................................................... 8

2. **Oral Explanations** .......................................................... 9
    2.1. Pre-authorisation procedure oral explanations ................................................ 9
        2.1.1. etirinotecan pegol - EMEA/H/C/003874 ................................................ 9
        2.1.2. midostaurin - Orphan - EMEA/H/C/004095 .......................................... 9
        2.1.3. padeliporfin - EMEA/H/C/004182 ....................................................... 9
    2.2. Re-examination procedure oral explanations ............................................. 10
    2.3. Post-authorisation procedure oral explanations ......................................... 10
        2.3.1. Opdivo - nivolumab - EMEA/H/C/003985/II/0029 ............................ 10
    2.4. Referral procedure oral explanations .................................................... 10
        2.4.1. Gadolinium-containing contrast agents (GdCA): gadoversetamide – OPTIMARK (CAP) Gadobenate dimeglumine; gadobutrol; gadodiamide; gadopentetic acid dimeglumine, gadoteric acid (intra articular formulation); gadoteric acid (intravenous and intravascular formulations); gadoteridol; gadoxetic acid disodium (NAP) ........................................... 10

3. **Initial applications** .......................................................... 11
    3.1. Initial applications; Opinions ........................................................................ 11
        3.1.1. Bavencio - avelumab - Orphan - EMEA/H/C/004338 .......................... 11
        3.1.2. Dupixent - dupilumab - EMEA/H/C/004390 ........................................ 11
        3.1.3. Entecavir Accord - entecavir - EMEA/H/C/004458 ............................... 12
        3.1.4. Entecavir Mylan - entecavir - EMEA/H/C/004438 ............................... 12
        3.1.5. Fanaptum - iloperidone - EMEA/H/C/004149 ........................................ 13
        3.1.6. Lacosamide Accord - lacosamide - EMEA/H/C/004438 ........................ 13
        3.1.7. Lutathera - lutetium (177Lu) oxodotreotide - Orphan - EMEA/H/C/004123 .... 13
        3.1.8. Onzeald - etirinotecan pegol - EMEA/H/C/003874 ............................. 14
        3.1.9. Rydapt - midostaurin - Orphan - EMEA/H/C/004095 ............................ 15
        3.1.10. Syntus - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/00439116 13
        3.1.11. Tecentriq - atezolizumab - EMEA/H/C/004143 ..................................... 16
        3.1.12. Verkazia ciclosporin - Orphan - EMEA/H/C/004411 ............................. 17
        3.1.13. Xermelo - telotristat ethyl - Orphan - EMEA/H/C/004319 ............................ 17
    3.2. Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable) ............................................. 18
        3.2.1. abaloparatide - EMEA/H/C/004157 ..................................................... 18
        3.2.2. carmustine - EMEA/H/C/004326 ............................................................ 18
        3.2.3. adalimumab - EMEA/H/C/004319 ....................................................... 18
3.2.4. fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781
3.2.5. guselkumab - EMEA/H/C/004271
3.2.6. neratinib - EMEA/H/C/004030
3.2.7. naloxone - EMEA/H/C/004325
3.2.8. trastuzumab - EMEA/H/C/004323
3.2.9. ritonavir - EMEA/H/C/004549
3.2.10. tacrolimus - EMEA/H/C/004435
3.2.11. padeliporfin - EMEA/H/C/004182
3.2.12. fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363
3.2.13. buprenorphine / naloxone - EMEA/H/C/004407

3.3. Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)

3.3.1. tildrakizumab - EMEA/H/C/004514
3.3.2. trastuzumab - EMEA/H/C/004361
3.3.3. letermovir - Orphan - EMEA/H/C/004536
3.3.4. naldemedine - EMEA/H/C/004256
3.3.5. brexpiprazole - EMEA/H/C/003841
3.3.6. sufentanil - EMEA/H/C/004335

3.4. Update on on-going initial applications for Centralised procedure

3.4.1. dapivirine - EMEA/H/W/002168, Article 58
3.4.2. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171
3.4.3. pegfilgrastim - EMEA/H/C/004262
3.4.4. andexanet alfa - EMEA/H/C/004108
3.4.5. metreleptin - Orphan - EMEA/H/C/004218
3.4.6. nitisinone - EMEA/H/C/004582
3.4.7. trastuzumab - EMEA/H/C/004346
3.4.8. sodium benzoate - Orphan - EMEA/H/C/004150
3.4.9. rotigotine - EMEA/H/C/004286

3.5. Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004

3.5.1. Masipro - masitinib - Orphan - EMEA/H/C/004159
3.5.2. Adlumiz - anamorelin - EMEA/H/C/003847
3.5.3. Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech - human IgG1 monoclonal antibody specific for human interleukin-1 alpha - EMEA/H/C/004388

3.6. Initial applications in the decision-making phase

3.7. Withdrawals of initial marketing authorisation application


4.1. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion
4.1.1. Prolia - denosumab - EMEA/H/C/001120/X/0059/G ............................................... 27
4.1.2. Samsca - tolvaptan - EMEA/H/C/000980/X/0024 .................................................. 27
4.1.3. Signifor - pasireotide - Orphan - EMEA/H/C/002052/X/0030/G ........................... 28
4.1.4. Xgeva - denosumab - EMEA/H/C/002173/X/0048/G ........................................ 28
4.1.5. Xtandi - enzalutamide - EMEA/H/C/002639/X/0029 ....................................... 28

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues** .................................................... 29

4.2.1. Tasigna - nilotinib - Orphan - EMEA/H/C/000798/X/0088/G ............................. 29

4.3. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question** ...................................................... 30

4.3.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0008 ....................... 30
4.3.2. Daliresp - roflumilast - EMEA/H/C/002398/X/0031 .......................................... 30
4.3.3. Daxas - roflumilast - EMEA/H/C/001179/X/0035 ............................................. 30
4.3.4. Humira - adalimumab - EMEA/H/C/000481/X/0164/G ................................. 31
4.3.5. Libertek - roflumilast - EMEA/H/C/002399/X/0032 .......................................... 31
4.3.6. Oncaspar - pegasparagase - EMEA/H/C/003789/X/0008 ............................... 31
4.3.7. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/X/0020 ...................... 32

4.4. **Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008** ........................................................................ 32

4.5. **Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008** ........................................... 32

5. **Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008** ........................................... 33

5.1. **Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information** .................................................. 33

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0048 ............... 33
5.1.2. Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0142 .................................. 33
5.1.3. Bydureon - exenatide - EMEA/H/C/002020/II/0041 .......................................... 34
5.1.4. Gazyvaro - obinutuzumab - Orphan - EMEA/H/C/002799/II/0016 .................. 34
5.1.5. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/0004042/II/0026 ................................................................. 35
5.1.6. Humira - adalimumab - EMEA/H/C/000481/II/0163 ....................................... 35
5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0023/G ......................... 36
5.1.8. Kineret - anakinra - EMEA/H/C/000363/II/0056 .............................................. 37
5.1.9. Olumiant - baricitinib - EMEA/H/C/000485/II/0001 ....................................... 37
5.1.10. Opdivo - nivolumab - EMEA/H/C/003985/II/0029 ...................................... 38
5.1.11. Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091 ..................... 38
5.1.12. Rapamune - sirolimus - EMEA/H/C/000273/II/0164 ..................................... 38
5.1.13. RoActemra - tocilizumab - EMEA/H/C/000955/II/0066 .............................. 39
### 5.1.14. Sovaldi - sofosbuvir - EMEA/H/C/002798/II/0036 ........................................................ 39
### 5.1.15. Sutent - sunitinib - EMEA/H/C/000687/II/0065 .......................................................... 40
### 5.1.16. Vimpat - lacosamide - EMEA/H/C/000863/II/0065/G ............................................... 40
### 5.1.17. Xgeva - denosumab - EMEA/H/C/002173/II/0055 .................................................. 41
### 5.1.18. Zytiga - abiraterone acetate - EMEA/H/C/002321/II/0047 ........................................ 41

#### 5.2. Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .................................... 42

##### 5.2.1. Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/02617/II/0072 ...... 42
##### 5.2.2. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/17 ..................................... 42

#### 5.3. Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008 .............................................. 42

### 6. Ancillary medicinal substances in medical devices 43

#### 6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions ............................................................... 43

#### 6.2. Update of Ancillary medicinal substances in medical devices ........................................ 43

### 7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 43

#### 7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use) 43

### 8. Pre-submission issues 43

#### 8.1. Pre-submission issue ............................................................................................. 43
##### 8.1.1. durvalumab - H0004771 .................................................................................... 43

#### 8.2. Priority Medicines (PRIME) .................................................................................. 43
##### 8.2.1. List of applications received .................................................................................. 43
##### 8.2.2. Recommendation for PRIME eligibility .............................................................. 44

### 9. Post-authorisation issues 44

#### 9.1. Post-authorisation issues ....................................................................................... 44

##### 9.1.2. CHMP request for PRAC advice on Fluoropyrimidines (Capecitabine-Xeloda and 5-FU), EMEA/H/C/0316/LEG-033.1 ...................................................................................... 44
##### 9.1.3. Vedrop - tocdfersolan – Orphan - EMEA/H/C/000920/II/0022 ................................. 45
##### 9.1.5. Opdivo - nivolumab - EMEA/H/C/003985/II/0030 ............................................... 46
9.1.6. Data collection on adverse events of anti-HIV drugs (D:A:D) study - Evaluation of D:A:D data

10. Referral procedures


10.2. Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004

10.3. Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004

10.4. Disagreement between Member States on application for medicinal product (potential serious risk to public health) - under Article 29(4) of Directive 2001/83/EC


10.6.1. Gadolinium-containing contrast agents (GdCA): gadoversetamide - OPTIMARK (CAP) Gadobenate dimeglumine; gadobutrol; gadodiamide; gadopentetic acid dimeglumine, gadoteric acid (intra articular formulation); gadoteric acid (intravenous and intravascular formulations); gadoteridol; gadoxetic acid disodium (NAP)


10.7.1. Alcover 750 mg, 1250 mg, 1750 mg Granulat im Beutel – Sodium oxybate – EMEA/H/A-29(4)/1451


10.9. Disagreement between Member States on Type II variation – Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003


10.11. Referral under Article 13 Disagreement between Member States on Type II variation – Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008

11. Pharmacovigilance issue

11.1. Early Notification System

12. Inspections

12.1. GMP inspections

12.2. GCP inspections

12.3. Pharmacovigilance inspections

12.4. GLP inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

13.2. Innovation Task Force briefing meetings


13.4. Nanomedicines activities
14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP
14.1.1. Time schedule of CHMP August written procedure
14.1.2. Pilot phase for abolition of signatures for divergent positions for referral procedures
14.1.3. Confirmation of joint CHMP/PDCO membership for Romania
14.1.4. Update to the CHMP templates on initial Marketing Authorisation

14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)
14.2.2. Committee for Advanced Therapies (CAT)
14.2.3. Paediatric Committee (PDCO)
14.2.4. Committee for Orphan Medicinal Products (COMP)
14.2.5. Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)

14.3. Coordination with EMA Working Parties/Working Groups/Drafting Groups

14.3.1. Scientific Advice Working Party (SAWP)
14.3.2. Quality Working Party (QWP)
14.3.3. Radiopharmaceutical Drafting Group (RadDG)
14.3.4. CHMP Guidelines Consistency Group (GCG)
14.3.5. Blood Product Working Party (BPWP)

14.4. Cooperation within the EU regulatory network

14.5. Cooperation with International Regulators

14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee

14.7. CHMP work plan

14.8. Planning and reporting

14.9. Others

15. Any other business

15.1. AOB topic

15.1.1. Working group on Committees’ operational preparedness for human medicines
15.1.2. Revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’
15.1.3. Bridging the regulator and the payer world

16. List of participants

17. Explanatory notes
1. **Introduction**

1.1. **Welcome and declarations of interest of members, alternates and experts**

In accordance with the Agency’s policy on handling of declarations of interests of scientific committees’ members and experts, based on the declarations of interest submitted by the Committee members, alternates and experts and based on the topics in the agenda of the current meeting, the Committee Secretariat announced that no restriction in the involvement of meeting participants in upcoming discussions was identified as included in the list of participants and restrictions. See (current) July 2017 CHMP minutes for the list of participants and restrictions in relation to declarations of interests applicable to the items of the agenda for the CHMP plenary session held 17-20 July 2017 (to be published post September 2017 CHMP meeting).

Participants in this meeting were asked to declare any changes, omissions or errors to their declared interests and/or additional restrictions concerning the matters for discussion. No new or additional interests or restrictions were declared.

Discussions, deliberations and voting took place in full respect of the restricted involvement of Committee members and experts in line with the relevant provisions of the Rules of Procedure and as included in the list of participants. All decisions taken at this meeting were made in the presence of a quorum of members (i.e. 22 or more members were present in the room). All decisions, recommendations and advice were agreed by consensus, unless otherwise specified.

The CHMP welcomed the new member Ewa Balkowiec Iskra from Poland replacing Piotr Fiedor and the new alternate Tomas Boran from Czech Republic replacing Radka Montoniova.

1.2. **Adoption of agenda**

CHMP agenda for 17-20 July 2017.

The CHMP adopted the agenda.

1.3. **Adoption of the minutes**

CHMP minutes for 19-22 June 2017.

The CHMP adopted the CHMP minutes for 19-22 June 2017.

The Minutes of the July 2017 CHMP ORGAM meeting held on 10 July 2017, together with all decisions taken at that meeting, were adopted.
2. Oral Explanations

2.1. Pre-authorisation procedure oral explanations

2.1.1. etirinotecan pegol - EMEA/H/C/003874

treatment of breast cancer with brain metastases
Scope: Oral explanation/Opinion, SAG report

**Action:** Oral explanation to be held on 19 July 2017 at time 09:00

Revised list of experts for the ad hoc expert group meeting adopted via written procedure on 11 July 2017.


The oral explanation to be held on 19 July 2017 at time 09:00 was cancelled.

See 3.1

2.1.2. midostaurin - Orphan - EMEA/H/C/004095

Novartis Europharm Ltd; treatment of mastocytosis and treatment of acute myeloid leukaemia
Scope: Oral explanation

**Action:** Oral explanation to be held on 19 July 2017 at time 11:00


An oral explanation was held on 19 July 2017 at time 09:00

See 3.1

2.1.3. padeliporfin - EMEA/H/C/004182

treatment of prostate cancer

Scope: Oral explanation

**Action:** Oral explanation to be held on 18 July 2017 at time 11:00


The CHMP agreed that an oral explanation is not needed this time.

See 3.2.
2.2. **Re-examination procedure oral explanations**

No items

2.3. **Post-authorisation procedure oral explanations**

2.3.1. **Opdivo - nivolumab - EMEA/H/C/003985/II/0029**

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Paula Boudewina van Hennik, PRAC
Rapporteur: Brigitte Keller-Stanislawski

Scope: Oral explanation

**Action**: Oral explanation to be held on 19 July 2017 at time 14:00

"Extension of Indication to include the treatment of hepatocellular carcinoma after prior sorafenib therapy in adults for Opdivo. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance. Moreover, the updated RMP version 8.0 has been submitted."

Request for Supplementary Information adopted on 22.06.2017, 23.03.2017.

An oral explanation was held on 19 July 2017 at time 15:00

See 5.1

2.4. **Referral procedure oral explanations**

2.4.1. **Gadolinium-containing contrast agents (GdCA): gadoversetamid – OPTIMARK (CAP)**

Gadobenate dimeglumine; gadobutrol; gadodiamide; gadopentetic acid dimeglumine, gadoteric acid (intra articular formulation); gadoteric acid (intravenous and intravascular formulations); gadoteridol; gadoxetic acid disodium (NAP)

Applicant(s): Guerbert (Optimark); various

Rapporteurs for the Article 31 referral: PRAC Rapporteur: Patrick Batty; PRAC Co-rapporteur: Doris Stenver

PRAC Rapporteur of the re-examination: Ulla Wändel Liminga; PRAC Co-rapporteur of the re-examination: Valerie Strassmann

Rapporteurs for Optimark: CHMP Rapporteur: Patrick Salmon, CHMP Co-rapporteur: Johann Lodewijk Hillege

Scope: Oral explanation

**Action**: Oral explanation to be held on 18 July 2017 at time 14:00

CHMP opinion following PRAC final recommendation

Four oral explanations were held on 18 July 2017.

See 10.6
3. **Initial applications**

3.1. **Initial applications; Opinions**

3.1.1. **Bavencio - avelumab - Orphan - EMEA/H/C/004338**

Merck Serono Europe Limited; treatment of Merkel cell carcinoma (MCC)

**Scope:** Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The members discussed the available efficacy and safety data and the different options of marketing authorisations.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a conditional marketing authorisation by majority (27 out of 30 votes) together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The divergent position (Johann Lodewijk Hillege, Natalja Karpova, Romaldas Maciulaitis) was appended to the opinion.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP adopted the BWP report.

3.1.2. **Dupixent - dupilumab - EMEA/H/C/004390**

sanofi-aventis groupe; treatment of moderate-to-severe atopic dermatitis

**Scope:** Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

List of Questions adopted on 23.03.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that dupilumab is a new active substance, as claimed by
the applicant.
The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendation dated 20 July 2017.
The CHMP adopted the BWP report.

3.1.3. **Entecavir Accord - entecavir - EMEA/H/C/004458**

Accord Healthcare Ltd; treatment of chronic hepatitis B virus infection

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Baraclude


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The summary of opinion was circulated for information.

3.1.4. **Entecavir Mylan - entecavir - EMEA/H/C/004377**

Mylan S.A.S; treatment of chronic hepatitis B virus infection

Scope: Opinion

**Action:** For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Baraclude


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.
The legal status was agreed as medicinal product subject to restricted medical prescription.
The CHMP noted the letter of recommendations dated 18 July 2017.
The summary of opinion was circulated for information.

3.1.5. Fanaptum - iloperidone - EMEA/H/C/004149

Vanda Pharmaceuticals Ltd.; treatment of schizophrenia

Scope: Opinion

**Action**: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The CHMP was reminded of previous discussions and the remaining issues.

The CHMP adopted a negative opinion by consensus, recommending the refusal of the marketing authorisation application. The CHMP adopted the assessment report.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The refusal question and answers document was circulated for information.

Post-meeting note: the applicant submitted the request for re-examination on 27.07.2017.

3.1.6. Lacosamide Accord - lacosamide - EMEA/H/C/004443

Accord Healthcare Ltd; treatment of epilepsy

Scope: Opinion

**Action**: For adoption

Generic application (Article 10(1) of Directive No 2001/83/EC), Generic of Vimpat


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.

The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 21 July 2017.

3.1.7. Lutathera - lutetium (177lu) oxodotreotide - Orphan - EMEA/H/C/004123

Advanced Accelerator Applications; treatment of gastro-entero-pancreatic neuroendocrine tumours

Scope: Opinion
Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that ‘lutetium (177Lu) oxodotreotide’ is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of undertaking dated 17 July 2017.

The summary of opinion was circulated for information.

3.1.8. Onzeald - etirinotecan pegol - EMEA/H/C/003874

Nektar Therapeutics UK Limited; treatment of breast cancer with brain metastases

Scope: Oral explanation/Opinion, SAG report

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

Revised list of experts for the ad hoc expert group meeting adopted via written procedure on 11 July 2017.


See 2.1

The CHMP noted SAG report. According to SAG, the available evidence is not sufficient to establish the efficacy of Onzeald in the proposed indication.

The CHMP noted the letter by the applicant concerning the SAG meeting.

The oral explanation to be held on 19 July 2017 at time 09:00 was cancelled, as the CHMP considered that there was no new data available in addition to what was presented during the oral explanation on 16.05.2017 and the responses to the list of outstanding issues adopted on 18.05.17.

The CHMP considered that the benefit of Onzeald in the treatment of breast cancer that had spread to the brain had not been sufficiently demonstrated.

The claim of effectiveness relied on data from a subgroup of patients from a main study which, overall, failed to convincingly show the effectiveness of Onzeald. The Committee considered that the data from this subgroup, which were not supported by additional studies, were not sufficient to prove the effectiveness of Onzeald in patients whose breast cancer had spread to the brain.
Therefore, the CHMP was of the opinion that the study did not provide enough evidence on the benefits of Onzeald and recommended that the marketing authorisation be refused.

The CHMP adopted a negative opinion by majority (23 out of 28 votes) recommending the refusal of the conditional marketing authorisation application. The CHMP adopted the assessment report.

The Norwegian member was in agreement with the CHMP recommendation and the Icelandic member was not.

The divergent position (Andrea Laslop, Dana Gabriela Marin, Katarina Vucic, Kolbeinn Gudmundsson, Robert Hemmings, David Lyons) was appended to the opinion.

The refusal questions and answers document was circulated for information.


### 3.1.9. Rydapt - midostaurin - Orphan - EMEA/H/C/004095

Novartis Europharm Ltd; treatment of mastocytosis and treatment of acute myeloid leukaemia

**Scope:** Oral explanation/Opinion

**Action:** For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


See 2.1

An oral explanation was held on 19 July 2017 at time 09:00. The presentation focused mainly on efficacy data in different age groups.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that midostaurin is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 20 July 2017.

The CHMP adopted the similarity assessment report for Rydapt.
3.1.10. **Syntuza - darunavir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004391**

Janssen-Cilag International N.V.; treatment of human immunodeficiency virus type 1 (HIV-1)

Scope: Opinion

**Action**: For adoption

Fixed combination application (Article 10b of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The CHMP noted the letter of recommendation dated 19 July 2017.

The summary of opinion was circulated for information.

3.1.11. **Tecentriq - atezolizumab - EMEA/H/C/004143**

Roche Registration Limited; treatment of locally advanced or metastatic urothelial carcinoma, treatment of non-small cell lung carcinoma (NSCLC)

Scope: Opinion

**Action**: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by majority (24 out of 30 votes) together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that atezolizumab is a new active substance, as claimed by the applicant.

The Icelandic Member was in agreement with the CHMP recommendation and the Norwegian Member was not.

The divergent position (Alar Irs, Alexandre Moreau, Daniela Melchiorri, Johann Lodewijk Hillege, Natalja Karpova, Sinan B. Sarac, Svein Rune Andersen) was appended to the
opinion.

The legal status was agreed as medicinal product subject to restricted medical prescription. The summary of opinion was circulated for information.

3.1.12. Verkazia - ciclosporin - Orphan - EMEA/H/C/004411

Accelerated assessment

Santen Oy; treatment of severe vernal keratoconjunctivitis (VKC)

Scope: Opinion

**Action**: For adoption

Known active substance (Article 8(3) of Directive No 2001/83/EC), Duplicate of IKERVIS


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to restricted medical prescription.

The summary of opinion was circulated for information.

3.1.13. Xermelo - telotristat ethyl - Orphan - EMEA/H/C/003937

Ipsen Pharma; treatment of carcinoid syndrome

Scope: Opinion

**Action**: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion recommending the granting of a marketing authorisation by consensus together with the CHMP assessment report and translation timetable.

Furthermore, the CHMP considered that telotristat is a new active substance, as claimed by the applicant.

The Icelandic and Norwegian Members were in agreement with the CHMP recommendation.

The legal status was agreed as medicinal product subject to medical prescription.
The summary of opinion was circulated for information.

The CHMP noted the letter of recommendation dated 18 July 2017.

3.2. **Initial applications; List of outstanding issues (Day 180; Day 120 for procedures with accelerated assessment timetable)**

3.2.1. **abaloparatide - EMEA/H/C/004157**

Treatment of osteoporosis

Scope: Day 180 list of outstanding issue

**Action**: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a 2nd list of outstanding issues.

The CHMP agreed to the request by the applicant for an extension to the clock stop to respond to the list of outstanding issues.

3.2.2. **carmustine - EMEA/H/C/004326**

Treatment of brain tumors, multiple myeloma, Hodgkin's disease and non-Hodgkin's lymphomas

Scope: Day 180 list of outstanding issue

**Action**: For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.3. **adalimumab - EMEA/H/C/004319**

Treatment of rheumatoid arthritis, axial spondyloarthritis, psoriasis, hidradenitis suppurativa (HS), Crohn's disease, ulcerative colitis and uveitis

Scope: Day 180 list of outstanding issue

**Action**: For adoption

List of Questions adopted on 23.03.2017.

The Committee was reminded of the status of this application and its remaining outstanding
issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP adopted the BWP report.

3.2.4. **fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781**

treatment of adult patients with chronic obstructive pulmonary disease (COPD)
Scope: Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.5. **guselkumab - EMEA/H/C/004271**

treatment of plaque psoriasis
Scope: Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP adopted the BWP report.

3.2.6. **neratinib - EMEA/H/C/004030**

extended adjuvant treatment of adult patients with early-stage HER2-overexpressed/amplified breast cancer who have received prior adjuvant trastuzumab based therapy
Scope: Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues. The Committee adopted a list of outstanding issues.

The CHMP agreed to the request for an extension to the clock stop to respond to the list of outstanding issues with a specific timetable
3.2.7. **naloxone - EMEA/H/C/004325**

intended for emergency use for known or suspected opioid overdose as manifested by respiratory and/or central nervous system depression

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption

List of Questions adopted on 23.03.2017.

The Committee was reminded of the status of this application and its remaining outstanding issues,

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.8. **trastuzumab - EMEA/H/C/004323**

treatment of breast cancer and metastatic gastric cancer

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

The CHMP adopted the BWP report.

3.2.9. **ritonavir - EMEA/H/C/004549**

treatment of HIV-1

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

3.2.10. **tacrolimus - EMEA/H/C/004435**

prophylaxis of transplant rejection and treatment of allograft rejection

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption

The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.11. padeliporfin - EMEA/H/C/004182

**treatment of prostate cancer**

**Scope:** Day 180 list of outstanding issue

**Action:** Oral explanation to be held on 18 July 2017 at time 11:00


See 2.1

The CHMP agreed that oral explanation is not needed this time.

The Committee adopted a 3rd list of outstanding issues with a specific timetable.

### 3.2.12. fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363

**treatment of adult patients with chronic obstructive pulmonary disease (COPD)**

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.

### 3.2.13. buprenorphine / naloxone - EMEA/H/C/004407

**treatment for opioid drug dependence, treatment for opioid drug dependence**

**Scope:** Day 180 list of outstanding issue

**Action:** For adoption


The Committee was reminded of the status of this application and its remaining outstanding issues.

The Committee adopted a list of outstanding issues with a specific timetable.
3.3. **Initial applications; List of questions (Day 120; Day 90 for procedures with accelerated assessment timetable)**

### 3.3.1. **tildrakizumab - EMEA/H/C/004514**

Treatment of adults with moderate-to-severe plaque psoriasis  
Scope: Day 120 list of questions  
**Action**: For adoption

The Committee discussed the issues identified in this application.  
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.  
The CHMP adopted the BWP report.

### 3.3.2. **trastuzumab - EMEA/H/C/004361**

Treatment of metastatic breast cancer, early breast cancer, metastatic gastric cancer  
Scope: Day 120 list of questions  
**Action**: For adoption

The Committee discussed the issues identified in this application.  
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.  
The CHMP adopted the BWP report.

### 3.3.3. **letermovir - Orphan - EMEA/H/C/004536**

Accelerated assessment  
Merck Sharp & Dohme Limited; prophylaxis of cytomegalovirus (CMV) reactivation and disease  
Scope: Day 120 list of questions  
**Action**: For adoption

The Committee discussed the issues identified in this application.  
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.4. **naldemedine - EMEA/H/C/004256**

Treatment of opioid-induced constipation (OIC) in adult patients  
Scope: Day 120 list of questions  
**Action**: For adoption

The Committee discussed the issues identified in this application
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.5. brexpiprazole - EMEA/H/C/003841

treatment of schizophrenia  
**Scope:** Day 120 list of questions  
**Action:** For adoption  
The Committee discussed the issues identified in this application.  
The CHMP agreed that SAG should be involved in the future.  
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

### 3.3.6. sufentanil - EMEA/H/C/004335

management of acute moderate to severe pain  
**Scope:** Day 120 list of questions  
**Action:** For adoption  
The Committee discussed the issues identified in this application.  
The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.  
The CHMP agreed to the request by the applicant for an extension to the clock stop with a specific timetable.

### 3.4. Update on on-going initial applications for Centralised procedure

#### 3.4.1. dapivirine - EMEA/H/W/002168, Article 58

reducing the risk of HIV-1 infection via vaginal intercourse in sexually active HIV-uninfected women  
**Scope:** Start of the article 58 procedure  
**Action:** For information  
The CHMP noted the start of procedure. See also B.6.1.

#### 3.4.2. dengue tetravalent vaccine (live, attenuated) - EMEA/H/C/004171

indicated for the prevention of dengue disease caused by dengue virus serotypes 1, 2, 3 and 4
Scope: Letter from the applicant requesting an additional extension of clock stop to respond to the List of Outstanding Issues adopted on 23.03.2017.

**Action:** For adoption


The CHMP agreed to the request by the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted on 23.03.2017.

3.4.3. **pegfilgrastim - EMEA/H/C/004262**

treatment of neutropenia

Scope: Letter from the applicant dated 12 July 2017 requesting an additional extension of clock stop to respond to the List of Questions adopted on 13 October 2016.

**Action:** For adoption


The CHMP did not accept the request by the applicant for an additional extension of clock stop to respond to the List of Questions adopted on 13 October 2016, because it was considered that the requested clock stop extension was excessively long and the applicant’s proposal was not realistic.

3.4.4. **andexanet alfa - EMEA/H/C/004108**

treatment of direct or indirect factor Xa(FXa) inhibitor when reversal of anticoagulation is needed

Scope: Letter from the applicant dated 7 July 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 15 December 2016

**Action:** For adoption


The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the List of Questions adopted on 15 December 2016.

3.4.5. **metreleptin - Orphan - EMEA/H/C/004218**

Aegerion Pharmaceuticals Limited; treatment of leptin deficiency (lipodystrophy)

Scope: Letter from the applicant dated 17 July 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 18.05.2017.

**Action:** For adoption

List of Questions adopted on 18.05.2017.

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the List of Questions adopted on 18.05.2017.
3.4.6. nitisinone - EMEA/H/C/004582

treatment of hereditary tyrosinemia type 1

Scope: Letter from the applicant dated 13 July 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 22 June 2017.

**Action:** For adoption

List of Questions adopted on 22 June 2017

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the List of Questions adopted on 22 June 2017.

3.4.7. trastuzumab - EMEA/H/C/004346

treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

Scope: Letter from the applicant dated 12 July 2017 requesting an extension of clock stop to respond to the List of Outstanding Issues adopted on 18.05.2017.

**Action:** For adoption


The CHMP did not accept the request by the applicant for an additional extension of clock stop to respond to the List of Outstanding Issues adopted on 18.05.2017, because it was considered that the requested clock stop extension was excessively long and the applicant’s proposal was not realistic.

3.4.8. sodium benzoate - Orphan - EMEA/H/C/004150

Lucane Pharma; treatment of non ketotic hyperglycinemia, urea cycle disorders including carbamoyl-phosphate synthase-1 deficiency, ornithine transcarbamylase deficiency, citrullinaemia type 1, argininosuccinic aciduria, hyperargininaemia, n-acetylglutamate synthase deficiency, ornithine translocase deficiency and lysinuric protein intolerance

Scope: Letter from the applicant dated 18 July 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 22.06.2017.

**Action:** For adoption

List of Questions adopted on 22.06.2017.

Rejected

The CHMP did not accept the request by the applicant for an additional extension of clock stop to respond to the List of Questions adopted on 22.06.2017.

Another request was made by the applicant to extend the clock-stop and CHMP agreed to this.
3.4.9. **rotigotine - EMEA/H/C/004286**

Treatment of idiopathic Restless Legs Syndrome and Parkinson's disease

Scope: Request by the applicant dated 11 July 2017 requesting an extension of clock stop to respond to the List of Questions adopted on 21 April 2017.

**Action:** For adoption

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the List of Questions adopted on 21 April 2017.

3.5. **Re-examination of initial application procedures under Article 9(2) of Regulation no 726/2004**

3.5.1. **Masipro - masitinib - Orphan - EMEA/H/C/004159**

AB Science; treatment of mastocytosis

Scope: SAG list of questions, re-examination timetable

Letter from the applicant dated 31 May 2017 requesting a re-examination of the Opinion adopted on 18 May 2017 and consultation of a Scientific Advisory Group

**Action:** For adoption

Opinion adopted on 18.05.2017.

The CHMP discussed the list of questions to the SAG and adopted the re-examination timetable. The final list of questions will be adopted via written procedure after the Plenary.

3.5.2. **Adlumiz - anamorelin - EMEA/H/C/003847**

Helsinn Birex Pharmaceuticals Ltd; treatment of anorexia, cachexia or unintended weight loss in adult patients with non-small cell lung cancer (NSCLC)

Scope: re-examination timetable

**Action:** For adoption

Opinion adopted on 18.05.2017.

The CHMP adopted the re-examination timetable.

3.5.3. **Human IGG1 monoclonal antibody specific for human interleukin-1 alpha XBiotech - human IgG1 monoclonal antibody specific for human interleukin-1 alpha - EMEA/H/C/004388**

XBiotech Germany GmbH; treatment of metastatic colorectal cancer

Scope: re-examination timetable

**Action:** For adoption

Opinion adopted on 18.05.2017.

The CHMP adopted the re-examination timetable.
3.6. **Initial applications in the decision-making phase**

No items

3.7. **Withdrawals of initial marketing authorisation application**

No items

4. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008**

4.1. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Opinion**

4.1.1. **Prolia - denosumab - EMEA/H/C/001120/X/0059/G**

Amgen Europe B.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: “Extension application.”

**Action**: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.2. **Samsca - tolvaptan - EMEA/H/C/000980/X/0024**

Otsuka Pharmaceutical Europe Ltd

Rapporteur: Greg Markey, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Julie Williams

Scope: “Extension application to add a new strength of 7.5 mg tablets.”

**Action**: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.3. **Signifor - pasireotide - Orphan - EMEA/H/C/002052/X/0030/G**

Novartis Europharm Ltd

Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension application to introduce two new strengths of the 'powder and solvent for suspension for injection pharmaceutical form' (10 mg and 30 mg) grouped with a type II variation (C.1.6.a) to extend the indication to include 'Treatment of adult patients with Cushing’s disease for whom surgery is not an option or for whom surgery has failed’ to the intramuscular injection formulations."

**Action**: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.4. **Xgeva - denosumab - EMEA/H/C/002173/X/0048/G**

Amgen Europe B.V.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension application."

**Action**: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.1.5. **Xtandi - enzalutamide - EMEA/H/C/002639/X/0029**

Astellas Pharma Europe B.V.

Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia
Scope: "To add new pharmaceutical form and strengths (film-coated tablets 40 mg and 80 mg) to the currently approved presentations for Xtandi."

Action: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

4.2. **Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 180 list of outstanding issues**

4.2.1. **Tasigna - nilotinib - Orphan - EMEA/H/C/000798/X/0088/G**

Novartis Europharm Ltd

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Harald Enzmann, PRAC Rapporteur: Doris Stenver

Scope: "Extension of Indication to include treatment of paediatric patients with newly diagnosed Philadelphia chromosome-positive chronic myelogenous leukemia in chronic phase (Ph+ CML-CP), or with Ph+ CML-CP resistant or intolerant to prior therapy including imatinib, based on results from two clinical studies in paediatric patients conducted in accordance with the approved Tasigna Paediatric Investigation Plan (PIP), the Phase I PK study CAMN107A2120 and the Phase II safety and efficacy study CAMN107A2203. An updated RMP version 18.0 was provided as part of the application. Extension application to add a new strength of 50mg hard capsules. In addition, the applicant proposes to merge the SmPCs for the 50 mg and 200 mg strengths."

Action: For adoption

List of Questions adopted on 23.03.2017.

The Committee discussed the issues identified in this application, mainly relating to the wording of the indication in terms of age cut-off of the paediatric population. The members discussed the available clinical data and considered the indication in newly diagnosed Ph+ CML patients below 6 years of age requires further justification.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of outstanding issues and a specific timetable.
4.3. Extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008; Day 120 List of question

4.3.1. Bortezomib Accord - bortezomib - EMEA/H/C/003984/X/0008

Accord Healthcare Ltd

Rapporteur: Milena Stain, PRAC Rapporteur: Carmela Macchiarulo

Scope: “Extension application to add a new strength of powder for solution for injection (1 mg) to the currently approved strength (3.5 mg) of Bortezomib Accord.”

Action: For adoption

The Committee discussed the issues identified in this application. The Committee noted the questions related quality, clinical aspects and similarity assessment. The applicant should update the similarity report including further quality information and adding a scientific comparison/discussion of the therapeutic indications, mechanism of action and molecular structure of the orphan drugs.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.2. Daliresp - roflumilast - EMEA/H/C/002398/X/0031

AstraZeneca AB

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: David Lyons, PRAC Rapporteur: Dolores Montero Corominas

Scope: “Extension application to add a new strength of 250 µg in a PVC/PVDC/Alu blister of 28 tablets.”

Action: For adoption

The Committee discussed the issues identified in this application. The main discussion related to some quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.3. Daxas - roflumilast - EMEA/H/C/001179/X/0035

AstraZeneca AB

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: David Lyons, PRAC Rapporteur: Dolores Montero Corominas

Scope: “Extension application to add a new strength of 250 µg in a PVC/PVDC/Alu blister of 28 tablets.”

Action: For adoption

The Committee discussed the issues identified in this application. The main discussion
related to some quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.4. **Humira - adalimumab - EMEA/H/C/000481/X/0164/G**

AbbVie Limited.

Rapporteur: Kristina Dunder

Scope: "Extension application to add a new strength/potency of 20 mg for adalimumab solution for injection in pre-filled syringe, grouped with a type II variation (C.I.4.z) to update of sections 4.2 of the SmPC in order to introduce new fixed dose regimen (posology) for the paediatric indications of JIA and Ps. The Package Leaflet and Labelling are updated accordingly.

In addition, the marketing authorisation holder took the opportunity to:
- introduce editorial changes to align wording and layout of the Product Information
- to amend the statement relating to anti-adalimumab antibody development in JIA patients, which will reside in section 5.1 of the Humira SmPCs (20 mg and 40 mg presentations)."

**Action**: For adoption

The Committee discussed the issues identified in this application. It was concluded that the clinical safety data that the applicant provided in support of the fixed dose is somewhat incomplete. Further information is needed before a final conclusion can be drawn and this information is requested.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.5. **Libertek - roflumilast - EMEA/H/C/002399/X/0032**

AstraZeneca AB

Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: David Lyons, PRAC Rapporteur: Dolores Montero Corominas

Scope: "Extension application to add a new strength of 250 µg in a PVC/PVDC/Alu blister of 28 tablets."

**Action**: For adoption

The Committee discussed the issues identified in this application. The main discussion related to some quality and clinical aspects.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.6. **Oncaspar - pegaspargase - EMEA/H/C/003789/X/0008**

Baxalta Innovations GmbH
Rapporteur: Alexandre Moreau, PRAC Rapporteur: Patrick Batty

Scope: “Extension application to add a new pharmaceutical form, powder for solution for injection/infusion (750 U/ml).”

Action: For adoption

The Committee noted the issues identified in this application. The identified issues related to the quality part, the pharmacokinetics, the RMP and some regulatory issues.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

4.3.7. Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/X/0020

Vertex Pharmaceuticals (Europe) Ltd.

Rapporteur: Nithyanandan Nagercoil, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Almath Spooner

Scope: “Extension application to add a new strength of film-coated tablets (100 mg Lumacaftor / 125 mg Ivacaftor) for paediatric use (6 to 11 years). The RMP (version 3.1) is updated accordingly.

CHMP assessment report on similarity
CHMP assessment report on significant clinical benefit (additional year of market exclusivity)”

Action: For adoption

The Committee discussed the issues identified in this application. The CHMP noted that there is still substantial concern around a transient drug-induced bronchoconstrictive effect that is not yet sufficiently understood or what the safety implications may be. Although there is no clear evidence that this is a greater risk in the younger age group there is also insufficient assurance this is not the case. The questions to be addressed by the applicant seek a more robust understanding.

The Committee adopted the CHMP recommendation and scientific discussion together with the list of questions.

The CHMP adopted the assessment report on similarity of Orkambi.

4.4. Update on on-going extension application according to Annex I of Commission Regulation (EC) No 1234/2008

No items

4.5. Re-examination procedure of extension of marketing authorisation according to Annex I of Commission Regulation (EC) No 1234/2008

No items
5. Type II variations - variation of therapeutic indication procedure according to Annex I of Commission Regulation (EC) No 1234/2008

5.1. Type II variations - variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008; Opinions or Requests for supplementary information

5.1.1. Adcetris - brentuximab vedotin - Orphan - EMEA/H/C/002455/II/0048

Takeda Pharma A/S

Rapporteur: Paula Boudewina van Hennik, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sabine Straus

Scope: "Extension of indication to include the new indication "ADCETRIS is indicated for the treatment of adult patients with CD30+ cutaneous T-cell lymphoma (CTCL) who require systemic therapy", based on data from study C25001 (the 'ALCANZA' study): "A Phase 3 Trial of brentuximab vedotin(SGN-35) Versus Physician's Choice (Methotrexate or Bexarotene) in Patients With CD30-Positive Cutaneous T-Cell Lymphoma". As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance. An updated RMP (version 10) has also been submitted."

Action: For adoption

The Committee discussed the issues identified in this application. The questions to be addressed by the applicant, are whether the positive benefit-risk established in MF and pcALCL can be extrapolated to other types of CTCL and to the first line treatment setting.

The Committee adopted a request for supplementary information with a specific timetable.

The CHMP adopted the BWP report.

The CHMP adopted the assessment report on similarity of Adcetris.

5.1.2. Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0142

Amgen Europe B.V.

Rapporteur: Martina Weise, Co-Rapporteur: Koenraad Norga, PRAC Rapporteur: Valerie Strassmann

Scope: "Extension of Indication to include treatment of anaemia in adult patients with low transfusion demand in low or intermediate-1-risk myelodysplastic syndromes for Aranesp; as a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to update the safety and efficacy information. The Package Leaflet is updated in accordance. Updated RMP version 8.0 has been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce QRD editorial changes in the SmPC, Annex IIIA and Annex IIIB."

Action: For adoption
The Committee discussed the issues identified in this application, which were related to biometrical and clinical aspects.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.3. Bydureon - exenatide - EMEA/H/C/002020/II/0041

AstraZeneca AB

Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension of indication for Bydureon to include the add-on use of exenatide in combination with dapagliflozin to patients whose diabetes is not adequately controlled with metformin based on the study D5553C00003 (Duration 8 study); section 4.1 of the SmPC is updated in order to align the indication wording with more recently approved glucose-lowering agents. Section 5.1 of the SmPC is also updated with the results of study D5553C00003 (Duration 8 study). The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes in the SmPC and Package Leaflet and to update the Irish local representative information in the Package Leaflet. Furthermore, the consolidated RMP version 27 has been agreed."

Action: For adoption

Request for Supplementary Information adopted on 23.03.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

5.1.4. Gazyvaro - obinutuzumab - Orphan - EMEA/H/C/002799/II/0016

Roche Registration Limited

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Alexandre Moreau, PRAC Rapporteur: Patrick Batty

Scope: "Extension of Indication to include a new indication for Gazyvaro in combination with chemotherapy, followed by Gazyvaro maintenance therapy in patients achieving a response, for the treatment of patients with previously untreated advanced follicular lymphoma. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet and the RMP are updated in accordance. In addition, the due date for provision of the final clinical study report of study BO21223/GALLIUM listed in the Gazyvaro RMP as Category 3 has been updated.

Furthermore, the PI is brought in line with the missing information of QRD template version 9.1 regarding annex II C. In addition, clarification or editorial changes to the SmPC are proposed for accuracy and clarity." Request for 1 year of market protection for a new indication (Article 14(11) of Regulation (EC) 726/2004)
**Action**: For adoption


The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by majority (26 out of 27 votes) together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The divergent position (Johann Lodewijk Hilleg) was appended to the opinion.

The summary of opinion was circulated for information.

The CHMP agreed to the request for 1 year of market protection for a new indication.

### 5.1.5. Genvoya - elvitegravir / cobicistat / emtricitabine / tenofovir alafenamide - EMEA/H/C/004042/II/0026

Gilead Sciences International Ltd

Rapporteur: Robert James Hemmings, PRAC Rapporteur: Amelia Cupelli

**Scope**: "Extension of Indication to include paediatric patients from 6 of age to less than 12 years of age, with body weight of at least 25kg, infected with human immunodeficiency virus-1 (HIV-1) without any known mutations associated with resistance to the integrase inhibitor class, emtricitabine or tenofovir, for Genvoya.

As a consequence, sections 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated based on the analysis of the paediatric study GS-US-292-0106 (Cohort 2) "A Phase 2/3, Open-Label Study of the Pharmacokinetics, Safety, and Antiviral Activity of the Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (E/C/F/TAF) Single Tablet Regimen (STR) in HIV-1 Infected Antiretroviral Treatment Naive Adolescents and Virologically Suppressed Children".

The Package Leaflet and the Risk Management Plan (v. 3) are updated in accordance."

**Action**: For adoption

Request for Supplementary Information adopted on 23.03.2017.

The Committee discussed the issues identified in this application. The Committee concluded that the extension of indication is not adequately supported by the data.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

### 5.1.6. Humira - adalimumab - EMEA/H/C/000481/II/0163

AbbVie Limited.

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

**Scope**: "Extension of Indication to include a new indication for Humira for the treatment of paediatric chronic non-infectious anterior uveitis in patients from 2 years of age who have had an inadequate response to or are intolerant to conventional therapy, or in whom
conventional therapy is inappropriate; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet was updated in accordance. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement an alternative format statement for blind/partially sighted patients in the Package Leaflet. Furthermore, the MAH has made some editorial changes to the Package Leaflet.”

**Action:** For adoption

Request for Supplementary Information adopted on 23.03.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The CHMP noted the letter of recommendation dated 17 July 2017.

The summary of opinion was circulated for information.

### 5.1.7. Keytruda - pembrolizumab - EMEA/H/C/003820/II/0023/G

Merck Sharp & Dohme Limited

Rapporteur: Daniela Melchiorri, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Sabine Straus

Scope: “Grouped application including:

*Extension of Indication to add treatment as monotherapy of locally advanced or metastatic urothelial carcinoma in adults who have received prior platinum-containing chemotherapy based on the results from study KEYNOTE-045; a phase 3, randomized, active-controlled, multi-site, open-label trial evaluating pembrolizumab administered at 200 mg Q3W versus investigators’ choice of paclitaxel, docetaxel, or vinflunine in patients previously treated with chemotherapy.*

*Extension of Indication to add treatment as monotherapy of locally advanced or metastatic urothelial carcinoma in adults who are not eligible for cisplatin-containing chemotherapy based on the results from study KEYNOTE-52; a phase 2, single-arm, multisite, open-label trial of pembrolizumab at 200 mg Q3W in the treatment of patients with locally advanced or metastatic urothelial carcinoma who are not eligible for cisplatin-containing chemotherapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC have been updated and the Package Leaflet has been updated accordingly. Further, the MAH is taking the opportunity to implement a change to section 4.4 of the SmPC adding possible hypersensitivity and anaphylaxis as part of infusion reactions. In addition, Annex II has been updated to include new Post-authorisation efficacy studies (PAES) as obligations under ‘conditions or restrictions with regard to the safe and effective use of the medicinal product’. An updated RMP version 7.2 was agreed during the procedure.”

**Action:** For adoption

Request for Supplementary Information adopted on 18.05.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by majority (24 out of 28 votes) together with the CHMP Assessment Report and translation timetable.

The Icelandic CHMP member was in agreement with the CHMP recommendations and the Norwegian CHMP member was not.

The divergent position (Johann Lodewijk Hilleg, Alexandre Moreau, Romalda Maciulaitis, Sinan B. Sarac, Svein Rune Andersen) was appended to the opinion.

The summary of opinion was circulated for information.

5.1.8. Kineret - anakinra - EMEA/H/C/000363/II/0056

Swedish Orphan Biovitrum AB (publ)

Rapporteur: Sinan B. Sarac, Co-Rapporteur: Fátima Ventura, PRAC Rapporteur: Torbjorn Callreus

Scope: "Extension of indication to include a new indication for Kineret 100 mg/0.67 ml solution for injection in pre-filled syringe for the treatment of active Still's disease, including Systemic Juvenile Idiopathic Arthritis and Adult-Onset Still's Disease. As a consequence, sections 4.1, 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the RMP (version 4.0) are updated accordingly.

In addition, the marketing authorisation holder took the opportunity to make some editorial changes in the SmPC and Package leaflet.”

Action: For adoption

The Committee discussed the issues identified in this application, which was related to the first line use of the product and severity of disease.

The Committee adopted a request for supplementary information with a specific timetable.

5.1.9. Olumiant - baricitinib - EMEA/H/C/004085/II/0001

Eli Lilly Nederland B.V.; treatment of moderate to severe active rheumatoid arthritis (RA)

Scope: "Update of section 4.4 of the SmPC in order to add a warning on venous thromboembolism based on analyses of the occurrence of venous thromboembolic events in clinical trials with baricitinib. The Package Leaflet is updated accordingly. The RMP version 2.0 has been submitted, as part of this application.”

Action: For adoption

New active substance (Article 8(3) of Directive No 2001/83/EC)

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
5.1.10. **Opdivo - nivolumab - EMEA/H/C/003985/II/0029**

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Paula Boudewina van Hennik, PRAC
Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of Indication to include the treatment of hepatocellular carcinoma after prior sorafenib therapy in adults for Opdivo.

As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The Package Leaflet is updated in accordance.

Moreover, the updated RMP version 8.0 has been submitted."

**Action:** For adoption

Request for Supplementary Information adopted on 22.06.2017, 23.03.2017.

See 2.3

An oral explanation was held on 19 July 2017 at time 15:00. The presentation mainly related to the clinical trial design and outcome.

The CHMP noted that the applicant withdrew the variation application.

5.1.11. **Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091**

Roche Registration Limited

Rapporteur: Filip Josephson, PRAC Rapporteur: Qun-Ying Yue

Scope: "Extension of Indication to include paediatric patients from 3 to less than 18 years of age with Chronic Hepatitis B in the immune-active phase for Pegasys.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add efficacy and safety information from study YV25718. The Package Leaflet is updated in accordance.

An updated EU RMP (version 8.0) is included in this application."

**Action:** For adoption


The Committee discussed the issues identified in this application, which were related to clinical efficacy and safety outstanding issues.

The Committee adopted a 2nd request for supplementary information with a specific timetable.

5.1.12. **Rapamune - sirolimus - EMEA/H/C/000273/II/0164**

Pfizer Limited

Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of indication to include the treatment of patients with lymphangioleiomyomatosis. As a consequence section 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet and the RMP (version 6.0) are updated in accordance. In addition the MAH took the opportunity to make very minor formatting
changes in the Labelling.”

**Action**: For adoption

The Committee discussed the issues identified in this application, which were related to the use of product in target population and its clinical relevance. The CHMP noted the need for similarity assessment, which was requested from the applicant to be submitted with the responses to the RSI.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.13. RoActemra - tocilizumab - EMEA/H/C/000955/II/0066

Roche Registration Limited

Rapporteur: Jan Mueller-Berghaus, Co-Rapporteur: Agnes Gyurasics, PRAC Rapporteur: Brigitte Keller-Stanislawski

Scope: "Extension of indication to include an indication in adult patients for the treatment of giant cell arteritis for the subcutaneous formulation of RoActemra. As a consequence, sections 4.1, 4.2, 4.4, 4.5, 4.8, 5.1 and 5.2 of the SmPC are updated to reflect information relevant to this indication. The Package Leaflet is updated in accordance."

**Action**: For adoption

Request for Supplementary Information adopted on 22.06.2017, 23.03.2017.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

### 5.1.14. Sovaldi - sofosbuvir - EMEA/H/C/002798/II/0036

Gilead Sciences International Ltd

Rapporteur: Filip Josephson, Co-Rapporteur: Alar Irs, PRAC Rapporteur: Julie Williams

Scope: "Extension of indication to add treatment of chronic hepatitis C in adolescents aged 12 to <18 years.

As a consequence, sections 4.1, 4.2, 4.4, 4.8, 5.1 and 5.2 of the SmPC are updated in order to add information on posology, warnings, safety, efficacy and pharmacokinetics.

The Package Leaflet and Risk Management Plan (RMP version 5.2) are updated in accordance.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

Furthermore, the Product Information is brought in line with the latest QRD template version 10."

**Action**: For adoption
The Committee confirmed that all issues previously identified in this application had been addressed.
The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.
The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.
The summary of opinion was circulated for information.

5.1.15.  Sutent - sunitinib - EMEA/H/C/000687/II/0065

Pfizer Limited
Rapporteur: Daniela Melchiorri, Co-Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Carmela Macchiarelo
Scope: "Extension of Indication to include adjuvant treatment of patients at high risk of recurrent renal cell carcinoma (RCC) following nephrectomy for Sutent; as a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated based on the study A6181109 ("a randomized double-blind phase 3 study of adjuvant sunitinib vs. placebo in subjects at high risk of recurrent RCC"). The Package Leaflet is updated accordingly.
In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes to the SmPC and Package Leaflet and in addition, to fulfil PAM (FU2 22.5). Furthermore, the PI is brought in line with the latest QRD template version 10. Moreover, updated RMP version 16 has been submitted."

Action: For adoption

The Committee discussed the issues identified in this application which were related to clinical efficacy and safety aspects. The Committee adopted a request for supplementary information with a specific timetable.

The CHMP adopted the similarity assessment report for Sutent.

5.1.16.  Vimpat - lacosamide - EMEA/H/C/000863/II/0065/G

UCB Pharma S.A.
Rapporteur: Filip Josephson, Co-Rapporteur: Luca Pani, PRAC Rapporteur: Qun-Ying Yue
Scope: "Extension of Indication to extend the indication for Vimpat to monotherapy and adjunctive therapy in the treatment of partial onset seizures with or without secondary generalisation in adolescents and children aged 4 to less than 16 years with epilepsy. For the treatment initiation pack, the use was only extended to adolescents weighting 50 kg or more as it is not suitable for the weight-based dosing regimen recommended for patients weighing less. Sections 4.1, 4.2, 4.4, 4.5, 4.6, 4.8, 5.1, 5.2 and 5.3 of the SmPC have been updated including the addition of a warning of the potential for electro-clinical worsening in specific epileptic syndromes. The Package Leaflet was updated in accordance. Moreover, section 6.3 of the SmPC of the syrup is updated to reflect the extension of shelf life after first opening from 4 weeks to 2 months. Furthermore, a 10 mL dosing syringe for the 200 ml and the 465 ml syrup bottles is introduced as additional dosing device for paediatric
population; section 6.5 of the SmPC of the syrup presentations is updated accordingly. Finally, the PI was also brought in line with the latest QRD template version and editorial amendments were made in several sections. The MAH also took the opportunity to introduce a combined SmPC for the film coated tablets. Moreover, updated RMP version 12.2 has been agreed.

**Action**: For adoption

Request for Supplementary Information adopted on 18.05.2017, 10.11.2016.

The Committee confirmed that all issues previously identified in this application had been addressed.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.

The summary of opinion was circulated for information.

### 5.1.17. Xgeva - denosumab - EMEA/H/C/002173/II/0055

Amgen Europe B.V.

Rapporteur: Kristina Dunder, Co-Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Ulla Wändel Liminga

Scope: "Extension of Indication to include "Prevention of skeletal related events (pathological fracture, radiation to bone, spinal cord compression or surgery to bone) in adults with multiple myeloma and in adults with bone metastases from solid tumours" for Xgeva; as a consequence, sections 4.1, 4.2, 4.8, 5.1 and 5.2 of the SmPC are updated. The Package Leaflet is updated in accordance."

**Action**: For adoption

The Committee discussed the issues identified in this application.

The Committee adopted a request for supplementary information with a specific timetable.

### 5.1.18. Zytiga - abiraterone acetate - EMEA/H/C/002321/II/0047

Janssen-Cilag International NV

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Robert James Hemmings, PRAC Rapporteur: Eva A. Segovia

Scope: "Extension of indication to include the treatment of newly diagnosed high risk metastatic hormone sensitive prostate cancer and in combination with androgen deprivation therapy. As a consequence, sections 4.1, 4.2, 4.4, 4.8 and 5.1 of the SmPC are updated. The package leaflet and the RMP (version 14.0) are updated accordingly. In addition, the MAH took the opportunity to update the list of local representatives in the Package Leaflet"

**Action**: For adoption

The Committee discussed the issues identified in this application, which were related to clinical efficacy and safety aspects.
The Committee adopted a request for supplementary information with a specific timetable.

5.2. **Update on on-going Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

5.2.1. **Fluenz Tetra - influenza vaccine (live attenuated, nasal) - EMEA/H/C/02617/II/0072**

AstraZeneca UK Ltd

Rapporteur: Bart Van der Schueren, Co-Rapporteur: Bart Van der Schueren

Scope: "To replace the strain of a seasonal vaccine against human influenza in line with the EU recommendations for the seasonal influenza vaccine composition for the season 2017/2018."

**Action:** For information

Request for Supplementary Information adopted on 22.06.2017

The CHMP was updated on HAI tests performed by the WHO.

The CHMP adopted the BWP report.

5.2.2. **Orkambi - lumacaftor / ivacaftor - EMEA/H/C/003954/II/17**

Vertex Pharmaceuticals (Europe) Ltd.

Rapporteur: Nithyanandan Nagercoil, Co-Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Almath Spooner

PM: Elisa Pedone, EPL: Andrea Taft, QM: Dolores Hernandez Perez de la Ossa

Scope: Request by the applicant dated 3 July 2017 requesting an extension of clock stop to respond to the second Request for Supplementary Information adopted on 18.05.2017.

**Action:** For adoption

Request for Supplementary Information adopted on 18.05.2017, 23.02.2017

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to the second Request for Supplementary Information adopted on 18.05.2017

5.3. **Re-examination of Type II variation; variation of therapeutic indication procedure according to Commission Regulation (EC) No 1234/2008**

No items
6. Ancillary medicinal substances in medical devices

6.1. Ancillary medicinal substances in medical devices; Opinions/ Day 180 list of outstanding issues / Day 120 list of questions

No items

6.2. Update of Ancillary medicinal substances in medical devices

No items

7. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

7.1. Procedure under Article 83(1) of Regulation (EC) 726/2004 (Compassionate Use)

No items

8. Pre-submission issues

8.1. Pre-submission issue

8.1.1. durvalumab - H0004771

treatment of patients with locally advanced, unresectable NSCLC whose disease has not progressed following platinum-based chemoradiation therapy

Scope: Briefing note and the Rapporteurs’ recommendation on the request for accelerated assessment.

Action: For adoption

The CHMP did not agree to the request for accelerated assessment and adopted the briefing note and Rapporteurs’ recommendation on the Request for Accelerated Assessment.

8.2. Priority Medicines (PRIME)

Information related to priority medicines cannot be released at the present time as these contain commercially confidential information.

8.2.1. List of applications received

Action: For information

The CHMP noted the list of applications received.
8.2.2. Recommendation for PRIME eligibility

**Action:** For adoption

The CHMP adopted the recommendation for PRIME eligibility. The CHMP reviewed 8 recommendations for eligibility to PRIME: 1 was accepted. 7 were denied. The individual outcomes are listed in PRIME Monthly Report on EMA website.

9. Post-authorisation issues

9.1. Post-authorisation issues


Applicants: Amgen Europe B.V. (Aranesp), Hexal AG (Epoetin Alfa Hexal), Hospira UK Limited (Retacrit), Medice Arzneimittel Pütter GmbH & Co. KG (Abseamed), Roche Registration Limited (Neorecormon, Mircera), Ratiopharm GmbH (Eporatio), Sandoz GmbH (Binocrit), Stada Arzneimittel AG (Silapo), Teva GmbH (Biopoin); various


Scope: DHPC letter and communication plan

**Action:** For adoption

The CHMP agreed to the DHPC and communication plan.

9.1.2. CHMP request for PRAC advice on Fluoropyrimidines (Capecitabine-Xeloda and 5-FU), EMEA/H/C/0316/LEG-033.1

Xeloda, Rapporteur: Harald Enzmann, PRAC Rapporteur: Martin Huber

Scope: PRAC Advice to ChMP following formal advice from PgWP regarding the proposed SmPC changes for upfront testing of patients for DPYD variants and dose reduction based on patient’s genotype to reduce the toxicity of capecitabine and 5-FU y

**Action:** For adoption

The CHMP endorsed the PRAC advice.
9.1.3. Vedrop - tocofersolan – Orphan - EMEA/H/C/000920/II/0022

Orphan Europe SARL

Rapporteur: Greg Markey, PRAC Rapporteur: Patrick Batty

Scope: "Submission of the final report for the registry of paediatric patients treated with Vedrop (tocofersolan) in Europe for vitamin E deficiency due to digestive malabsorption in congenital or hereditary chronic cholestasis. Consequentially, the remaining specific obligation is fulfilled and Annex II is updated accordingly."

**Action:** For adoption

The Committee confirmed that the remaining specific obligations on this marketing authorisation had been fulfilled. As the data are still not as comprehensive as a full marketing authorisation would require, the MAH shall therefore continue to provide yearly updates on any new information concerning efficacy and safety of the product in patients with congenital chronic cholestasis or hereditary cholestasis as a condition (specific obligation) to the marketing authorisation under exceptional circumstances.

The Committee adopted a positive opinion by consensus together with the CHMP Assessment Report and translation timetable.

The Icelandic and Norwegian CHMP members were in agreement with the CHMP recommendations.


MAH: Amgen Europe B.V.

Rapporteur: Pierre Demolis

Scope: "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the safety information with the data from the study 103311. This study is fulfilling the specific obligation for the conditional MA. The SO is removed from annex II. The Package Leaflet is updated accordingly. The MAH takes this opportunity to amend the format of the preparation instructions to improve clarity. The content is not impacted."

Rapporteur: Pierre Demolis, Co-Rapporteur: Daniela Melchiorri

Scope: Renewal

Action: For adoption

Request for Supplementary Information adopted on 26.01.2017.

The Committee discussed the issues identified in this application.

The Committee adopted a 2nd request for supplementary information.

The CHMP agreed to harmonise the timetable for the renewal and the type II variation II/09.

The CHMP agreed to consult the SAG Oncology and adopted a list of question to this group.
9.1.5. **Opdivo - nivolumab - EMEA/H/C/003985/II/0030**

Bristol-Myers Squibb Pharma EEIG

Rapporteur: Jorge Camarero Jiménez, Co-Rapporteur: Paula Boudewina van Hennik, PRAC
Rapporteur: Brigitte Keller-Stanislawski

Scope: Letter from the applicant dated 04 July 2017 requesting an extension of clock stop to respond to Request for supplementary information adopted on 23.03.2017

**Action:** For adoption

Request for Supplementary Information adopted on 23.03.2017.

The CHMP agreed to the request by the applicant for an extension of clock stop to respond to Request for supplementary information adopted on 23.03.2017.

9.1.6. **Data collection on adverse events of anti-HIV drugs (D:A:D) study - Evaluation of D:A:D data**

**Action:** For adoption

The CHMP adopted the data merger report.

10. **Referral procedures**


No items

10.2. **Requests for CHMP Opinion under Article 5(3) of Regulation (EC) No 726/2004**

No items

10.3. **Procedure under Articles 5(2) and 10 of the Regulation (EC) No 726/2004**

No items

10.4. **Disagreement between Member States on application for medicinal product (potential serious risk to public health) –under Article 29(4) of Directive 2001/83/EC**

No items

10.5. **Harmonisation - Referral procedure under Article 30 of Directive 2001/83/EC**

No items

10.6.1. Gadolinium-containing contrast agents (GdCA):
gadoversetamide – OPTIMARK (CAP)
Gadobenate dimeglumine; gadobutrol; gadodiamide; gadopentetic acid dimeglumine, gadoteric acid (intra articular formulation); gadoteridol; gadoxetic acid disodium (NAP)

Applicant(s): Guerbert (Optimark); various

Rapporteurs for the Article 31 referral: PRAC Rapporteur: Patrick Batty; PRAC Co-rapporteur: Doris Stenver

PRAC Rapporteur of the re-examination: Ulla Wändel Liminga; PRAC Co-rapporteur of the re-examination: Valerie Strassmann

Rapporteurs for Optimark: CHMP Rapporteur: Patrick Salmon, CHMP Co-rapporteur: Johann Lodewijk Hillege

Scope: Oral explanation/Opinion

Action: For adoption

CHMP opinion following PRAC final recommendation

See 2.4

Four oral explanations were held on 18 July 2017. The companies invited to take part in the oral explanations were Bayer, Bracco, GE Healthcare and Guerbet. The presentations focused on data in relation to gadolinium deposition in brain and other tissues and the overall benefit-risk profiles of these products

The CHMP was updated on discussions at the PRAC and discussed the grounds for the PRAC recommendation and the conditions for lifting the suspension.

The CHMP discussed further the PRAC recommendation and possible divergent views.

The CHMP, having considered the PRAC recommendation, adopted an opinion by majority (19 out of 31 votes) recommending that the marketing authorisations for products containing gadodiamide, gadopentetic acid and gadoversetamide for intravenous use should be suspended. Furthermore, the CHMP recommended that the marketing authorisations for medicinal products containing intravenous gadobutrol, gadoteric acid, gadoteridol, gadoxetic acid, gadobenic acid, intra-articular gadoteric acid and intra-articular gadopentetic acid should be varied.

The Icelandic and Norwegian Members were not in agreement with the CHMP recommendation.

The divergent positions (Agnes Gyurasics, Alar Irs, Andrea Laslop, Bruno Sepodes, Daniela Melchiorri, David Lyons, John Joseph Borg, Kristina Dunder, Natalja Karpova, Romaldas Maciulaitis, Tomas Boran, Ewa Balkowiec Iskra, Svein Rune Andersen, Kolbeinn Gudmundsson) were appended to the opinion.

DHPC and communication plan were adopted via written procedure on 18.08.2017.

10.7.1. **Alcover 750 mg, 1250 mg, 1750 mg Granulat im Beutel – Sodium oxybate – EMEA/H/A-29(4)/1451**

D&A Pharma

Rapporteur: Andrea Laslop, Co-Rapporteur: Fatima Ventura,

Scope: Appointment of re-examination rapporteurs, draft timetable, SAG involvement

Letter from the applicant dated 30 June 2017 requesting a re-examination of the Opinion adopted on 22 June 2017 and consultation of a Scientific Advisory Group

**Action:** For adoption

Decentralised Procedure number: AT/H/0552/01-03/DC, notification by the Austrian Agency dated 22 December 2016 notifying of the start of a referral under Article 29(4) of Directive 2001/83/EC.


The CHMP appointed a re-examination Rapporteur and a re-examination Co-Rapporteur.

The CHMP noted the draft re-examination timetable.

10.8. **Procedure under Article 107(2) of Directive 2001/83/EC**

No items

10.9. **Disagreement between Member States on Type II variation– Arbitration procedure initiated by MAH under Article 6(13) (EC) No 1084/2003**

No items

10.10. **Procedure under Article 29 Regulation (EC) 1901/2006**

No items

10.11. **Referral under Article 13 Disagreement between Member States on Type II variation– Arbitration procedure initiated by Member State under Article 13 (EC) No 1234/2008**

No items
11. Pharmacovigilance issue

11.1. Early Notification System

July 2017 Early Notification System on envisaged CHMP/CMDh outcome accompanied by communication to the general public.

Action: For information

The CHMP noted the July 2017 Early Notification System.

12. Inspections

12.1. GMP inspections

Disclosure of information related to GMP inspections will not be published as it undermines the purpose of such inspections

12.2. GCP inspections

Disclosure of information related to GCP inspections will not be published as it undermines the purpose of such inspections

12.3. Pharmacovigilance inspections

Disclosure of information related to Pharmacovigilance inspections will not be published as it undermines the purpose of such inspections

12.4. GLP inspections

Disclosure of information related to GLP inspections will not be published as it undermines the purpose of such inspections

13. Innovation Task Force

13.1. Minutes of Innovation Task Force

Action: For information

The CHMP noted the minutes.

13.2. Innovation Task Force briefing meetings

Information related to briefing meetings taking place with applicants cannot be released at the present time as deemed to contain commercially confidential information.

No items

13.4. Nanomedicines activities

No items

14. Organisational, regulatory and methodological matters

14.1. Mandate and organisation of the CHMP

14.1.1. Time schedule of CHMP August written procedure

**Action:** For information

The CHMP noted the time schedule of the CHMP August written procedure.

14.1.2. Pilot phase for abolition of signatures for divergent positions for referral procedures

The proposal is to start new process from September onwards.

**Action:** For information

The CHMP agreed to the proposal for abolition of signatures for divergent positions for referral procedures. The new process might be extended to other divergent positions in the future.

14.1.3. Confirmation of joint CHMP/PDCO membership for Romania

Romania - Simona Badoi and Dana Gabriela Marin

**Action:** For adoption

The CHMP appointed Simona Badoi and Dana Gabriela Marin as joint CHMP/PDCO members.

14.1.4. Update to the CHMP templates on initial Marketing Authorisation

Update to the Rapporteurs’ D80 AR overview guidance document to add guidance specific to biosimilars (including a revised Benefit/Risk balance section). When adopted, the changes will be implemented in all relevant templates on initial MA.

**Action:** For adoption

The CHMP noted the update on the assessment report templates. Any comments should be sent by **1st September 2017**. In the absence of comments the document will be considered adopted.
14.2. Coordination with EMA Scientific Committees

14.2.1. Pharmacovigilance Risk Assessment Committee (PRAC)

Summary of recommendations and advice of PRAC meeting held on 3-6 July 2017

**Action:** For information

The CHMP noted the Summary of recommendations and advice of PRAC meeting held on 3-6 July 2017.

List of Union Reference Dates and frequency of submission of Periodic Safety Update Reports (EURD list) for July 2017

**Action:** For adoption

The CHMP adopted the EURD list.

14.2.2. Committee for Advanced Therapies (CAT)

CAT draft minutes of meeting held on 12-14 July 2017

**Action:** For information

The CHMP noted the minutes.

Revision of Procedural advice on the evaluation of Advanced Therapy Medicinal Product in accordance with Article 8 of Regulation (EC) NO 1394/2007

**Action:** For information

The CHMP noted the revision. Comments should be sent by 31 July 2017.

14.2.3. Paediatric Committee (PDCO)

PIPs reaching D30 at July 2017 PDCO

**Action:** For information

The CHMP noted the information.

Report from the PDCO meeting held on 18-21 July 2017

**Action:** For information

The CHMP noted the information.

Advice from the CHMP and PDCO task force on how to address issues related to therapeutic equivalence for orally inhaled products for children

**Action:** For adoption

No comments from members were received on the CHMP PDCO advice.

The CHMP adopted the advice.
EMA/FDA/Health Canada workshop on paediatric pulmonary hypertension (PAH) – meeting highlights

**Action:** For information

The CHMP noted the information.

14.2.4. **Committee for Orphan Medicinal Products (COMP)**

Report from the COMP meeting held on 11-13 July 2017

**Action:** For information

The CHMP noted the report.

14.2.5. **Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh)**

Report from the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh) on the meeting held on 17-19 July 2017.

**Action:** For information

The CHMP noted the report.

14.3. **Coordination with EMA Working Parties/Working Groups/Drafting Groups**

14.3.1. **Scientific Advice Working Party (SAWP)**

Report from the SAWP meeting held on 3-6 July 2017. Table of conclusions

**Action:** For information

The CHMP noted the report.

Scientific advice letters: Information related to scientific advice letters cannot be released at the present time as these contain commercially confidential information.

14.3.2. **Quality Working Party (QWP)**

Chair: Keith Pugh

Election of QWP Vice Chair, the term of the current Chair ending in July 2017.

**Action:** For adoption

The CHMP elected Blanka Hirschlerova (CZ) as vice-chair of the QWP.

Guideline on Manufacture of the Finished Dosage Form (EMA/CHMP/QWP/BWP/245074)

**Action:** For adoption

The CHMP adopted the guideline. The guideline replaces the note for guidance on the manufacture of the finished dosage form (CPMP/QWP/486/95). The note for guidance has been updated to reflect the requirements as laid down in the current legislation (Directive
2001/83/EC, and to follow the format and content of the Common Technical Document (CTD) Module 3 dossier. It also addresses current manufacturing practices in terms of complex supply chains and worldwide manufacture. In addition, the content and principles of the ICH Q8 guideline are also taken into account.

### 14.3.3. Radiopharmaceutical Drafting Group (RadDG)

**Chair:** Anabel Cortes

**Guideline on core SmPC and Package Leaflet for (68Ge-68Ga) generator (EMA/313282/2017)**

**Action:** For adoption

Overview of comments ‘Guideline on core SmPC and Package Leaflet for (68Ge68Ga)’ (EMA/313283/2017)

**Action:** For information

The CHMP adopted the guideline and noted the overview of comments. The purpose of this core SmPC and package leaflet is to provide applicants and regulators with harmonised guidance on the information to be included in the Summary of product characteristics (SmPC) for (68Ge/68Ga) generator. This guideline should be read in conjunction with the core SmPC and package leaflet for Radiopharmaceuticals, the QRD product information templates and the guideline on Summary of Product Characteristics.

### 14.3.4. CHMP Guidelines Consistency Group (GCG)

**Chair:** Barbara van Zwieten-Boot

Nomination of new member to the GCG

**Action:** For adoption

The CHMP appointed Andreas Kirisits (AT) as new member to the GCG.

### 14.3.5. Blood Product Working Party (BPWP)

**Chair:** Jacqueline Kerr

BPWP 2017 work plan has been modified with a change of date of face-to-face meeting in November 2017.

**Action:** For adoption

The CHMP adopted the revised BPWP 2017 work plan

### 14.4. Cooperation within the EU regulatory network

None

### 14.5. Cooperation with International Regulators

None
14.6. Contacts of the CHMP with external parties and interaction with the Interested Parties to the Committee
None

14.7. CHMP work plan

14.7.1. CHMP 2017 Work Plan: mid-year update

**Action:** For information

The CHMP noted the status update of work plan activities. Members were invited to send any comments over the summer.

14.8. Planning and reporting

None

14.9. Others

None

15. Any other business

15.1. AOB topic

15.1.1. Working group on Committees’ operational preparedness for human medicines

Scope: CHMP representatives to this Cross-Committee working group

**Action:** For information

The CHMP was updated on recent discussions.

15.1.2. Revision of the ‘Guideline on strategies to identify and mitigate risks for first-in-human clinical trials with investigational medicinal products’

CHMP Rapporteur: Harald Enzmann

Scope: Final revised guideline to be published

**Action:** For adoption

The CHMP adopted the revised guideline. The revision is intended to further assist stakeholders in the transition from non-clinical to early clinical development and in identifying factors influencing risk for new investigational medicinal products (IMPs). The document includes considerations on quality aspects, non-clinical and clinical testing strategies, study design and on conduct of FIH/early CTs. Strategies for mitigating and managing risks are
given, including principles on the calculation of the starting dose to be used in humans, the subsequent dose escalations, the criteria for maximum dose and the conduct of the trial inclusive of multiple parts.

15.1.3. Bridging the regulator and the payer world

Scope: presentation

**Action:** For information

The CHMP noted the update.
### 16. List of participants

List of participants including any restrictions with respect to involvement of members/alternates/ experts following evaluation of declared interests for the 17 – 20 July 2017 meeting.

<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Tomas Salmonson</td>
<td>Chair</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Andrea Laslop</td>
<td>Member</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Milena Stain</td>
<td>Alternate</td>
<td>Austria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bart van der Schueren</td>
<td>Member</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Mila Vlaskovska</td>
<td>Member</td>
<td>Bulgaria</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Katarina Vučić</td>
<td>Member</td>
<td>Croatia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tomas Boran</td>
<td>Alternate</td>
<td>Czech Republic</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sinan B. Sarac</td>
<td>Member</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Hanne Lomholt Larsen</td>
<td>Alternate</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alar Irs</td>
<td>Member</td>
<td>Estonia</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Outi Mäki-Ikola</td>
<td>Member</td>
<td>Finland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Tuomo Lapveteläinen</td>
<td>Alternate</td>
<td>Finland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Alexandre Moreau</td>
<td>Member</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Joseph Emmerich</td>
<td>Alternate</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Harald Enzmann</td>
<td>Member (Vice-Chair)</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Martina Weise</td>
<td>Alternate</td>
<td>Germany</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Eleftheria Nikolaidi</td>
<td>Member</td>
<td>Greece</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Agnes Gyurasics</td>
<td>Member</td>
<td>Hungary</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kolbeinn Gudmundsson</td>
<td>Member</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>David Lyons</td>
<td>Member</td>
<td>Ireland</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>---------------------------</td>
<td>---------------</td>
<td>-----------------------------</td>
<td>---------------------------------------------------------------------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Patrick Salmon</td>
<td>Alternate</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Daniela Melchiorri</td>
<td>Member</td>
<td>Italy</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Luca Pani</td>
<td>Alternate</td>
<td>Italy</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Natalja Karpova</td>
<td>Alternate</td>
<td>Latvia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Romaldas Mačiulaitis</td>
<td>Member</td>
<td>Lithuania</td>
<td>No participation in final deliberations and voting on:</td>
<td>3.1.11. Tecentriq - atezolizumab - EMEA/H/C/004143</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.1.4. Gazyvaro - obinutuzumab - Orphan - EMEA/H/C/002799/II/0016</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.1.11. Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091</td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td>5.1.13. RoActemra - tocilizumab - EMEA/H/C/000955/II/0066</td>
</tr>
<tr>
<td>Jacqueline Genoux-Hames</td>
<td>Member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>John Joseph Borg</td>
<td>Member</td>
<td>Malta</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Johann Lodewijk Hillege</td>
<td>Member</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Paula Boudewina van Hennik</td>
<td>Alternate</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Svein Rune Andersen</td>
<td>Member</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bjorg Bolstad</td>
<td>Alternate</td>
<td>Norway</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-------------------------</td>
<td>-----------------------</td>
<td>----------------------------</td>
<td>--------------------------------------------------</td>
<td>-----------------------------------------------</td>
</tr>
<tr>
<td>Ewa Balkowiec Iskra</td>
<td>Member</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Aldona Paluchowska</td>
<td>Alternate</td>
<td>Poland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Bruno Sepodes</td>
<td>Member</td>
<td>Portugal</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Fatima Ventura</td>
<td>Alternate</td>
<td>Portugal</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Dana Gabriela Marin</td>
<td>Alternate</td>
<td>Romania</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Eva Malikova</td>
<td>Member – via Adobe</td>
<td>Slovakia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nevenka Trsinar Brodt</td>
<td>Alternate</td>
<td>Slovenia</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Concepcion Prieto Yerro</td>
<td>Member</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
</tbody>
</table>
| Jorge Camarero Jiménez  | Member                | Spain                      | No participation in final deliberations and voting on: | 3.1.11. Tecentriq - atezolizumab - EMEA/H/C/004143  
5.1.4. Gazyvaro - obinutuzumab - Orphan - EMEA/H/C/002799/II/0016  
5.1.11. Pegasys - peginterferon alfa-2a - EMEA/H/C/000395/II/0091  
5.1.13. RoActemra - toclizumab - EMEA/H/C/000955/II/0066  
9.1.1. Neorecormon (CAP) - epoetin beta – EMEA/H/C/000116/SD A/055; MIRCERA (CAP) - methoxy polyethylene glycol-epoetin beta - EMEA/H/C/000739/SD A/039 |
<p>| Kristina Dunder         | Member                | Sweden                     | No interests declared                            |                                               |
| Filip Josephson         | Alternate             | Sweden                     | No interests declared                            |                                               |</p>
<table>
<thead>
<tr>
<th>Name</th>
<th>Role</th>
<th>Member State or affiliation</th>
<th>Outcome restriction following evaluation of e-DoI</th>
<th>Topics on agenda for which restrictions apply</th>
</tr>
</thead>
<tbody>
<tr>
<td>Greg Markey</td>
<td>Member</td>
<td>United Kingdom</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Nithyanandan Nagercoil</td>
<td>Alternate</td>
<td>United Kingdom</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Robert James Hemmings</td>
<td>Co-opted member</td>
<td>United Kingdom</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Koenraad Norga</td>
<td>Co-opted member</td>
<td>Belgium</td>
<td>No participation in final deliberations and voting on:</td>
<td>3.2.4. - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004781 3.2.12. - fluticasone furoate / umeclidinium / vilanterol - EMEA/H/C/004363</td>
</tr>
<tr>
<td>Jan Mueller-Berghaus</td>
<td>Co-opted member</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jean-Louis Robert</td>
<td>Co-opted member</td>
<td>Luxembourg</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sol Ruiz</td>
<td>Co-opted member</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Kristina Bech Jensen</td>
<td>Expert - in person*</td>
<td>Denmark</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Örn Gudmundsson</td>
<td>Expert - in person*</td>
<td>Iceland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ulla Wändel Liminga</td>
<td>Expert - in person*</td>
<td>Sweden</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Valerie Strassmann</td>
<td>Expert - in person*</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sabine Mayrhofer</td>
<td>Expert - in person*</td>
<td>Germany</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Maria Escudero Galindo</td>
<td>Expert - in person*</td>
<td>Spain</td>
<td>No participation in final deliberations and voting on:</td>
<td>3.1.4. - Entecavir Mylan - entecavir - EMEA/H/C/004377 3.4.3. - pegfilgrastim - EMEA/H/C/004262 3.4.7. - trastuzumab - EMEA/H/C/004346 3.4.9. - rotigotine - EMEA/H/C/004286</td>
</tr>
<tr>
<td>Valerie Lescrainier</td>
<td>Expert - in</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>-----------------------------------</td>
<td>-------------------------------</td>
<td>----------------------------</td>
<td>---------------------------------------------------</td>
<td>----------------------------------------------</td>
</tr>
<tr>
<td>Peter Kiely</td>
<td>Expert - in person*</td>
<td>Ireland</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Sylvan Gueho</td>
<td>Expert - in person*</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Pierre Demolis</td>
<td>Expert - via telephone*</td>
<td>France</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Barbara Spruce</td>
<td>Expert - via telephone*</td>
<td>UK</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Benoy Daniel</td>
<td>Expert – via telephone*</td>
<td>UK</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Jan-Willem van der Laan</td>
<td>Expert - via telephone*</td>
<td>Netherlands</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Wang</td>
<td>Expert - via telephone*</td>
<td>Norway</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>June Raine</td>
<td>Expert - via telephone*</td>
<td>UK</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>John Clements</td>
<td>Expert - via telephone*</td>
<td>UK</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Jonas Bergh</td>
<td>Expert - via telephone*</td>
<td>Sweden</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Patrick Batty</td>
<td>Expert - via telephone*</td>
<td>UK</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ingrid Bourges</td>
<td>Expert - via telephone*</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>João Freire</td>
<td>Expert - via telephone*</td>
<td>Portugal</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Anabel Cortés Blanco</td>
<td>Expert - via telephone*</td>
<td>Spain</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Susanne Brendler-Schwaab</td>
<td>Expert - via Adobe*</td>
<td>Germany - BfArM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Janet Schriever</td>
<td>Expert - via Adobe*</td>
<td>Germany - BfArM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Ralf Meyer</td>
<td>Expert – via Adobe*</td>
<td>Germany - BfArM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tobias Lamkemeyer</td>
<td>Expert - via Adobe*</td>
<td>Germany - BfArM</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Tim Leest</td>
<td>Expert - via Adobe*</td>
<td>Belgium</td>
<td>No restrictions applicable to this meeting</td>
<td></td>
</tr>
<tr>
<td>Coraline Claeyys</td>
<td>Expert - via Adobe*</td>
<td>Belgium</td>
<td>No interests declared</td>
<td></td>
</tr>
<tr>
<td>Name</td>
<td>Role</td>
<td>Member State or affiliation</td>
<td>Outcome restriction following evaluation of e-DoI</td>
<td>Topics on agenda for which restrictions apply</td>
</tr>
<tr>
<td>------</td>
<td>------</td>
<td>-----------------------------</td>
<td>--------------------------------------------------</td>
<td>---------------------------------------------</td>
</tr>
</tbody>
</table>

A representative from the European Commission attended the meeting

Meeting run with support from relevant EMA staff
17. Explanatory notes

The notes below give a brief explanation of the main sections and headings in the CHMP agenda and should be read in conjunction with the agenda or the minutes.

**Oral explanations** *(section 2)*

The items listed in this section are those for which marketing authorisation holders (MAHs) or applicants have been invited to the CHMP plenary meeting to address questions raised by the Committee. Oral explanations normally relate to on-going applications (section 3, 4 and 5) or referral procedures (section 10) but can relate to any other issue for which the CHMP would like to discuss with company representatives in person.

**Initial applications** *(section 3)*

This section lists applications for marketing authorisations of new medicines that are to be discussed by the Committee.

Section 3.1 is for medicinal products nearing the end of the evaluation and for which the CHMP is expected to adopt an opinion at this meeting on whether marketing authorisation should be granted. Once adopted, the CHMP opinion will be forwarded to the European Commission for a final legally binding decision valid throughout the EU.

The other items in the section are listed depending on the stage of the evaluation, which is shown graphically below:

The assessment of a new medicine takes up to 210 ‘active’ days. This active evaluation time is interrupted by at least one ‘clock-stop’ during which time the applicant prepares the answers to questions from the CHMP. The clock stop happens after day 120 and may also happen after day 180, when the CHMP has adopted a list of questions or outstanding issues to be addressed by the company. Related discussions are listed in the agenda under sections 3.2 (*Day 180 List of outstanding issues*) and 3.3 (*Day 120 list of questions*).

CHMP discussions may also occur at any other stage of the evaluation, and these are listed under section 3.4, *update on ongoing new applications for centralised procedures*.

The assessment leads to an opinion from the CHMP by day 210. Following a CHMP opinion the European Commission takes usually 67 days to issue a legally binding decision (i.e. by day 277 of the procedure). CHMP discussions on products that have received a CHMP opinion and are awaiting a decision are listed under section 3.6, *products in the decision making phase*.

**Extension of marketing authorisations according to Annex I of Reg. 1234/2008** *(section 4)*

Extensions of marketing authorisations are applications for the change or addition of new strengths,
formulations or routes of administration to existing marketing authorisations. Extension applications follow a 210-day evaluation process, similarly to applications for new medicines (see figure above).

**Type II variations - Extension of indication procedures** *(section 5)*

Type II variations are applications for a change to the marketing authorisation which requires an update of the product information and which is not covered in section 4. Type II variations include applications for a new use of the medicine (extension of indication), for which the assessment takes up to 90 days. For the applications listed in this section, the CHMP may adopt an opinion or request supplementary information from the applicant.

**Ancillary medicinal substances in medical devices** *(section 6)*

Although the EMA does not regulate medical devices it can be asked by the relevant authorities (the so-called Notified Bodies) that are responsible for regulating these devices to give a scientific opinion on a medicinal substance contained in a medical device.

**Re-examination procedures (new applications) under article 9(2) of regulation no 726/2004** *(section 3.5)*

This section lists applications for new marketing authorisation for which the applicant has requested a re-examination of the opinion previously issued by the CHMP.

**Re-examination procedures** *(section 5.3)*

This section lists applications for type II variations (including extension of indication applications) for which the applicant has requested re-examination of the opinion previously issued by the CHMP.

**Withdrawal of application** *(section 3.7)*

Applicants may decide to withdraw applications at any stage during the assessment and a CHMP opinion will therefore not be issued. Withdrawals are included in the agenda for information or discussion, as necessary.

**Procedure under article 83(1) of regulation (EC) 726/2004 (compassionate use)** *(section 7)*

Compassionate use is a way of making available to patients with an unmet medical need a promising medicine which has not yet been authorised (licensed) for their condition. Upon request, the CHMP provides recommendations to all EU Member States on how to administer, distribute and use certain medicines for compassionate use.

**Pre-submission issues** *(section 8)*

In some cases the CHMP may discuss a medicine before a formal application for marketing authorisation is submitted. These cases generally refer to requests for an accelerated assessment for medicines that are of major interest for public health or can be considered a therapeutic innovation. In case of an accelerated assessment the assessment timetable is reduced from 210 to 150 days.

**Post-authorisation issues** *(section 9)*

This section lists other issues concerning authorised medicines that are not covered elsewhere in the agenda. Issues include supply shortages, quality defects, some annual reassessments or renewals or type II variations to marketing authorisations that would require specific discussion at the plenary.

**Referral procedures** *(section 10)*

This section lists referrals that are ongoing or due to be started at the plenary meeting. A referral is a procedure used to resolve issues such as concerns over the safety or benefit-risk balance of a medicine or a class of medicines. In a referral, the EMA is requested to conduct a scientific assessment of a
particular medicine or class of medicines on behalf of the EU. Further information on such procedures can be found here.

**Pharmacovigilance issues (section 11)**

This section lists issues that have been discussed at the previous meeting of the PRAC, the EMA’s committee responsible for evaluating and monitoring safety issues for medicines. Feedback is provided by the PRAC. This section also refers to the early notification system, a system used to notify the European regulatory network on proposed EMA communication on safety of medicines.

**Inspections Issues (section 12)**

This section lists inspections that are undertaken for some medicinal products. Inspections are carried out by regulatory agencies to ensure that marketing authorisation holders comply with their obligations. Inspection can relate to good manufacturing practice (GMP), good clinical practice (GCP), good laboratory practice (GLP) or good pharmacovigilance practice (GVP).

**Innovation task force (section 13)**

The Innovation Task Force (ITF) is a body set up to encourage early dialogue with applicants developing innovative medicines. Minutes from the last ITF meeting as well as any related issue that requires discussion with the CHMP are listed in this section of the agenda. Further information on the ITF can be found here.

**Scientific advice working party (SAWP) (section 14.3.1)**

This section refers to the monthly report from the CHMP’s Scientific Advice Working Party (SAWP) on scientific advice given to companies during the development of medicines. Further general information on SAWP can be found here.

**Satellite groups / other committees (section 14.2)**

This section refers to the reports from groups and committees making decisions relating to human medicines: the Coordination Group for Mutual Recognition and Decentralised Procedures – Human (CMDh), the Committee for Orphan Medicinal Products (COMP), the Committee for Herbal Medicinal Products (HMPC), Paediatric Committee (PDCO), the Committee for Advanced Therapies (CAT) and the Pharmacovigilance Risk Assessment Committee (PRAC).

**Invented name issues (section 14.3)**

This section list issues related to invented names proposed by applicants for new medicines. The CHMP has established the Name Review Group (NRG) to perform reviews of the invented names. The group’s main role is to consider whether the proposed names could create a public-health concern or potential safety risk. Further information can be found here.

More detailed information on the above terms can be found on the EMA website: www.ema.europa.eu/
Annex to July 2017 CHMP Minutes
Pre submission and post authorisations issues

A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS
A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications
A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes
B.1.1. Annual reassessment for products authorised under exceptional circumstances
B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES
B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal
B.2.2. Renewals of Marketing Authorisations for unlimited validity
B.2.3. Renewals of Conditional Marketing Authorisations
B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES
B.4. EPARs / WPARs
B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES
B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects
B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects
B.5.3. CHMP-PRAC assessed procedures
B.5.4. PRAC assessed procedures
B.5.5. CHMP-CAT assessed procedures
B.5.6. CHMP-PRAC-CAT assessed procedures
B.5.7. PRAC assessed ATMP procedures
B.5.8. Unclassified procedures and worksharing procedures of type I variations
B.5.9. Information on withdrawn type II variation / WS procedure
B.5.10. Information on type II variation / WS procedure with revised timetable
B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION
B.6.1. Start of procedure for New Applications: timetables for information
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information
B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information
B.6.4. Annual Re-assessments: timetables for adoption
<table>
<thead>
<tr>
<th>Section</th>
<th>Description</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>B.6.5.</strong></td>
<td>Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed.</td>
</tr>
<tr>
<td><strong>B.6.6.</strong></td>
<td>VARIATIONS – START OF THE PROCEDURE</td>
</tr>
<tr>
<td><strong>B.6.7.</strong></td>
<td>Type II Variations scope of the Variations: Extension of indication</td>
</tr>
<tr>
<td><strong>B.6.8.</strong></td>
<td>CHMP assessed procedures scope: Pharmaceutical aspects</td>
</tr>
<tr>
<td><strong>B.6.9.</strong></td>
<td>CHMP assessed procedures scope: Non-Clinical and Clinical aspects</td>
</tr>
<tr>
<td><strong>B.6.10.</strong></td>
<td>CHMP-PRAC assessed procedures</td>
</tr>
<tr>
<td><strong>B.6.11.</strong></td>
<td>PRAC assessed procedures</td>
</tr>
<tr>
<td><strong>B.6.12.</strong></td>
<td>CHMP-CAT assessed procedures</td>
</tr>
<tr>
<td><strong>B.6.13.</strong></td>
<td>CHMP-PRAC-CAT assessed procedures</td>
</tr>
<tr>
<td><strong>B.6.14.</strong></td>
<td>PRAC assessed ATMP procedures</td>
</tr>
<tr>
<td><strong>B.6.15.</strong></td>
<td>Unclassified procedures and worksharing procedures of type I variations</td>
</tr>
<tr>
<td><strong>B.7.</strong></td>
<td>DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY</td>
</tr>
<tr>
<td><strong>B.7.1.</strong></td>
<td>Yearly Line listing for Type I and II variations</td>
</tr>
<tr>
<td><strong>B.7.2.</strong></td>
<td>Monthly Line listing for Type I variations</td>
</tr>
<tr>
<td><strong>B.7.3.</strong></td>
<td>Opinion on Marketing Authorisation transfer (MMD only)</td>
</tr>
<tr>
<td><strong>B.7.4.</strong></td>
<td>Notifications in accordance with Article 61(3) of Council Directive 2001/83/EC (MMD only)</td>
</tr>
<tr>
<td><strong>B.7.5.</strong></td>
<td>Request for supplementary information relating to Notification of Type I variation (MMD only)</td>
</tr>
<tr>
<td><strong>B.7.6.</strong></td>
<td>Notifications of Type I Variations (MMD only)</td>
</tr>
<tr>
<td><strong>C.</strong></td>
<td>Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)</td>
</tr>
<tr>
<td><strong>D.</strong></td>
<td>Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)</td>
</tr>
<tr>
<td><strong>E.</strong></td>
<td>Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES</td>
</tr>
<tr>
<td><strong>E.1.</strong></td>
<td>PMF Certification Dossiers:</td>
</tr>
<tr>
<td><strong>E.1.1.</strong></td>
<td>Annual Update</td>
</tr>
<tr>
<td><strong>E.1.2.</strong></td>
<td>Variations</td>
</tr>
<tr>
<td><strong>E.1.3.</strong></td>
<td>Initial PMF Certification</td>
</tr>
<tr>
<td><strong>E.2.</strong></td>
<td>Time Tables – starting &amp; ongoing procedures: For information</td>
</tr>
<tr>
<td><strong>F.</strong></td>
<td>ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver</td>
</tr>
<tr>
<td><strong>F.1.</strong></td>
<td>Parallel Distribution - Pursuant to Article 9 of Council Regulation (EC) No. 2743/98 of 14 December 1998, as amended</td>
</tr>
<tr>
<td><strong>F.2.</strong></td>
<td>Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health</td>
</tr>
<tr>
<td><strong>G.</strong></td>
<td>ANNEX G</td>
</tr>
<tr>
<td><strong>G.1.</strong></td>
<td>Final Scientific Advice (Reports and Scientific Advice letters):</td>
</tr>
<tr>
<td><strong>G.2.</strong></td>
<td>Ongoing procedures</td>
</tr>
<tr>
<td><strong>G.3.</strong></td>
<td>PRIME</td>
</tr>
<tr>
<td><strong>G.3.1.</strong></td>
<td>List of procedures concluding at 17-20 July 2017 CHMP plenary:</td>
</tr>
<tr>
<td><strong>G.3.2.</strong></td>
<td>List of procedures starting in July 2017 for August 2017 CHMP adoption of outcomes</td>
</tr>
<tr>
<td><strong>H.</strong></td>
<td>ANNEX H - Product Shared Mailboxes – e-mail address</td>
</tr>
</tbody>
</table>
A. PRE SUBMISSION ISSUES

A.1. ELIGIBILITY REQUESTS

Report on Eligibility to Centralised Procedure for July 2017: For adoption

A.2. Appointment of Rapporteur / Co-Rapporteur Full Applications

Final Outcome of Rapporteurship allocation for July 2017: For adoption

A.3. PRE-SUBMISSION ISSUES FOR INFORMATION

Information related to pre-submission of initial applications cannot be released at the present time as these contain commercially confidential information.

B. POST-AUTHORISATION PROCEDURES OUTCOMES

B.1. Annual re-assessment outcomes

B.1.1. Annual reassessment for products authorised under exceptional circumstances

**Elaprase - idursulfase -**

EMEA/H/C/000700/S/0070

MAH: Shire Human Genetic Therapies AB,

Rapporteur: Greg Markey, PRAC Rapporteur: Patrick Batty

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

The Marketing Authorisation remains under exceptional circumstances.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP opinion.

B.2. RENEWALS OF MARKETING AUTHORISATIONS OUTCOMES

B.2.1. Renewals of Marketing Authorisations requiring 2nd Renewal

B.2.2. Renewals of Marketing Authorisations for unlimited validity

**Amyvid - florbetapir (18F) -**

EMEA/H/C/002422/R/0026

MAH: Eli Lilly Nederland B.V., Rapporteur: Harald Enzmann, Co-Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Valerie Strassmann

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members
<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMA/H/C/Number/R/Number</th>
<th>MAH</th>
<th>Rapporteur</th>
<th>Co-Rapporteur</th>
<th>PRAC Rapporteur</th>
<th>Request for Supplementary Information</th>
<th>Positive Opinion</th>
<th>CHMP Opinion</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Betmiga - mirabegron</strong>&lt;br&gt;EMEA/H/C/002388/R/0026</td>
<td>Astellas Pharma Europe B.V., Rapporteur: Concepcion Prieto Yerro, Co-Rapporteur: Nithyanandan Nagarcoil, PRAC Rapporteur: Dolores Montero Corominas</td>
<td>Request for Supplementary Information adopted on 18.05.2017.</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Bexsero - meningococcal group B vaccine (rDNA, component, adsorbed)</strong>&lt;br&gt;EMEA/H/C/002333/R/0053</td>
<td>GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, Co-Rapporteur: Svein Rune Andersen, PRAC Rapporteur: Qun-Ying Yue</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ibandronic acid Accord - ibandronic acid</strong>&lt;br&gt;EMEA/H/C/002638/R/0013</td>
<td>Accord Healthcare Limited, Generic, Generic of Bondronat, Rapporteur: Alar Irs, PRAC Rapporteur: Doris Stenver</td>
<td>Request for Supplementary Information adopted on 18.05.2017.</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Imatinib Teva - imatinib</strong>&lt;br&gt;EMEA/H/C/002585/R/0028</td>
<td>Teva B.V., Generic, Generic of Glivec, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Lyxumia - lixisenatide</strong>&lt;br&gt;EMEA/H/C/002445/R/0023</td>
<td>sanofi-aventis groupe, Rapporteur: Kristina Dunder, Co-Rapporteur: Bart Van der Schueren, PRAC Rapporteur: Qun-Ying Yue</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Ryzodeg</strong> - insulin degludec / insulin aspart</td>
<td>Positive Opinion adopted by consensus together with the CHMP assessment report.</td>
<td>Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.</td>
<td>The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the renewal of the marketing authorisation can be granted with unlimited validity.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

Positive Opinion adopted by consensus together with the CHMP assessment report.

Based on the review of the available information, the CHMP was of the opinion that the renewal of this conditional Marketing Authorisation can be
The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

**Ninlaro - ixazomib - EMEA/H/C/003844/R/0003, Orphan**

Positive Opinion adopted by consensus together with the CHMP assessment report and translation timetable.

The CHMP was of the opinion that the renewal for this conditional Marketing Authorisation can be granted.

The Marketing Authorisation remains conditional.

The Icelandic and Norwegian CHMP Members were in agreement with the CHMP Opinion.

**Venclyxto - venetoclax - EMEA/H/C/004106/R/0005, Orphan**
MAH: AbbVie Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Patrick Batty


**B.3. POST-AUTHORISATION PHARMACOVIGILANCE OUTCOMES**

**Signal detection**

Noted.

PRAC recommendations on signals adopted at the PRAC meeting held on 3-6 July 2017 PRAC:

**Aranesp - Darbepoetin alfa - EMEA/H/C/000332; MAH: Amgen Europe B.V.; Rapporteur: Martina Weise, Co-Rapporteur: Koenraad Norga, PRAC Rapporteur: Valerie Strassmann,**

Adopted.


**NeoRecormon – Epoetin beta - EMEA/H/C/000116; MAH: Roche Registration Limited; Rapporteur: Martina Weise, Co-Rapporteur: Alexandre Moreau,**

Adopted.
PRAC Rapporteur: Valerie Strassmann,

Biopoin – Epoetin theta -
EMEA/H/C/001036; MAH: TEVA GmbH;
Eporatio – Epoetin theta -
EMEA/H/C/001033; ratiopharm GmbH;
Rapporteur: Alexandre Moreau,
Co-Rapporteur: Martina Weise, PRAC
Rapporteur: Ghania Chamouni,

Retacrit – Epoetin zeta -
EMEA/H/C/000872; MAH: Hospira UK Ltd; &
Silapo – Epoetin zeta -
EMEA/H/C/000760; MAH: STADA Arzneimittel AG;
Rapporteur: Martina Weise, Co-Rapporteur:
Nithyanandan Nagercoil, PRAC Rapporteur:
Valerie Strassmann,

Mircera – Methoxy polyethylene
glycol-epoetin beta - EMEA/H/C/000739;
MAH: Roche Registration Limited; Rapporteur:
Alexandre Moreau, Co-Rapporteur: Martina
Weise, PRAC Rapporteur: Ghania Chamouni,

Signal of severe cutaneous adverse reactions
(SCARs) including Stevens-Johnson syndrome
(SJS) and toxic epidermal necrolysis (TEN) –
PRAC recommendation on a variation, DHPC
letter and Communication plan (DHPC and
Communication plan are being finalised via
written procedure): For adoption

Faslodex - Fulvestrant –
EMEA/H/C/000540; MAH: AstraZeneca UK
Ltd; Rapporteur: Filip Josephson,
Co-Rapporteur: Tuomo Lapveteläinen, PRAC
Rapporteur: Ulla Wändel Liminga,
Signal of anaphylactic reactions: For adoption

Adopted.

PSUR procedures for which PRAC adopted a
recommendation for variation of the terms of
the MA at its July 2017 meeting:

EMEA/H/C/PSUSA/00000425/201611 (bosentan)
CAPS:
Stayveer (EMEA/H/C/002644) (bosentan),
MAH: Marklas Nederlands BV, Rapporteur:
Alexandre Moreau
Tracleer (EMEA/H/C/000401) (bosentan), MAH:
Actelion Registration Limited, Rapporteur:
Alexandre Moreau

The CHMP, having considered in accordance with
Article 28 of Regulation (EC) No 726/2004 and
Article 107g(3) of Directive 2001/83/EC the PSUR
on the basis of the PRAC recommendation and
the PRAC assessment report as appended,
recommends by consensus, the variation to the
terms of the marketing authorisation(s) for the
medicinal products containing the above referred
active substance(s), concerning the following change(s):

Update of section 4.5 of the SmPC to add the interaction between bosentan and tadalafil. In addition, the following interactions which could have clinical relevance and which are already mentioned in bosentan SmPC should be added to the package leaflet: warfarin, simvastatin, ketoconazole and sildenafil.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00001730/201611
(indacaterol)
CAPS:
Hirobriz Breezhaler (EMEA/H/C/001211) (indacaterol), MAH: Novartis Europharm Ltd, Rapporteur: Hanne Lomholt Larsen
Onbrez Breezhaler (EMEA/H/C/001114) (indacaterol), MAH: Novartis Europharm Ltd, Rapporteur: Hanne Lomholt Larsen

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends, the variation to the terms of the marketing authorisations for the above mentioned medicinal products, concerning the following change:

To remove the additional risk minimisation measures, as information in the educational materials for Health Care professionals is sufficiently described in relevant sections of the SmPC and no new safety information has arisen regarding the incorrect use of the products containing indacaterol alone. Consequently Annex II.D and the RMP are updated (RMP Version 10.2 is agreed).

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

EMEA/H/C/PSUSA/00001838/201612
(lenalidomide)
CAPS:

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change:

Update of sections 4.2, 4.4 and 4.8 of the SmPC to introduce dose modifications in case of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS), to add a relevant warning and to include DRESS in the list of adverse reactions with a frequency unknown. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change(s):

Update of section 4.4 and 4.8 of the SmPC to add information on the post marketing cases reported of splenomegaly and splenic rupture.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following changes:

Update of section 4.4 and 4.8 of the SmPC to add serious allergic reactions including anaphylactic reaction with a frequency not known and to add a warning on hypersensitivity reactions. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following changes:

Update of section 4.2 of the SmPC to update the recommendations for dose modifications for neutropenia and thrombocytopenia that are unrelated to leukaemia as well as for pancreatic adverse events. No changes to the package leaflet are required.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisation(s) for the above mentioned medicinal product(s), concerning the following change(s):

Update of section 4.8 of the SmPC to add the adverse reaction rash with a frequency common and hypersensitivity and dermatitis with a frequency uncommon. The Package leaflet is updated accordingly.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus the variation to the terms of the marketing authorisation for the above mentioned medicinal product, concerning the following change:

Update of sections 4.4 and 4.8 of the SmPC to add Vogt-Koyanagi-Harada-Syndrome. The Package leaflet needs no update.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.

The CHMP, having considered in accordance with Article 28 of Regulation (EC) No 726/2004 the PSUR on the basis of the PRAC recommendation and the PRAC assessment report as appended, recommends by consensus, the variation to the terms of the marketing authorisations for the above mentioned medicinal products, concerning the following changes:

Update of section 4.4 of the SmPC to introduce warnings in relation to myelosuppression, renal irradiation and haematological disorders and of section 4.8 of the SmPC to introduce anaemia, thrombocytopenia, leukopenia and lymphopenia as new ADRs with frequency ‘very common’ as well as a description of dry mouth in association with prostate cancer therapy including Lutetium (177Lu)-labelled radioligands.

The Icelandic and the Norwegian CHMP members agree with the above-mentioned recommendation of the CHMP.
recommendation of the CHMP.

EMEA/H/C/PSUSA/00010460/201612  
(blinatumomab)  
CAPS:  
Blinicyto (EMEA/H/C/003731) (blinatumomab),  
MAH: Amgen Europe B.V., Rapporteur:  
Alexandre Moreau, PRAC Rapporteur: Eva  
Jirsová, "24 May 2016 - 02 December 2016"  
The CHMP, having considered in accordance with  
Article 28 of Regulation (EC) No 726/2004 the  
PSUR on the basis of the PRAC recommendation  
and the PRAC assessment report as appended,  
recommends by consensus the variation to the  
terms of the marketing authorisation for the  
above mentioned medicinal product, concerning  
the following change:  
Update of section 4.8 of the SmPC to add Cranial  
nerve disorders with a frequency uncommon  
(≥1/1000 to <1/100). The Package leaflet is  
updated accordingly.  
The Icelandic and the Norwegian CHMP members  
agree with the above-mentioned  
recommendation of the CHMP.

B.4. EPARs / WPARs

Fotivda - tivozanib - EMEA/H/C/004131  
Applicant: EUSA Pharma (UK) Limited, treatment  
of adult patients with advanced renal cell  
carcinoma (RCC), New active substance (Article  
8(3) of Directive No 2001/83/EC)  

Imraldi - adalimumab - EMEA/H/C/004279  
Applicant: Samsung Bioepis UK Limited (SBUK),  
treatment of rheumatoid arthritis, psoriatic  
arthritis and ankylosing spondylitis, Similar  
biological application (Article 10(4) of Directive  
No 2001/83/EC)  

Kisqali - ribociclib - EMEA/H/C/004213  
Applicant: Novartis Europharm Ltd, treatment of  
breast cancer, New active substance (Article 8(3)  
of Directive No 2001/83/EC)  

Mavenclad - cladribine - EMEA/H/C/004230  
Applicant: Merck Serono Europe Limited,  
treatment of highly active relapsing-remitting  
multiple sclerosis (MS), Known active substance  
(Article 8(3) of Directive No 2001/83/EC)  

Maviret - glecaprevir / pibrentasvir -  
EMEA/H/C/004430  
Applicant: AbbVie Limited, indicated for the  
treatment of chronic hepatitis C virus (HCV)  
infection in adults, New active substance (Article  
8(3) of Directive No 2001/83/EC)  

adopted.
<table>
<thead>
<tr>
<th>Application</th>
<th>EMA/H/C/ID</th>
<th>Applicant</th>
<th>Indication</th>
<th>Regulatory Pathway</th>
</tr>
</thead>
<tbody>
<tr>
<td>Nitisinone MendeliKABS - nitisinone</td>
<td>EMA/H/C/004281</td>
<td>MendeliKABS Europe Ltd</td>
<td>Hepatorenal tyrosinemia type 1</td>
<td>Article 10(1) of Directive No 2001/83/EC</td>
</tr>
<tr>
<td>Qinprezo (WD) - vosaroxin - Orphan</td>
<td>EMA/H/C/004118</td>
<td>Sunesis Europe Ltd</td>
<td>Treatment of acute myeloid leukaemia</td>
<td>Article 8(3) of Directive No 2001/83/EC</td>
</tr>
<tr>
<td>Rixathon – rituximab</td>
<td>EMA/H/C/003903</td>
<td>Sandoz GmbH</td>
<td>Treatment of Non-Hodgkin's lymphoma (NHL), Chronic lymphocytic leukaemia (CLL), Rheumatoid arthritis and Granulomatosis with polyangiitis and microscopic polyangiitis</td>
<td>Article 10(4) of Directive No 2001/83/EC</td>
</tr>
<tr>
<td>Riximyo - rituximab</td>
<td>EMA/H/C/004729</td>
<td>Sandoz GmbH</td>
<td>Treatment of Non-Hodgkin's lymphoma (NHL), Rheumatoid arthritis and Granulomatosis with polyangiitis and microscopic polyangiitis</td>
<td>Article 10(4) of Directive No 2001/83/EC</td>
</tr>
<tr>
<td>Vosevi - sofosbuvir / velpatasvir / voxilaprevir</td>
<td>EMA/H/C/004350</td>
<td>Gilead Sciences International Limited</td>
<td>Treatment of chronic hepatitis C virus in adults (HCV) infection in adults</td>
<td>Article 8(3) of Directive No 2001/83/EC</td>
</tr>
</tbody>
</table>

**B.5. TYPE II VARIATION, WORKSHARING PROCEDURE OUTCOMES**

Scopes related to Chemistry, Manufacturing, and Controls cannot be released at the present time as these contain commercially confidential information.

**B.5.1. CHMP assessed procedures scope: Pharmaceutical aspects**

**Advate - octocog alfa -**

- EMEA/H/C/000520/II/0082/G
  - MAH: Baxter AG, Rapporteur: Jan Mueller-Berghaus

- Request for Supplementary Information adopted with a specific timetable.
<table>
<thead>
<tr>
<th>EMEA/H/C/000520/II/0085</th>
<th>with a specific timetable.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAH: Baxter AG, Rapporteur: Jan Mueller-Berghaus</td>
<td></td>
</tr>
</tbody>
</table>

**Afstyla** - lonoctocog alfa -  
**EMEA/H/C/004075/II/0001**  
MAH: CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus  
Request for Supplementary Information adopted with a specific timetable.  

**Alprolix** - eftrenonacog alfa -  
**EMEA/H/C/004142/II/0006/G, Orphan**  
MAH: Swedish Orphan Biovitrum AB (publ), Rapporteur: Andrea Laslop  
Request for Supplementary Information adopted on 09.06.2017.  
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  

**Ciambra** - pemetrexed -  
**EMEA/H/C/003788/II/0002/G**  
MAH: Menarini International Operations Luxembourg S.A., Generic, Generic of Alimta, Rapporteur: Juris Pokrotnieks  
Request for Supplementary Information adopted on 06.04.2017.  
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  

**Cimzia** - certolizumab pegol -  
**EMEA/H/C/001037/II/0061/G**  
MAH: UCB Pharma S.A., Rapporteur: Kristina Dunder  
Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  

**Cosentyx** - secukinumab -  
**EMEA/H/C/003729/II/0024**  
MAH: Novartis Europharm Ltd, Rapporteur: Tuomo Lapveteläinen  
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  

**Elonva** - corifollitropin alfa -  
**EMEA/H/C/001106/II/0036/G**  
MAH: Merck Sharp & Dohme Limited, Rapporteur: Paula Boudewina van Henrikk  
Request for Supplementary Information adopted on 09.06.2017.  
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.  

**Envarsus** - tacrolimus -  
**EMEA/H/C/002655/II/0008/G**  
MAH: Chiesi Farmaceutici S.p.A., Rapporteur: John Joseph Borg  
Request for Supplementary Information adopted with a specific timetable.  

---

Annex to July 2017 CHMP Minutes  
EMA/CHMP/628544/2017  
Page 13/85
<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA Code</th>
<th>MAH</th>
<th>Rapporteur</th>
<th>Opinion Date</th>
<th>Recommendation Details</th>
</tr>
</thead>
<tbody>
<tr>
<td>Fabrazyme - agalsidase beta</td>
<td>EMEA/H/C/000370/II/0099/G</td>
<td>Genzyme Europe BV</td>
<td>Johann Lodewijk Hillege</td>
<td>06.07.2017</td>
<td>Positive Opinions were agreed with the CHMP recommendation.</td>
</tr>
<tr>
<td>Gardasil 9 - human papillomavirus vaccine</td>
<td>EMEA/H/C/003852/II/0019/G</td>
<td>MSD Vaccins</td>
<td>Kristina Dunder</td>
<td>13.07.2017</td>
<td>Positive Opinions were agreed with the CHMP recommendation.</td>
</tr>
<tr>
<td>Inflectra - infliximab</td>
<td>EMEA/H/C/002778/II/0050/G</td>
<td>Hospira UK Limited</td>
<td>Greg Markey</td>
<td>29.06.2017</td>
<td>Positive Opinions were agreed with the CHMP recommendation.</td>
</tr>
<tr>
<td>Jakavi - ruxolitinib</td>
<td>EMEA/H/C/002464/II/0034</td>
<td>Novartis Europharm Ltd</td>
<td>Filip Josephson</td>
<td>13.07.2017</td>
<td>Positive Opinions were agreed with the CHMP recommendation.</td>
</tr>
<tr>
<td>Kadcyla - trastuzumab emtansine</td>
<td>EMEA/H/C/002389/II/0034</td>
<td>Roche Registration Limited</td>
<td>Sinan B. Sarac</td>
<td>29.06.2017</td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
</tr>
<tr>
<td>Keytruda - pembrolizumab</td>
<td>EMEA/H/C/003820/II/0026/G</td>
<td>Merck Sharp &amp; Dohme Limited</td>
<td>Daniela Melchiorri</td>
<td>13.07.2017</td>
<td>Positive Opinions were agreed with the CHMP recommendation.</td>
</tr>
<tr>
<td>Keytruda - pembrolizumab</td>
<td>EMEA/H/C/003820/II/0030</td>
<td>Merck Sharp &amp; Dohme Limited</td>
<td>Daniela Melchiorri</td>
<td>01.06.2017</td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
</tr>
<tr>
<td>---------------------------------------------------------------</td>
<td>-------------------------------------------------------------</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Keytruda - pembrolizumab - EMEA/H/C/003820/II/0031/G</strong></td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Memantine ratiopharm - memantine - EMEA/H/C/002671/II/0008</strong></td>
<td>Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Myozyme - alglucosidase alfa - EMEA/H/C/000636/II/0063/G</strong></td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Pemetrexed Fresenius Kabi - pemetrexed - EMEA/H/C/003895/II/0002</strong></td>
<td>Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Perjeta - pertuzumab - EMEA/H/C/002547/II/0030</strong></td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Plavix - clopidogrel - EMEA/H/C/000174/II/0127/G</strong></td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Praluent - alirocumab - EMEA/H/C/003882/II/0024/G</strong></td>
<td>Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Privigen - human normal immunoglobulin</strong></td>
<td>Positive Opinion adopted by consensus on</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Product Code</td>
<td>MAH</td>
<td>Rapporteur</td>
<td>Opinion Date</td>
<td>CHMP Recommendation</td>
<td></td>
</tr>
<tr>
<td>--------------</td>
<td>-----</td>
<td>------------</td>
<td>--------------</td>
<td>---------------------</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/000831/II/0118</td>
<td>CSL Behring GmbH</td>
<td>Jan Mueller-Berghaus</td>
<td>06.07.2017</td>
<td>Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/000825/II/0053/G</td>
<td>ratiopharm GmbH</td>
<td>Outi Mäki-Ikola</td>
<td>06.07.2017</td>
<td>Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/000240/II/0205</td>
<td>Janssen Biologics B.V.</td>
<td>Kristina Dunder</td>
<td>06.07.2017</td>
<td>Request for Supplementary Information adopted on 05.05.2017.</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/000831/II/0118</td>
<td>CSL Behring GmbH</td>
<td>Jan Mueller-Berghaus</td>
<td>06.07.2017</td>
<td>Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
<td></td>
</tr>
<tr>
<td>EMEA/H/C/000240/II/0205</td>
<td>Janssen Biologics B.V.</td>
<td>Kristina Dunder</td>
<td>06.07.2017</td>
<td>Request for Supplementary Information adopted on 05.05.2017.</td>
<td></td>
</tr>
</tbody>
</table>
### EMEA/H/C/002647/II/0019
MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder
Request for Supplementary Information adopted on 01.06.2017.
20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### Yervoy - ipilimumab -
EMEA/H/C/002213/II/0048/G
MAH: Bristol-Myers Squibb Pharma EIEI, Rapporteur: Paula Boudewina van Henrik
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1143
Aflunov-EMEA/H/C/002094/WS1143/003
Foclivia-EMEA/H/C/001208/WS1143/0028
MAH: Seqirus S.r.l, Lead Rapporteur: Daniela Melchiorri
Request for Supplementary Information adopted on 15.06.2017, 05.05.2017.
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1159
Neulasta-EMEA/H/C/000420/WS1159/0095
Ristempa-EMEA/H/C/003910/WS1159/0011
MAH: Amgen Europe B.V., Lead Rapporteur: Robert James Hemmings
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### WS1186/G
Fertavid-EMEA/H/C/001042/WS1186/0036/G
Puregon-EMEA/H/C/000086/WS1186/0094/G
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Nithyanandan Nagercoil
Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

### B.5.2. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

### Arzerra - ofatumumab -
EMEA/H/C/001131/II/0050, Orphan
MAH: Novartis Europharm Ltd, Rapporteur: Sinan B. Sarac, "Update of sections 4.2, 4.4 and 4.8 of the SmPC in order to add a recommendation to permanently discontinue Arzerra in case of anaphylactic reaction and revise the adverse drug reaction profile based on cumulative safety
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
pool data analysis from clinical trials, the company safety database and updated company core data sheet.
The Package Leaflet is updated accordingly.“
Request for Supplementary Information adopted on 15.06.2017.

**Arzerra - ofatumumab -**
**EMEA/H/C/001131/II/0051, Orphan**
MAH: Novartis Europharm Ltd, Rapporteur: Sinan B. Sarac, "Update to sections 4.6 and 5.3 of the SmPC based on a cumulative review of data from completed non-clinical safety studies, cases reported in the pharmacovigilance database related to pregnancy and foetal exposure while receiving ofatumumab therapy.

Update to the section 4.5 of the SmPC based on results from clinical study OMB11360 investigating pharmacokinetic interactions between ofatumumab and bendamustine.

Updates to sections 4.2, 5.1 and 5.2 of the SmPC were made to simplify them and ease their understanding. Editorial updates were made to sections 4.4 and 4.8.

Furthermore, the MAH took the opportunity to combine the SmPCs of the different strengths (100 mg and 1000 mg concentrate for solution for infusion), to introduce editorial changes and to bring the PI in line with the latest QRD template version 10. In addition, the list of local representatives in the Package Leaflet has been updated.”
Request for Supplementary Information adopted on 15.06.2017.

**Bexsero - meningococcal group B vaccine (rDNA, component, adsorbed) -**
**EMEA/H/C/002333/II/0054**
MAH: GSK Vaccines S.r.l, Rapporteur: Kristina Dunder, "Update of section 4.8 of the SmPC in order to add the adverse reactions “injection site reactions (including extensive swelling of the vaccinated limb)” and “injection site nodule which may persist for more than one month” with a frequency not known. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to bring the product information in line with the latest QRD template version

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Table of Contents

Blincyto - blinatumomab - EMEA/H/C/003731/II/0009, Orphan
MAH: Amgen Europe B.V., Rapporteur: Alexandre Moreau, “Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to update the safety information with the data from the study 103311. This study is fulfilling the specific obligation for the conditional MA. The SO is removed from annex II. The Package Leaflet is updated accordingly. The MAH takes this opportunity to amend the format of the preparation instructions to improve clarity. The content is not impacted.” Request for Supplementary Information adopted on 20.07.2017, 26.01.2017.

Cosentyx - secukinumab - EMEA/H/C/003729/II/0020
MAH: Novartis Europharm Ltd, Rapporteur: Tuomo Lapveteläinen, “Update of section 4.5 of the SmPC in order to revise general information on CYP450/CYP3A4 as a result of data provided by the clinical drug-drug interaction study A2110.” Opinion adopted on 20.07.2017. Request for Supplementary Information adopted on 01.06.2017.

Cyanokit - hydroxocobalamin - EMEA/H/C/000806/II/0031
MAH: SERB SA, Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on renal disorders and to update the safety information on skin and subcutaneous tissue disorders, renal and urinary disorders following a safety signal on renal disorders and based on a safety review including review of clinical data, preclinical data, literature and cumulative review of renal disorders cases occurring after hydroxocobalamin administration. The package leaflet is updated accordingly.” Opinion adopted on 20.07.2017. Request for Supplementary Information adopted on 18.05.2017.

Dacogen - decitabine - EMEA/H/C/002221/II/0031, Orphan
MAH: Janssen-Cilag International N.V., Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information with the data from the study 103311. This study is fulfilling the specific obligation for the conditional MA. The SO is removed from annex II. The Package Leaflet is updated accordingly. The MAH takes this opportunity to amend the format of the preparation instructions to improve clarity. The content is not impacted.” Request for Supplementary Information adopted on 20.07.2017, 26.01.2017.

Cosentyx - secukinumab - EMEA/H/C/003729/II/0020
MAH: Novartis Europharm Ltd, Rapporteur: Tuomo Lapveteläinen, “Update of section 4.5 of the SmPC in order to revise general information on CYP450/CYP3A4 as a result of data provided by the clinical drug-drug interaction study A2110.” Opinion adopted on 20.07.2017. Request for Supplementary Information adopted on 01.06.2017.

Cyanokit - hydroxocobalamin - EMEA/H/C/000806/II/0031
MAH: SERB SA, Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on renal disorders and to update the safety information on skin and subcutaneous tissue disorders, renal and urinary disorders following a safety signal on renal disorders and based on a safety review including review of clinical data, preclinical data, literature and cumulative review of renal disorders cases occurring after hydroxocobalamin administration. The package leaflet is updated accordingly.” Opinion adopted on 20.07.2017. Request for Supplementary Information adopted on 18.05.2017.

Dacogen - decitabine - EMEA/H/C/002221/II/0031, Orphan
MAH: Janssen-Cilag International N.V., Rapporteur: Alexandre Moreau, “Update of sections 4.4 and 4.8 of the SmPC in order to update the safety information with the data from the study 103311. This study is fulfilling the specific obligation for the conditional MA. The SO is removed from annex II. The Package Leaflet is updated accordingly. The MAH takes this opportunity to amend the format of the preparation instructions to improve clarity. The content is not impacted.” Request for Supplementary Information adopted on 20.07.2017, 26.01.2017.
section 6.6. of the SmPC in order to update the reconstitution procedure by narrowing the concentration range of the diluted solution of Dacogen from '0.1 mg/ml-1.0 mg/ml' to '0.15 mg/ml-1.0 mg/ml' due to an update of Chapter 5.1.10 'Guidelines for using the test for bacterial endotoxins' in edition 8.8 of the European Pharmacopoeia.“

**Edurant - rilpivirine - EMEA/H/C/002264/II/0025**

MAH: Janssen-Cilag International NV,
Rapporteur: Johann Lodewijk Hillege, “Update of section 4.5 of the SmPC in order to include Pharmacokinetics data of drug-drug interactions between simeprevir and rilpivirine, based on final result from study TMC435-TiDP16-C114; this is a Phase I, 2-panel, open-label, randomized, cross-over study in healthy subjects to investigate the potential drug-drug interaction between simeprevir and RPV.

In addition, the drug-drug interaction information for telaprevir is removed from the SmPC as this product is no longer available since its marketing authorization was not renewed.

The Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.”
Request for Supplementary Information adopted on 11.05.2017.

**Elonva - corifollitropin alfa - EMEA/H/C/001106/II/0034**

MAH: Merck Sharp & Dohme Limited,
Rapporteur: Paula Boudewina van Hennik,
"Update of section 4.5 of the SmPC to add information pertaining to potential hCG cross-reactivity resulting in a false positive pregnancy test.
In addition, the MAH is taking the opportunity to implement changes in the annexes in line with the QRD templates (versions 9.1 and 10) and to propose combined versions of the SmPCs and Package Leaflets for the different strengths.”

**Emend - aprepitant - EMEA/H/C/000527/II/0055**

Request for Supplementary Information adopted with a specific timetable.
| **MAH:** Merck Sharp & Dohme Limited,  
**Rapporteur:** Filip Josephson,  
"Update of sections 4.2 of the SmPC in order to replace the nomogram for the paediatric formulation provided in ml/kg with purely weight-based dosing instructions (in mg/kg) This is based on data that were already submitted as part of the paediatric application X/49. The Package Leaflet is updated accordingly.  
In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0.”  
| Empliciti - elotuzumab -  
**EMEA/H/C/003967/II/0006**  
**MAH:** Bristol-Myers Squibb Pharma EEIG,  
**Rapporteur:** Paula Boudewina van Hennik,  
"Update of section 5.2 of the SmPC to update the volume of distribution and elimination of elotuzumab based on an updated analysis of study HuLuc63-1701.”  
| Esbriet - pirfenidone -  
**EMEA/H/C/002154/II/0043, Orphan**  
**MAH:** Roche Registration Limited,  
**Rapporteur:** Greg Markey,  
"Update of sections 4.2 and 5.2 of the SmPC in order to update the existing safety information with revised recommendations for patients with moderate renal impairment based on the totality of data from clinical studies; the Package Leaflet is updated accordingly.”  
Request for Supplementary Information adopted on 29.06.2017. |
| Forsteo - teriparatide -  
**EMEA/H/C/000425/II/0046**  
**MAH:** Eli Lilly Nederland B.V.,  
**Rapporteur:** Greg Markey,  
"Update of section 5.1 of the SmPC of the SmPC based on the results of study B3D-EW-GHDW (VERO), a phase 4 multi-centre, prospective, randomized, parallel, double-blind, double-dummy, active controlled study comparing the effect of teriparatide for injection versus risendronate on the incidence of fractures and low bone mass. In addition, the Marketing authorisation holder (MAH) took the opportunity to correct the formatting throughout the Product Information and to bring Annex II in line with the latest QRD template version 10.”  
Request for Supplementary Information adopted with a specific timetable. |
|----------|---------------------------------------------------------|
| **Galafold - migalastat -**  
EMEA/H/C/004059/II/0010, Orphan  
MAH: Amicus Therapeutics UK Ltd, Rapporteur: Johann Lodewijk Hillege, "Submission of the final report from study AT1001-041: A phase 3 open label extension study to assess the safety and efficacy of 150 mg migalastat HCl QOD in subjects with Fabry disease who have completed Studies AT1001-011, AT1001-012 or FAB-CL-205, listed as a category 3 study in the RMP."  
Request for Supplementary Information adopted with a specific timetable. |
| **Giotrif - afatinib -**  
EMEA/H/C/002280/II/0023  
MAH: Boehringer Ingelheim International GmbH, Rapporteur: Filip Josephson, “Update of section 4.8 of the SmPC in order to add the adverse reaction nail disorders with a frequency common based on the results of study 1200.131 and supportive evidence from EGFR TKJ comparator studies. The package leaflet is updated accordingly. In addition, the MAH took the opportunity to make some editorial changes to the polish product information.”  
Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. |
| **Harvoni - ledipasvir / sofosbuvir -**  
EMEA/H/C/003850/II/0053  
MAH: Gilead Sciences International Limited, Rapporteur: Filip Josephson, “Update of section 4.5 of the SmPC in order to revise information related to the Cytochrome P450 3A (CYP3A) mediated drug-drug interaction potential of ledipasvir based on final results from study GS-US-337-1887, listed as a category 3 study in the RMP”  
Request for Supplementary Information adopted with a specific timetable. |
| **Hetlioz - tasimelteon -**  
EMEA/H/C/003870/II/0008, Orphan  
MAH: Vanda Pharmaceuticals Ltd., Rapporteur: Greg Markey, "Update of sections 4.4, 4.5 of the SmPC, based on in vitro studies and pooled analyses from clinical studies, with cautionary statements regarding the coadministration of Hetlioz with strong CYP1A2 inhibitors and removal, from the Risk Management Plan (RMP),”  
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation. |
of the commitment to conduct a human CYP2C19 Drug-Drug Interaction Study to evaluate the single-dose pharmacokinetics of tasimelteon 20 mg alone and in combination with a CYP2C19 inhibitor, omeprazole, at steady-state. Section 5.2 is also updated with data of the pooled analyses of the clinical studies and the in vitro studies.”

Request for Supplementary Information adopted on 06.04.2017.

Humira - adalimumab -
EMEA/H/C/000481/II/0168
MAH: AbbVie Limited, Rapporteur: Kristina Dunder, “Update of section 5.1 of the SmPC in order to update information on the long-term safety, tolerability, and efficacy of adalimumab in subjects with moderate to severe hidradenitis suppurativa after finalisation of phase III open-label extension study M12-555.”
Request for Supplementary Information adopted on 15.06.2017.

Humira - adalimumab -
EMEA/H/C/000481/II/0169
MAH: AbbVie Limited, Rapporteur: Kristina Dunder, "Update of section 5.1 of the SmPC in order to update the clinical data section based on interim data from the OLE Study M11-327 in non-infectious uveitis (A Multicenter Open-Label Study of the Long-term Safety and Efficacy of the Human Anti-TNF Monoclonal Antibody Adalimumab in Subjects with Non-infectious Intermediate, Posterior, or Panuveitis)"

Imnovid - pomalidomide -
EMEA/H/C/002682/II/0025, Orphan
MAH: Celgene Europe Limited, Rapporteur: Robert James Hemmings, "Submission of a biomarker analysis report following a recommendation from CHMP in MAA procedure (EMEA/H/C/2682/0000) to present the biomarker analysis report based on clinical studies CC-4047-MM-008 and CC-4047-MM-010."
Request for Supplementary Information adopted on 06.07.2017.

Intelease - etravirine -
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Request for Supplementary Information adopted with a specific timetable.
**EMEA/H/C/000900/II/0050**

MAH: Janssen-Cilag International NV, Rapporteur: Joseph Emmerich, "Update of sections 4.3, 4.4 and 4.5 of the SmPC to include additions to the drug-drug interaction (DDI) information of etravirine with hepatitis C virus (HCV) direct-acting antivirals (DAAs) elbasvir/grazoprevir, daclastavir and simeprevir and human immunodeficiency virus (HIV) protease inhibitors (PIs) atazanavir/cobicistat and darunavir/cobicistat, following the same changes in medicinal products containing these active substances. Section 4.9 of the SmPC is also updated with regard to treatment of etravirine overdose. In addition, the Marketing Authorisation Holder (MAH) took the opportunity to introduce minor editorial changes, to align the PL with SmPC regarding co-administration of etravirine with anti-HIV medicines efavirenz, nevirapine, rilpivirine, indinavir, nelfinavir, to update the list of local representative for the Netherlands in the PL and to align the PI with the latest the QRD template (version 10.0)."


**Invega - paliperidone -**

**EMEA/H/C/000746/II/0056/G**

MAH: Janssen-Cilag International NV, Rapporteur: Kristina Dunder, "Update of section 4.2 and 4.9 of the SmPC in order to add 3 mg every other day dosing for patients with moderate and severe renal impairment and to delete the recommendation for gastric lavage in accordance with current best practices for management of overdose, respectively. Furthermore, the MAH is proposing the deletion of the Invega1.5 mg strength (all presentations) which has never been marketed in the EU. In addition, the details of the local representatives for Latvia, the Netherlands, Estonia and Lithuania are updated in the PL. The Company also proposes to combine the SmPCs for the different Invega strengths (3mg, 6mg, 9mg, 12mg) and to align the package leaflet to the latest QRD template (version 10.0)."


**Kadcyla - trastuzumab emtansine -**

**EMEA/H/C/002389/II/0033**

MAH: Roche Registration Limited, Rapporteur: Sinan B. Sarac, "Submission of the final clinical study results from study TDM4788g/ BO22589 Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
(MARIANNE) listed as a specific obligation in Annex II.D; this is an interventional randomised, 3-arm, phase III study to evaluate the efficacy and safety of trastuzumab emtansine combined with pertuzumab, or trastuzumab emtansine combined with pertuzumab-placebo versus trastuzumab plus taxane, as first line treatment in HER2-positive progressive or recurrent locally advanced breast cancer or previously untreated metastatic breast cancer.

As a result of this submission, Annex II of the product information is affected.”

**Lenvima - lenvatinib -**  
**EMEA/H/C/003727/II/0008, Orphan**  

**Norvir - ritonavir -**  
**EMEA/H/C/000127/II/0146**  
MAH: AbbVie Limited, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.6 of the SmPC in order to update the safety information on pregnancy and lactation based on the company’s core data sheet information.”  
Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Norvir - ritonavir -**  
**EMEA/H/C/000127/II/0147**  
MAH: AbbVie Limited, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.3 and 4.5 of the SmPC in order to add a contraindication regarding the interaction between ritonavir and venetoclax based on the company’s core data sheet. The Package Leaflet is updated accordingly to also include some minor editorial updates.”  
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Ofev - nintedanib -**  
**EMEA/H/C/003821/II/0016, Orphan**  
MAH: Boehringer Ingelheim International GmbH, Rapporteur: David Lyons, “Update of section 4.4 of the SmPC to amend the current warning on the hepatic function to include low body weight, Asian origin, female sex and age as factors of increased risk of liver enzymes elevations, update of section 4.8 of the SmPC to revised the

Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
frequency of the ADR 'drug-induced liver injury' (DILI) from 'not known' to 'uncommon' and update of section 5.2 of the SmPC to amend the current information related to the mean exposure to nintedanib by race, based on a review of clinical trials and post-marketing data on DILI and on the exposure safety relationship between nintedanib plasma exposure and liver enzyme elevations. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to make a small correction in section 5.2 of the SmPC.”


<table>
<thead>
<tr>
<th>Pradaxa - dabigatran etexilate - EMEA/H/C/000829/II/0103</th>
<th>Request for Supplementary Information adopted with a specific timetable.</th>
</tr>
</thead>
</table>

<table>
<thead>
<tr>
<th>Pyramax - pyronaridine / artesunate - EMEA/H/W/002319/II/0015</th>
<th>Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</th>
</tr>
</thead>
<tbody>
<tr>
<td>MAH: Shin Poong Pharmaceutical Co., Ltd., Rapporteur: Joseph Emmerich, “Update of sections 4.8 and 5.1 of the SmPC in order to reflect the main efficacy and safety results from the final report from study SP-C-013-11 listed as a category 3 study in the RMP. This is a phase IIIb/IV comparative, randomised, multi-centre, open label, parallel 3-arm clinical study to assess the safety and efficacy of repeated administration of pyronaridine-artesunate, dihydroartemisinin-piperaquine or artemether-lumefantrine or artesunate-amodiaquine over a 2-year period in children and adult patients with acute uncomplicated Plasmodium sp. malaria. In addition, the SOH took the opportunity to make some editorial changes to the product information.” Opinion adopted on 13.07.2017. Request for Supplementary Information adopted</td>
<td></td>
</tr>
</tbody>
</table>
Selinco - nalmefene -
EMEA/H/C/002583/II/0020/G
MAH: H. Lundbeck A/S, Rapporteur: Harald
Enzmann, "Update of section 4.7 of the SmPC to
add new information regarding effects on ability
to drive and use machines, based on clinical
study and post-marketing data.
Update of section 4.8 of the SmPC in order to add
the adverse drug reaction "diarrhoea" with
frequency "common", based on clinical study and
post-marketing data.
The Package Leaflet is updated accordingly.
In addition, the Marketing authorisation holder
(MAH) took the opportunity to update the list of
local representatives in the Package Leaflet."
Request for Supplementary Information adopted
on 01.06.2017.
Positive Opinion adopted by consensus on
06.07.2017. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

Sirturo - bedaquiline -
EMEA/H/C/002614/II/0021, Orphan
MAH: Janssen-Cilag International NV,
Rapporteur: Filip Josephson, "Update of section
4.4 of the SmPC in order to add delamanid as an
example of a drug that prolongs the QT interval
following the review of the global safety database
for all serious cases received from 28 December
2012 to 30 September 2016.
The Package Leaflet is updated accordingly.
In addition, the Marketing authorisation holder
(MAH) took the opportunity to update the list of
local representatives in the Package Leaflet."
Opinion adopted on 29.06.2017.
Request for Supplementary Information adopted
on 18.05.2017, 06.04.2017.
Positive Opinion adopted by consensus on
29.06.2017. The Icelandic and Norwegian CHMP
Members were in agreement with the CHMP
recommendation.

Tafinlar - dabrafenib -
EMEA/H/C/002604/II/0024
MAH: Novartis Europharm Ltd, Rapporteur: Filip
Josephson, "Update of section 4.5 of the SmPC in
order to include some warning on a drug-drug
interaction between dabrafenib and rifampicin (a
CYP3A4/CYP2C8 inducer) and between
dabrafenib and rabeprazole (a pH elevating
agent), based on the final results of study
200072, a phase I open-label fixed sequence
study to evaluate the effects of potent CYP3A4
inducer (rifampicin) and of a pH elevating agent
(rabeprazole) on the repeat dose
pharmacokinetics of dabrafenib in subjects with
BRAFV60 mutation positive tumours, to fulfil MEA 005."

**Tagrisso - osimertinib -**  
**EMEA/H/C/004124/II/0014/G**  
MAH: AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, "Update of section 5.3 of the SmPC to include information regarding CNS distribution based on non-clinical data."

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Tagrisso - osimertinib -**  
**EMEA/H/C/004124/II/0015**  
MAH: AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, "Update of section 5.2 of the SmPC to include data from studies performed to investigate human plasma protein binding (Study No. BS001265-53-AZD9291), the assessment of non-specific incubational binding in transporter inhibition assays (Study No. BS000760-92) and the implications on transporter DDI risk assessment. In addition, the MAH took the opportunity to implement minor updates and editorial changes in the SmPC and to update the address of the MAH and manufacturer in SmPC section 7, the labelling and the Package Leaflet."

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Tarceva - erlotinib -**  
**EMEA/H/C/000618/II/0052**  
MAH: Roche Registration Limited, Rapporteur: Sinan B. Sarac, "Update of section 4.4 of the SmPC in order to include recommendations on Epidermal Growth Factor Receptor (EGFR) mutation status testing, to be in line with current technical and scientific progress. In addition, the Marketing authorisation holder (MAH) took the opportunity to make minor editorial changes and to bring the PI in line with the latest QRD template version 10. Moreover, the MAH took the opportunity to make minor correction of section 4.2 of the SmPC. Furthermore, the Annex II has been corrected, as requested by the EMA, to include Educational Material as an additional risk minimisation measure, which has been already in place in the RMP."

Request for Supplementary Information adopted with a specific timetable.

**Torisel - temsirolimus -**  
**EMEA/H/C/000799/II/0066, Orphan**  
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP
MAH: Pfizer Limited, Rapporteur: Harald Enzmann, "Submission of the further analysis of a possible association of corticosteroid (pre-)treatment and frequency and severity of hypersensitivity/infusion reactions in study 3066K1-4438-WW (B1771007), as requested by the CHMP during procedures EMEA/H/C/799/MEA 023.1 and EMEA/H/C/799/MEA 024.1."


Request for Supplementary Information adopted on 16.03.2017.

Members were in agreement with the CHMP recommendation.

---

**Victrelis - boceprevir - EMEA/H/C/002332/II/0042**

MAH: Merck Sharp & Dohme Limited, Rapporteur: Joseph Emmerich, "Update of section 4.4 of the SmPC to add a warning regarding HBV reactivation observed in patients with HCV/HBV co-infection treated with some direct-acting antivirals not given in combination with peginterferon alfa and ribavirin. The Package Leaflet is updated accordingly.

In addition, the MAH took the opportunity to implement minor editorial updates in the Product Information."

Opinion adopted on 29.06.2017.

Positive Opinion adopted by consensus on 29.06.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

---

**Xarelto - rivaroxaban - EMEA/H/C/000944/II/0050**

MAH: Bayer AG, Rapporteur: Kristina Dunder, "Update of sections 4.2, 4.4 and 5.1 of the Summary of Product Characteristics (SmPC) to reflect information on posology in patients with non valvular atrial fibrillation and information on safety and efficacy in patients who undergo PCI (percutaneous coronary intervention) with stent placement based on the final results of study 16523 (PIONEER AF-PCI): An Open-label, Randomized, Controlled, Multicenter Study Exploring Two Treatment Strategies of Rivaroxaban and a Dose-Adjusted Oral Vitamin K Antagonist Treatment Strategy in Subjects With Atrial Fibrillation Who Undergo Percutaneous Coronary Intervention. The package Leaflet is updated accordingly.

In addition, the marketing authorisation holder took the opportunity to update the telephone number of local representatives for UK in the Package Leaflet. Correction was also made in Annex IIIA to remove the recording of blood type in the patient alert card."


Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Xeplion - paliperidone -**
**EMEA/H/C/002105/II/0035**
MAH: Janssen-Cilag International NV,  
Rapporteur: Kristina Dunder, "Update of section 4.2 of the SmPC in order to add a dosage conversion table to provide guidance for healthcare professionals when switching patients from paliperidone ER tablets to paliperidone palmitate long acting injection (PP1M). The Package Leaflet is updated accordingly."

---

**WS1092**
**Ebymect-EMEA/H/C/004162/WS1092/0017**
**Edistride-EMEA/H/C/004161/WS1092/0013**
**Forxiga-EMEA/H/C/002322/WS1092/0032**
**Xigduo-EMEA/H/C/002672/WS1092/0028**
MAH: AstraZeneca AB, Lead Rapporteur: Kristina Dunder, "Update of sections 4.4 and 5.1 of the SmPC in order to reflect the results of the Phase 3 study D5553C00003: 28-week safety and efficacy, randomised, double-blind comparison of simultaneous administration of exenatide once weekly 2 mg an dapagliflozin once daily 10 mg to exenatide once weekly 2 mg alone and dapagliflozin once daily 10 mg alone in patients with type 2 diabetes with inadequate glycaemic control on metformin.

The Package Leaflet is updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflets for Ebymect and Edistride and to introduce minor editorial changes throughout the Product Informations."

---

**WS1136**
**Descovy-EMEA/H/C/004094/WS1136/0017**
**Genvoya-EMEA/H/C/004042/WS1136/0031**
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Odefsey-EMEA/H/C/004156/WS1136/001

MAH: Gilead Sciences International Limited, Lead Rapporteur: Robert James Hemmings, "Update of sections 4.4, 4.8, 5.1 and 5.2 of the SmPC in order to provide 48 weeks data from Study GS-US-292-1249; this is a Phase 3b open-label study of the efficacy and safety of elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide single-tablet regimen in HIV-1/Hepatitis B co-infected adults. The Package Leaflet is updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to make minor administrative changes in the SmPC and the Package Leaflet."


Request for Supplementary Information adopted on 05.05.2017.

WS1144/G

Afinitor-EMEA/H/C/001038/WS1144/005 G

Votubia-EMEA/H/C/002311/WS1144/004 G

MAH: Novartis Europharm Ltd, Lead Rapporteur: Harald Enzmann, "Update of sections 4.4 and 5.1 of the SmPC in order to include new safety information on stomatitis and its management based on final results from study CRAD001JUS226: a phase II, single arm study of the use of steroid-based mouthwash to prevent stomatitis in postmenopausal women with advanced or metastatic hormone receptor positive breast cancer being treated with everolimus plus exemestane

Update of section 4.6 of the SmPC in order to add new information on breast-feeding based on pre-clinical data.

The Package Leaflets were updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to bring the Afinitor PI in line with the latest QRD template version 10."

Opinion adopted on 29.06.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Request for Supplementary Information adopted with a specific timetable.
Edistride-EMEA/H/C/004161/WS1167/0016
Forxiga-EMEA/H/C/002322/WS1167/0036
Xigduo-EMEA/H/C/002672/WS1167/0032

MAH: AstraZeneca AB, Lead Rapporteur: Kristina Dunder, "Update of sections 4.8 and 5.1 of the SmPC in order to add information regarding two initial combination studies (MB102021 and MB102034) in treatment-naïve patients of dapagliflozin 5 mg + metformin and dapagliflozin 10 mg + metformin, respectively, compared to each component separately.
In addition, the Worksharing applicant (WSA) took the opportunity to bring the PI in line with the latest QRD template version 10.”

WS1178
Aluvia-EMEA/H/W/000764/WS1178/0102
Kaletra-EMEA/H/C/000368/WS1178/0164

MAH: AbbVie Limited, Lead Rapporteur: Joseph Emmerich, “Update of sections 4.3 and 4.5 of the SmPC in order to add new contraindications and interaction information of lopinavir/ritonavir with venetoclax, with elbasvir/grazoprevir and with ombitasvir/paritaprevir/ritonavir with or without dasabuvir based on the company’s core data sheet; the package Leaflet is updated accordingly. In addition, the MAH/SOH is taking the opportunity to update section 4.5 of the SmPC to reflect information already contained in section 4.3 for drug-drug interactions with astemizole, terfenadine, pimozide, ergot alkaloids and cisapride.”

WS1179
Invega-EMEA/H/C/000746/WS1179/0055
Trevicta-EMEA/H/C/004066/WS1179/0010
Xeplion-EMEA/H/C/002105/WS1179/0034

MAH: Janssen-Cilag International NV, Lead Rapporteur: Kristina Dunder, “Update of section 4.6 (Fertility, pregnancy and lactation) of the SmPC in order to add new information concerning a retrospective observational cohort study with risperidone and risk of congenital malformations. Nationally approved products are also affected by this variation.”
Request for Supplementary Information adopted with a specific timetable.
### B.5.3. CHMP-PRAC assessed procedures

<table>
<thead>
<tr>
<th>MAH</th>
<th>Rapporteur/CoRapporteur</th>
<th>Summary</th>
<th>CHMP Recommendation</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>WS1189</strong></td>
<td><strong>ANORO-EMEA/H/C/002751/WS1189/0017</strong></td>
<td><strong>Laventair-EMEA/H/C/003754/WS1189/0019</strong></td>
<td>Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
</tr>
<tr>
<td><strong>MAH: Glaxo Group Ltd, Lead Rapporteur:</strong> Nithyanandan Nagercoil</td>
<td>&quot;Update of section 4.8 of the SmPC and relevant section of the PL to add &quot;dysphonia&quot; with rare frequency.&quot;</td>
<td>Opinion adopted on 13.07.2017.</td>
<td></td>
</tr>
<tr>
<td><strong>WS1191</strong></td>
<td><strong>Incruse-EMEA/H/C/002809/WS1191/0016</strong></td>
<td><strong>Rolufta-EMEA/H/C/004654/WS1191/0001</strong></td>
<td>Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
</tr>
<tr>
<td><strong>MAH: Glaxo Group Ltd, Lead Rapporteur:</strong> Concepcion Prieto Yerro</td>
<td>&quot;Update of section 4.8 of the SmPC and relevant section of the PL to add &quot;Eye pain&quot; with a rare frequency.&quot;</td>
<td>Opinion adopted on 13.07.2017.</td>
<td></td>
</tr>
<tr>
<td><strong>B.5.3. CHMP-PRAC assessed procedures</strong></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td><strong>Adcetris - brentuximab vedotin - EMEA/H/C/002455/II/0043, Orphan</strong></td>
<td><strong>MAH: Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus</strong></td>
<td>&quot;Update of sections 4.8 and 5.1 of the SmPC to reflect the final study results from study C25007: a single-arm study of brentuximab vedotin in patients with relapsed or refractory hodgkin lymphoma who are not suitable for stem cell transplantation or multiagent chemotherapy. The submission of the clinical study report fulfils SOB 011 of the conditional marketing authorisation for Adcetris Annex II is updated accordingly.&quot;</td>
<td>Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
</tr>
<tr>
<td><strong>Aranesp - darbepoetin alfa - EMEA/H/C/000332/II/0141</strong></td>
<td><strong>MAH: Amgen Europe B.V., Rapporteur: Martina Weise, PRAC Rapporteur: Valerie Strassmann</strong></td>
<td>&quot;Update of sections 4.4 and 4.8 of the SmPC in order to add a warning on severe cutaneous conditions including Erythema multiforme and Stevens-Johnson Syndrome (SJS) and Toxic Epidermal Necrolysis (TEN) following a request for cumulative review triggered by EMA signal&quot;</td>
<td>Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
</tr>
</tbody>
</table>
adopted by PRAC on 09 February 2017. The Package Leaflet is updated accordingly. The RMP version 7 has also been submitted.”

**Dificlir - fidaxomicin -**
**EMEA/H/C/002087/II/0028**
MAH: Astellas Pharma Europe B.V., Rapporteur: Filip Josephson, PRAC Rapporteur: Qun-Ying Yue, “C.I.11: Submission of an updated RMP version 7 in order to remove the post-authorization measure (PAM) MEA003 (concerning clinical study 2819-CL-2001 in patients with Clostridium difficile Infection who will receive a second course of fidaxomicin) due to the non-feasibility of the study.”
Request for Supplementary Information adopted on 05.05.2017.

Edurant - rilpivirine -
**EMEA/H/C/002264/II/0024**
MAH: Janssen-Cilag International NV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2, 4.4, 4.6, 5.1 and 5.2 of the SmPC in order to include information: use of rilpivirine in combination with a background regimen for the treatment of HIV-1 infection during pregnancy and postpartum, without dose adjustment following final results from study TMC114HIV3015 listed as a category 3 study in the RMP. This is a single arm, open-label trial to assess the pharmacokinetics of darunavir/ritonavir, etravirine, and rilpivirine in HIV-1-infected pregnant women.
The Package Leaflet is updated accordingly. The RMP version 7.0 has also been submitted.
In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce the latest renewal date in section 9 of the SmPC and the physical address of the Netherlands Local Operating Company in the PIL section 6.”
Request for Supplementary Information adopted on 09.06.2017, 06.04.2017.

Jinarc - tolvaptan -
**EMEA/H/C/002788/II/0006**
MAH: Otsuka Pharmaceutical Europe Ltd, Rapporteur: Greg Markey, PRAC Rapporteur: Julie Williams, “Update of section 5.1 of the SmPC

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
based on final results from study 156-08-271 (TEMPO 4:4) listed as a PAES in Annex II. This study is a Multicenter, Open-label, Extension Study (Extension of Trial 156-04-251) to Evaluate the Long-term Safety and Efficacy of Oral Tolvaptan Tablet Regimens in Patients With Autosomal Dominant Polycystic. It provides data for Jinarc treatment of autosomal dominant polycystic kidney disease (ADPKD) over 5 years. Reference to submission of this study is being deleted from Annex II.

In addition, the Marketing authorisation holder (MAH) took the opportunity to add the current ATC code applicable for tolvaptan as it has been assigned by WHO.

The RMP version 13.1 has also been submitted to reflect the completion of the 156-08-271 study."

Request for Supplementary Information adopted on 05.05.2017.

**Keytruda - pembrolizumab -**
**EMEA/H/C/003820/II/0028**
MAH: Merck Sharp & Dohme Limited, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Sabine Straus, "Update sections 4.4 and 4.8 of the SmPC to include the risk of myocarditis that has been reported in patients treated with pembrolizumab. The Package Leaflet has been updated accordingly. An updated RMP version 10.0 was provided as part of the application."

Request for Supplementary Information adopted on 22.06.2017.

**Keytruda - pembrolizumab -**
**EMEA/H/C/003820/II/0029**
MAH: Merck Sharp & Dohme Limited, Rapporteur: Daniela Melchiorri, PRAC Rapporteur: Sabine Straus, "Submission of the final study report for non-clinical study "Anti-Murine PD-1 Antibody (muDX400 L-005571333): Exploratory Multiple-Dose Subcutaneous Immunotoxicity Study in Mice with Hepatitis B Vaccine (L-005552770)”. An updated RMP version 11.0 was agreed during the procedure."


**Latuda - lurasidone -**
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
EMEA/H/C/002713/II/0016
MAH: Sunovion Pharmaceuticals Europe Ltd, Rapporteur: Filip Josephson, PRAC Rapporteur: Qun-Ying Yue, "Submission of the final CSR for Study D1001057, an extension of study of SM-13496 evaluating the long-term safety and efficacy of lurasidone (40 mg/day or 80 mg/day) in Pan-Asian (Japanese, Korean, Taiwanese and Malaysian) subjects with schizophrenia. The RMP is being updated (ver. 5.0) with information relative to this study and also information relative to Study D1050301, which has already been assessed in P46/006."

Lemtrada - alemtuzumab -
EMEA/H/C/003718/II/0017
MAH: Genzyme Therapeutics Ltd, Duplicate, Duplicate of Lemtrada (WD), Rapporteur: Hanne Lomholt Larsen, PRAC Rapporteur: Torbjorn Callreus, "Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the safety and long term use information in the posology following final results from study CAMMS03409 - An Extension Protocol For Multiple Sclerosis Patients Who Participated in Genzyme-Sponsored Studies of Alemtuzumab (ongoing at the time of the initial MAA) to evaluate the long term safety and efficacy of alemtuzumab in MS patients who received alemtuzumab during prior company-sponsored studies. The RMP version 3.0 has also been submitted. The PL has been updated accordingly.
In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0 and to introduce editorial corrections in the PI."

Mozobil - plerixafor -
EMEA/H/C/001030/II/0032, Orphan
MAH: Genzyme Europe BV, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus, "Update of sections 4.2 and 5.2 of the SmPC in order to reflect the results of the completed study MSC12830 (MOZ11809), entitled "A Phase 4, Multicenter, Randomized, Comparator Trial Evaluating the Standard Weight-Based Dose (0.24 mg/kg) Compared to a Fixed Dose (20 mg) of Plerixafor Injection in
Request for Supplementary Information adopted with a specific timetable.
Combination with G-CSF to Mobilize and Collect ≥5 x 10^6 CD34+ cells/kg in ≤4 Days and to Evaluate the Difference in Total Systemic Exposure in Patients with Non-Hodgkin's Lymphoma Weighing ≤70 kg” listed as a category 3 study in the RMP.

The Package Leaflet is updated accordingly. The RMP version 9.0 has also been submitted.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet."

Request for Supplementary Information adopted on 06.07.2017.

**Ninlaro - ixazomib -**

**EMEA/H/C/003844/II/0002, Orphan**

MAH: Takeda Pharma A/S, Rapporteur: Greg Markey, PRAC Rapporteur: Ulla Wändel Liminga, “Update of sections 4.8 and 5.1 of the SmPC to reflect the final overall survival analysis of C16010 China continuation study, a phase III study comparing ixazomib plus lenalidomide and dexamethasone versus placebo plus lenalidomide in patients with relapsed and/or refractory multiple myeloma, in order to fulfil SOB (Specific Obligation) 002. Annex II.E and the RMP (version 2.0) are updated accordingly. In addition the Marketing Authorisation Holder (MAH) took the opportunity to make a small correction in sections 4.7 and 9 of the SmPC and to the German translations.”


Request for Supplementary Information adopted on 05.05.2017.

**Odomzo - sonidegib -**

**EMEA/H/C/002839/II/0011**

MAH: Sun Pharmaceutical Industries Europe B.V., Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Patrick Batty, “Submission of the final results from studies CLDE225C2301 and CLDE225X2104. Study CLDE225C2301 is a phase II, multi-center, open-label, single-arm study of the efficacy and safety of oral LDE225 in patients with Hhpathway activated relapsed medulloblastoma. Study CLDE225X2104 is a Phase I/II study of LDE225 in pediatric patients with recurrent or refractory medulloblastoma or other tumors potentially dependent on the Hedgehog-signaling

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
pathway and adult patients with recurrent or refractory medulloblastoma. The RMP has been updated accordingly. The product information remains unchanged.”
Request for Supplementary Information adopted on 09.06.2017.

**Olumiant - baricitinib -**
EMEA/H/C/004085/II/0001
MAH: Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Patrick Batty, "Update of section 4.4 of the SmPC in order to add a warning on venous thromboembolism based on analyses of the occurrence of venous thromboembolic events in clinical trials with baricitinib. The Package Leaflet is updated accordingly. The RMP version 2.0 has been submitted, as part of this application.”

**Olysio - simeprevir -**
EMEA/H/C/002777/II/0031
MAH: Janssen-Cilag International NV, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Julie Williams, "Update of section 5.1 of the SmPC in order to update the efficacy information following results from study HPC3002 A Prospective 3-year Follow-up Study in Subjects Previously Treated in a Phase IIb or Phase III Study with a TMC435-containing Regimen for the Treatment of Hepatitis C Virus (HCV) Infection listed as a category 3 study in the RMP and in fulfilment of MEA005. The RMP version 4.2 has also been submitted which includes updates of changes already agreed in procedures EMEA/H/C/002777/II/0021, EMEA/H/C/002777/II/0027 and EMEA/H/A-20/1438/C/2777/0019.”
Request for Supplementary Information adopted on 18.05.2017.

**Perjeta - pertuzumab -**
EMEA/H/C/002547/II/0029
MAH: Roche Registration Limited, Rapporteur: Sinan B. Sarac, PRAC Rapporteur: Doris Stenver, "Update of sections 4.2, 4.4, 4.8, 5.1 of the SmPC, annex II and relevant sections of the PL in order to update information on cardiac safety and reflect the results from study BERNICE Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
(WO29217) listed as a specific obligation in the Annex II; BERNICE is an ongoing Multicenter, Multinational, Phase II Study to Evaluate Perjeta in Combination with Herceptin and Standard Neoadjuvant Anthracycline-Based Chemotherapy in Patients with HER2- Positive, Locally Advanced, Inflammatory, or Early-Stage Breast Cancer.

The RMP v.9 has also been submitted.”
Request for Supplementary Information adopted on 22.06.2017.

**Praxbind - idarucizumab - EMEA/H/C/003986/II/0007**

MAH: Boehringer Ingelheim International GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to reflect the final results from a study 1321.3 titled “A Phase III, case series clinical study of the reversal of the anticoagulant effects of dabigatran by intravenous administration of 5.0 g idarucizumab (BI 655075) in patients treated with dabigatran etexilate who have uncontrolled bleeding or require emergency surgery or procedures. RE-VERSE-AD (A study of the RE-VERSal Effects of Idarucizumab on Active Dabigatran) trial” listed as a category 3 study in the RMP (MEA 001).

The RMP version 3.0 has also been submitted.

In addition, the Marketing authorisation holder took the opportunity to update the immunogenicity section in 5.1 of SmPC and to bring the PI in line with the latest QRD template version 10.”

**Privigen - human normal immunoglobulin - EMEA/H/C/000831/II/0119**

MAH: CSL Behring GmbH, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Update of sections 4.8 and 5.1 of the SmPC to include the PATH (IgPro20_3003) study results (safety & efficacy study with chronic inflammatory demyelinating polyneuropathy (CIDP) patients). Minor changes are also introduced to section 4.2 of the SmPC. In addition, the MAH took the opportunity to make some editorial changes to sections 4.3 and 5.2 of

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
<table>
<thead>
<tr>
<th>Topic</th>
<th>Details</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Sivextro - tedizolid phosphate</strong>&lt;br&gt;<strong>EMEA/H/C/002846/II/0019</strong>&lt;br&gt;MAH: Merck Sharp &amp; Dohme Limited, Rapporteur: Bruno Sepodes, PRAC Rapporteur: Dolores Montero Corominas, “Update of section 4.8 of the SmPC of the concentrate for solution for infusion formulation, in order to add information from BAY119-2631/16121, a Phase 3 randomized, double-blind, multi-centre study comparing the efficacy and safety of intravenous to oral 6-day tedizolid phosphate and intravenous to oral 10 day linezolid for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and change the reported expected frequency of the adverse reaction “infusion site phlebitis” from “uncommon” to “common”. The Package Leaflet is updated accordingly. An updated RMP (version 3.0) has also been submitted, proposing to collect safety information regarding tedizolid phosphate by conducting three investigator initiated studies and deleting the original proposed long term safety study. The MAH also took the opportunity to make minor editorial corrections throughout the product information.” Request for Supplementary Information adopted on 06.07.2017.</td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
</tr>
<tr>
<td><strong>Sylvant - siltuximab</strong>&lt;br&gt;<strong>EMEA/H/C/003708/II/0023, Orphan</strong>&lt;br&gt;MAH: Janssen-Cilag International NV, Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Brigitte Keller-Stanislawski, “Submission of the final report from study CNTO328SMM2001 listed as a category 3 study in the RMP This is a ‘Phase 2, Randomized, Double-blind, Placebo-controlled, Multicenter Study of Siltuximab (Anti IL-6 Monoclonal Antibody) in Subjects with High-risk Smoldering Multiple Myeloma’ to evaluate immunogenicity data. No changes to the PI are proposed. The RMP is being updated accordingly.” Opinion adopted on 06.07.2017.</td>
<td>Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.</td>
</tr>
<tr>
<td><strong>Synflorix - pneumococcal polysaccharide conjugate vaccine (adsorbed)</strong>&lt;br&gt;<strong>EMEA/H/C/000973/II/0117</strong></td>
<td>Request for Supplementary Information adopted with a specific timetable.</td>
</tr>
</tbody>
</table>
MAH: GlaxoSmithkline Biologicals SA,
Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, “Update of sections 4.2, 4.4 and 5.1 of the SmPC in order to reflect the results from study10PN-PD-DIT-072, a phase III, open, controlled, multi-centric study to evaluate the immunogenicity, safety and reactogenicity of Synflorix in children at an increased risk of pneumococcal infection. The Package Leaflet is updated accordingly. An updated RMP version 16 has also been submitted. This submission fulfils the post-authorisation measure MEA 065.” Request for Supplementary Information adopted on 06.07.2017. Clockstop extension of, responses expected 12.09.2017. Adopted. Letter from the applicant dated 17.07.2017 requesting a clock stop extension. For information.

Tagrisso - osimertinib -
EMEA/H/C/004124/II/0016
MAH: AstraZeneca AB, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Sabine Straus, “Provision of the final CSR for Study Aura 17; a phase II, open label, single-arm study to assess the safety and efficacy of AZD9291 in Asia pacific patients with locally advanced/metastatic non-small cell lung cancer whose disease has progressed with previous epidermal growth factor receptor tyrosine kinase inhibitor therapy and whose tumours harbour a T790M mutation within the epidermal growth factor receptor gene). An updated RMP version 7.0 was agreed during the procedure.” Opinion adopted on 06.07.2017. Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Tamiflu - oseltamivir -
EMEA/H/C/000402/II/0128
MAH: Roche Registration Limited, Rapporteur: Outi Mäki-Ikola, PRAC Rapporteur: Kirsti Villikka, "Update of section 4.6 of the SmPC in order to reflect the final study results from non-interventional safety study BV29684, which assessed the safety of oseltamivir exposure in pregnant women, and was listed as a category 3 study in the RMP (MEA099). The RMP version 15.0 has also been updated to reflect the study results.” Request for Supplementary Information adopted on 20.07.2017. Request for Supplementary Information adopted with a specific timetable.
Tyverb - lapatinib - EMEA/H/C/000795/II/0048/G
MAH: Novartis Europharm Ltd, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wåndel Liminga, “1) C.I.4 (type II): Update of sections 4.4, 4.8, and 5.1 of the SmPC in order to add a warning on concentration-dependent increase of the QTc interval, concomitant use of CYP3A4 inhibitors, a strengthened recommendation of ECG monitoring (section 4.4), to add to the tabulated list of adverse reactions ‘Ventricular arrhythmias/Torsades de Pointes, electrocardiogram QT prolonged’ (frequency Not known)(section 4.8) and to update safety information (section 5.1) following the submission of study report EGF114271 (a phase IV placebo controlled single sequence crossover study to evaluate the effect of repeat oral doses of lapatinib on cardiac repolarization in patients with advanced cancer). The Package Leaflet is updated accordingly.
2) C.I.4 (type II): Update of section 4.8 of the SmPC reflecting, in the tabulated list of adverse reactions, that amongst serious cutaneous reactions, Stevens - Johnson syndrome and Toxic Epidermal Necrolysis has been observed (frequency Not known), further to the review of the Novartis safety database. The Package Leaflet is updated accordingly.
In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10 and update the list of local representatives. Moreover, the MAH took the opportunity to update Annex II to delete an Annex II condition related to study EGF114299, fulfilled with procedure ANX. 28.2. The RMP (version 32) is updated to upgrade QTc prolongation, severe cutaneous reactions and food effect from important potential risks to important identified risks and to introduce template-related changes and study milestones updates.”
Opinion adopted on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Uptravi - selexipag - EMEA/H/C/003774/II/0009
MAH: Actelion Registration Ltd., Rapporteur: Martina Weise, PRAC Rapporteur: Julie Williams, “Update of section 4.5 of the SmPC to add Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Annex to July 2017 CHMP Minutes
EMACHMP/628544/2017
information on the effect of selexipag administration on the pharmacokinetics of midazolam, its metabolite 1-hydroxymidazolam and the CYP3A4 metabolism, based on data from the completed clinical pharmacology study AC-065-114, a single-centre, open-label, randomized, two-treatment crossover Phase 1 study investigating the effect of selexipag on the pharmacokinetics of midazolam and its metabolite 1-hydroxymidazolam in healthy male subjects. An updated RMP (version 5.1) has also been submitted, to add the results of study AC-065-114, reclassify 'hyperthyroidism' as an important identified risk and update the PASS timelines and protocol versions in accordance with the current EXPOSURE protocol version 3 and the EDUCATE protocol version 2.”

Vedrop - tocofersolan - EMEA/H/C/000920/II/0022
MAH: Orphan Europe SARL, Rapporteur: Greg Markey, PRAC Rapporteur: Patrick Batty,
"Submission of the final report for the registry of paediatric patients treated with Vedrop (tocofersolan) in Europe for vitamin E deficiency due to digestive malabsorption in congenital or hereditary chronic cholestasis. Consequentially, the remaining specific obligation is fulfilled and Annex II is updated accordingly.”
See 9.1. of the main agenda

Xalkori - crizotinib - EMEA/H/C/002489/II/0049/G
MAH: Pfizer Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni,
"Submission of the final results related of the Non_Interventional Post-Authorisation Safety Study (PASS) A8081049 "A cross-sectional study to evaluate the effectiveness of XALKORI (PF_02341066, also referred to as crizotinib) Therapeutic Management Guide among physicians prescribing XALKORI in Europe” and PASS A8081050 "A cross-sectional study to evaluate the effectiveness of XALKORI Patient Information Brochure among non-small cell lung cancer (NSCLC) patients receiving XALKORI treatment in Europe”.
In the light of the results from PASS study A8081049, the MAH is proposing to update Annex II to remove the XALKORI TMG from the Educational Materials. The MAH is also taking the
Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
opportunity to state “monotherapy” in section 4.1 of the SmPC as requested by CHMP and to bring the PI in line with the latest QRD template.”

**Xarelto - rivaroxaban - EMEA/H/C/000944/II/0052/G**

MAH: Bayer AG, Rapporteur: Kristina Dunder,
PRAC Rapporteur: Qun-Ying Yue, “Group of variations consisting of:
1) C.1.4. To add the authorised indications “Treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and prevention of recurrent DVT and PE in adults” to Xarelto 10 mg based on Einstein Choice trial (A randomised phase III clinical study to evaluate efficacy and safety of Reduced-dosed rivaroxaban and standard-dosed rivaroxaban versus ASA in the long-term prevention of recurrent symptomatic venous thromboembolism in patients with symptomatic deep-vein thrombosis and/or pulmonary embolism) in section 4.1 of the SmPC 10 mg.
Consequently:
- Changes in sections 4.2, 4.8 and 5.1 for Xarelto 10mg, 15mg and 20 mg are made in order to update the posology, efficacy and safety information.
- Annex III is updated to include Xarelto 10 mg into Patient alert card to support management of bleeding when the 10 mg is treated for long-term prevention of recurrent VTE
- RMP (version 10) is updated
2) B.II.e.5.a.1- to add a new pack size of 14 film coated tablets in blister (PP/alu) for Xarelto 10 mg
3) B.II.e.5.a.1- to add a new pack size of 28 film coated tablets in blister (PP/alu) for Xarelto 10 mg
4) B.II.e.5.a.1- to add a new pack size of 98 film coated tablets in blister (PP/alu) for Xarelto 10 mg
5) B.II.e.1.b.1 to change immediate packaging of the finished product for 10 mg film coated tablets to introduce HDPE bottle with screw cap including new presentation (pack containing 100 film coated tablets for 10 mg strength)
6) C.1.4 To add information on interactions with SSRIs and SNRIs in section 4.5 and a related warning in section 4.4 of the SmPC based on post-hoc analyses to investigate bleeding risk for
rivaroxaban in patients with and without use of SSRI or SNRIs from the pivotal studies. In addition, MedDRA terminology is updated in the adverse drug reactions table in section 4.8 of the SmPC

7) C.1.11.z To delete from the summary of safety concerns: "Patients undergoing major orthopaedic surgery other than elective hip or knee replacement surgery" and "Remedial pro-coagulant therapy for excessive haemorrhage". Part II - Modules SVIII: Summary of the safety concerns, Part III, Section 1 Safety Concerns and overview of planned pharmacovigilance action were amended accordingly. In addition, Part II, Safety Specification, module SIV, Populations not studied in clinical trials: "Patients undergoing major orthopaedic surgery other than elective hip or knee replacement surgery" and "Remedial pro-coagulant therapy for excessive haemorrhage" was updated.


Xgeva - denosumab -
EMEA/H/C/002173/II/0051
MAH: Amgen Europe B.V., Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, "To update to the Risk Management Plan (RMP) with addition of the important potential risk 'hypercalcemia several months after the last dose in patients with GCTB' and the modification of the important identified risk 'hypercalcemia following treatment discontinuation in patients with growing skeletons' to 'hypercalcemia in patients with growing skeletons several months after the previous dose'; the MAH is also taking the opportunity to implement a minor correction to the RMP for correction or to add clarification."
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

Zavesca - miglustat -
EMEA/H/C/000435/II/0056, Orphan
MAH: Actelion Registration Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue, "Submission of 8th Niemann-Pick type C (NP-C) Registry report and update of Annex II-D to delete the NP-C Registry listed as an obligation to the marketing authorisation.
Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
The RMP version 12.1 has also been submitted to reflect the above changes.
In addition, the Marketing authorisation holder took the opportunity to introduce minor changes and bring the Product Information and Annex A in line with the latest QRD template version 10.”

**WS1117/G**
Stocrin-EMEA/H/C/000250/WS1117/0110
Sustiva-EMEA/H/C/000249/WS1117/0139

MAH: Bristol-Myers Squibb Pharma EEIG, Lead Rapporteur: Bruno Sepodes, Lead PRAC
Rapporteur: Ana Sofia Diniz Martins, “C.I.4 (Type II) - Update of sections 4.4, 4.5 and 5.1 of the SmPC in order to add a warning and update the safety information on QTc prolongation based on the final results from study AI266959; this is an interventional study to determine the concentration-electrocardiographic effects of efavirenz in healthy subjects enriched for cyp2b6 polymorphisms; the Package Leaflet is updated accordingly. The RMP version 8 has also been submitted.

C.I.4 (Type II) – Update of sections 4.4 and 4.8 to add catatonia as a Psychiatric symptom following an assessment of catatonia cases reported in the literature and via the United States (US) Food and Drug Administration Adverse Event Reporting System (FAERS).”

**WS1182**
AMGEVITA-EMEA/H/C/004212/WS1182/001
SOLYMBIC-EMEA/H/C/004373/WS1182/001

MAH: Amgen Europe B.V., Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Ulla Wändel Liminga, “Submission of the final report from study/studies 20130258, An open-label, single-arm extension study to evaluate the long-term safety and efficacy of ABP 501 in subjects with moderate to severe rheumatoid arthritis, listed as a category 3 study in the RMP (MEA002). No changes of the PI are proposed,

Request for Supplementary Information adopted with a specific timetable.
the RMP is updated accordingly.”
Request for Supplementary Information adopted on 06.07.2017.

**B.5.4. PRAC assessed procedures**

PRAC Led

**Aclasta - zoledronic acid -**
**EMEA/H/C/000595/II/0069**
MAH: Novartis Europharm Ltd, Rapporteur: Kristina Dunder, PRAC Rapporteur: Ulla Wändel Liminga, PRAC-CHMP liaison: Kristina Dunder,
“Submission of the final 5-year report from study (ZOL446H2422) listed as a category 3 study in the RMP. This is a non-interventional post-authorisation safety study using health registries to compare safety of Aclasta against oral bisphosphonates and untreated population controls.”
Request for Supplementary Information adopted on 06.07.2017.

PRAC Led

**Inovelon - rufinamide -**
**EMEA/H/C/000660/II/0041, Orphan**
MAH: Eisai Ltd, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, PRAC-CHMP liaison: Alexandre Moreau,
“Submission of the final clinical study report for study E2080-E044-401, the European registry of anti-epileptic drug use in patients with Lennox-Gastaut Syndrome (LAG), listed as a category 3 study in the RMP, in order to fulfil MEA 002.1. This is a non-interventional EU registry study entering patients (aged ≥4 years) with LGS who required a modification in anti-epileptic therapy (either the addition of another AED or the change of one drug to another) to evaluate the long-term safety of rufinamide.”
Request for Supplementary Information adopted on 05.05.2017.

PRAC Led

**NovoEight - turoctocog alfa -**
**EMEA/H/C/002719/II/0020**
Request for Supplementary Information adopted with a specific timetable.
Submission of an updated RMP version 3 to update the timelines of the milestones in order to integrate the required additional pharmacovigilance activities, which include a change in the Last Patient Last Visit (LPLV) date and a change in the Clinical Trial Report (CTR) finalisation date. In addition, the duration of the trial has been amended from 4 to 7 years.’’

Request for Supplementary Information adopted on 06.07.2017.

**Rebif - interferon beta-1a - EMEA/H/C/000136/II/0129**

MAH: Merck Serono Europe Limited, PRAC Rapporteur: Qun-Ying Yue, PRAC-CHMP liaison: Filip Josephson, “Submission of an updated RMP version 9.0 in order to upgrade the important potential risk “Immunogenicity/safety risk associated with the formation of neutralizing antibodies” to important identified risk”


Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Retacrit - epoetin zeta - EMEA/H/C/000872/II/0077**

MAH: Hospira UK Limited, Rapporteur: Martina Weise, PRAC Rapporteur: Valerie Strassmann, PRAC-CHMP liaison: Martina Weise, “Submission of the final report from the registry based healthcare database study linked to PASCO (PMS-830-07-0043)) listed as a category 3 study in the RMP. This is an observational study on the incidence of thromboembolic events in patients with renal anaemia treated with erythropoietin-zeta as compared with erythropoietin-alpha and other erythropoiesis-stimulating agents.”


Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

**Revlimid - lenalidomide - EMEA/H/C/000717/II/0095, Orphan**

MAH: Celgene Europe Limited, Rapporteur: Alexandre Moreau, PRAC Rapporteur: Ghania Chamouni, PRAC-CHMP liaison: Alexandre Moreau, “Submission of the final results of the non-interventional, observational category 3 post-authorisation safety study (Study CC-5013-PASS-001) in subjects treated with lenalidomide to further characterise the safety

Request for Supplementary Information adopted with a specific timetable.
profile of lenalidomide plus dexamethasone in the
treatment of relapsed and/or refractory (R/R) MM
in a real-world setting.”

PRAC Led
Silapo - epoetin zeta -
EMEA/H/C/000760/II/0045
MAH: STADA Arzneimittel AG, Rapporteur: Martina Weise, PRAC Rapporteur: Valerie Strassmann, PRAC-CHMP liaison: Martina Weise,
"Submission of the final report from the registry based healthcare database study linked to PASCO (PMS-830-07-0043)) listed as a category 3 study in the RMP. This is an observational study on the incidence of thromboembolic events in patients with renal anaemia treated with erythropoietin-zeta as compared with erythropoietin-alpha and other erythropoiesis-stimulating agents. In addition, an updated RMP (version 11) is submitted to reflect the outcome of the study.”

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led
Tysabri - natalizumab -
EMEA/H/C/000603/II/0101
MAH: Biogen Idec Ltd, Rapporteur: Jan Mueller-Berghaus, PRAC Rapporteur: Brigitte Keller-Stanislawski, PRAC-CHMP liaison: Jan Mueller-Berghaus, "Submission of the final clinical study report for TYGRIS, a post-marketing safety observational cohort program designed to obtain long-term safety data (approximately 5 years) in subjects with MS treated with natalizumab, and comprising parallel studies 101MS402 (United States and Canada) and 101MS403 (Rest of World). The application included an updated RMP version 23.”
Request for Supplementary Information adopted on 06.04.2017.

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led
Yervoy - ipilimumab -
EMEA/H/C/002213/II/0049
MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Paula Boudewina van Henriek, PRAC Rapporteur: Sabine Straus, PRAC-CHMP liaison: Johann Lodewijk Hilleg, "Submission of an updated RMP (version 17) in order to amend the

Request for Supplementary Information adopted with a specific timetable.
study objectives and milestones for two studies:
- study CA184332, a multi-site retrospective observational study of US patients with unresectable or metastatic melanoma receiving ipilimumab (Yervoy) as first line therapy in a community setting, a category 3 study in the RMP (MEA 029): to submit the final study report with 2-years of follow-up
- study CA184338, a multi-site retrospective observational study of US patients with unresectable or metastatic melanoma receiving ipilimumab (Yervoy) as first line therapy, a category 3 study in the RMP (MEA 030): to submit the final study report with 4-years of follow-up.”
Request for Supplementary Information adopted on 06.07.2017.

PRAC Led
WS1163
Harvoni-EMEA/H/C/003850/WS1163/0051
Sovaldi-EMEA/H/C/002798/WS1163/0041
MAH: Gilead Sciences International Ltd, Lead PRAC Rapporteur: Julie Williams, PRAC-CHMP liaison: Greg Markey, “To provide updated RMPs for Sovaldi and Harvoni following the CHMP opinion, endorsing a PRAC recommendation, issued on 15 December 2016 (EMA/CHMP/847450/2016) on the Article 20 procedure for Direct-acting antivirals (DAAs) indicated for the treatment of hepatitis C (interferon free). The PRAC requested ‘hepatitis B reactivation’ to be considered as important identified risk for all direct-acting antivirals. In addition, ‘emergence of hepatocellular carcinoma’ and ‘recurrence of hepatocellular carcinoma’ have been included as important potential risks. ‘Patients with previous HCC’ have been reflected as missing information in the RMP of the DAAs, since this population was excluded from existing clinical trials. The requested studies have also been reflected in the RMPs.”
Request for Supplementary Information adopted on 05.05.2017.

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

PRAC Led
WS1169
Exviera-EMEA/H/C/003837/WS1169/0028
Viekirax-EMEA/H/C/003839/WS1169/0032
MAH: AbbVie Limited, Lead Rapporteur: Filip

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Josephson, Lead PRAC Rapporteur: Dolores Montero Corominas, PRAC-CHMP liaison: Concepcion Prieto Yerro, “To provide updated RMPs for Exviera and Viekirax following the CHMP opinion, endorsing a PRAC recommendation, issued on 15 December 2016 (EMA/CHMP/847450/2016) on the Article 20 procedure for Direct-acting antivirals (DAAs) indicated for the treatment of hepatitis C (interferon free). The PRAC requested ‘hepatitis B reactivation’ to be considered as important identified risk for all direct-acting antivirals. In addition, ‘emergence of hepatocellular carcinoma’ and ‘recurrence of hepatocellular carcinoma’ have been included as important potential risks. ‘Patients with previous HCC’ have been reflected as missing information in the RMP of the DAAs, since this population was excluded from existing clinical trials. The requested studies have also been reflected in the RMPs.” Opinion adopted on 06.07.2017. Request for Supplementary Information adopted on 05.05.2017.

MAH: Eli Lilly Nederland B.V., Lead Rapporteur: Robert James Hemmings, Lead PRAC Rapporteur: Julie Williams, PRAC-CHMP liaison: Robert James Hemmings, "Submission of the final report of a non-interventional post-authorisation safety study EUPAS 13422. This study is aimed to evaluate the impact of additional risk minimisation measures on healthcare professionals and on patients’ understanding and their behaviour regarding the risk of hypoglycaemia and/or hyperglycaemia due to medication errors associated with administration of Humalog 200 U/ml KwikPen.” Request for Supplementary Information adopted on 06.07.2017.

Positive Opinion adopted by consensus on 20.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.
Forxiga-EMEA/H/C/002322/WS1198/003

Xigduo-EMEA/H/C/002672/WS1198/0033

MAH: AstraZeneca AB, Lead Rapporteur: Kristina Dunder, Lead PRAC Rapporteur: Qun-Ying Yue, PRAC-CHMP liaison: Kristina Dunder, "Implement the outcome of the article 20 referral regarding lower limb amputations in the RMP. The variation is submitted in order to give the rapporteur the possibility to review and assess the way the requested information has been included in the RMPs.”

B.5.5. CHMP-CAT assessed procedures

B.5.6. CHMP-PRAC-CAT assessed procedures

Strimvelis - autologous CD34+ enriched cell fraction that contains CD34+ cells transduced with retroviral vector that encodes for the human ADA cDNA sequence - EMEA/H/C/003854/II/0006, Orphan, ATMP
MAH: GlaxoSmithKline Trading Services Limited, Rapporteur: Christiane Niederlaender, PRAC Rapporteur: Sabine Straus

B.5.7. PRAC assessed ATMP procedures

B.5.8. Unclassified procedures and worksharing procedures of type I variations

WS1081
Hexacima-EMEA/H/C/002702/WS1081/00 55
Hexamin-EMEA/H/W/002495/WS1081/00 62
Hexyon-EMEA/H/C/002796/WS1081/005 9
MAH: Sanofi Pasteur SA, Lead Rapporteur: Jan Mueller-Berghaus

WS1122/G
Hexacima-EMEA/H/C/002702/WS1122/00 60/G
Positive Opinion adopted by consensus on 13.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP
<table>
<thead>
<tr>
<th>MAH</th>
<th>Product Code</th>
<th>CHMP Reference</th>
<th>Request Date</th>
<th>Recommendation Date</th>
<th>CHMP Members Agreement</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Glyxambi-EMEA/H/C/003833/WS1173/006</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Jardiance-EMEA/H/C/002677/WS1173/0032</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td>Synjardy-EMEA/H/C/003770/WS1173/0028</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**WS1192**
Hexacima-EMEA/H/C/002702/WS1192/0066
Hexaxim-EMEA/H/W/002495/WS1192/0072
Hexyon-EMEA/H/C/002796/WS1192/0070
MAH: Sanofi Pasteur SA, Lead Rapporteur: Kristina Dunder


**WS1200**
Lyrica-EMEA/H/C/000546/WS1200/0089
Pregabaline
Pfizer-EMEA/H/C/003880/WS1200/0019
MAH: Pfizer Limited, Lead Rapporteur: Johann Lodewijk Hillege

Positive Opinion adopted by consensus on 06.07.2017. The Icelandic and Norwegian CHMP Members were in agreement with the CHMP recommendation.

B.5.9. Information on withdrawn type II variation / WS procedure

**Blincyto - blinatumomab -**
EMEA/H/C/003731/II/0014, Orphan
MAH: Amgen Europe B.V., Rapporteur: Alexandre Moreau, PRAC Rapporteur: Eva Jirsová

The MAH withdrew the procedure on 13.07.2017.

**Strensiq - asfotase alfa -**
EMEA/H/C/003794/II/0020, Orphan
MAH: Alexion Europe SAS, Rapporteur: Greg Markey

The MAH withdrew the procedure on 10.07.2017.

**Xeljanz - tofacitinib -**
EMEA/H/C/004214/II/0002
MAH: Pfizer Limited, Rapporteur: Robert James Hemmings
Withdrawal request submitted on 06.07.2017.

The MAH withdrew the procedure on 06.07.2017.

B.5.10. Information on type II variation / WS procedure with revised timetable

B.6. START OF THE PROCEDURES TIMETABLES FOR INFORMATION

B.6.1. Start of procedure for New Applications: timetables for information

- **glycopyrronium / formoterol fumarate dihydrate -**
  EMEA/H/C/004245
, indicated as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease (COPD)

- **bictegravir / emtricitabine / tenofovir alafenamide** - EMEA/H/C/004449, treatment of adults infected with human immunodeficiency virus-1 (HIV-1)

- **dapivirine** - EMEA/H/W/002168, Article 58, Reducing the risk of HIV-1 infection via vaginal intercourse in sexually active HIV-uninfected women

- **darunavir** - EMEA/H/C/004891, treatment of HIV-1 infection

- **deferiprone** - EMEA/H/C/004710, treatment of iron overload in thalassemia major

- **lesinurad / allopurinol** - EMEA/H/C/004412, gout

- **pacritinib** - EMEA/H/C/004793, Orphan Applicant: CTI Life Sciences Limited, treatment of disease-related splenomegaly and control of symptoms in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essential thrombocythemia myelofibrosis (PET-MF) who have thrombocytopenia (platelet counts ≤100,000 /μL).

- **emicizumab** - EMEA/H/C/004406, routine prophylaxis to prevent bleeding or reduce the frequency of bleeding episodes in patients with haemophilia A (congenital factor VIII deficiency) with factor VIII inhibitors. **Accelerated review**

- **botulinum toxin type a** - EMEA/H/C/004587, temporary improvement in the appearance of moderate to severe vertical lines between the eyebrows

- **trastuzumab** - EMEA/H/C/004463, treatment of metastatic and early breast cancer and metastatic gastric cancer (MGC)

- **meropenem / vaborbactam** - EMEA/H/C/004669, treatment of infections

See 3.4. of the main agenda
B.6.2. Start of procedure for Extension application according to Annex I of Reg. 1234/2008): timetables for information

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>EMA/H/C/Reference</th>
<th>MAH:</th>
</tr>
</thead>
<tbody>
<tr>
<td>Dasatinib Monohydrate -</td>
<td>EMEA/H/C/000709/X/0556/G</td>
<td>Novartis Europharm Ltd</td>
</tr>
<tr>
<td>everolimus -</td>
<td>EMEA/H/C/002311/X/0045, Orphan</td>
<td></td>
</tr>
</tbody>
</table>

B.6.3. Restart of procedure - responses received to Day 120 List of Questions timetables: for information

<table>
<thead>
<tr>
<th>Drug Name</th>
<th>EMA/H/C/Reference</th>
<th>Applicant:</th>
<th>Disease:</th>
</tr>
</thead>
<tbody>
<tr>
<td>ulipristal acetate -</td>
<td>EMEA/H/C/001027/X/0045</td>
<td>Pharma Mar, S.A.,</td>
<td></td>
</tr>
<tr>
<td>imatinib -</td>
<td>EMEA/H/C/004748</td>
<td>Pharma Mar, S.A.,</td>
<td>treatment of newly diagnosed and chronic Philadelphia chromosome (bcr-abl) positive (Ph+) chronic myeloid leukaemia (CML), gastrointestinal stromal tumours (GIST), unresectable dermatofibrosarcoma protuberans (DFSP) and recurrent and/or metastatic DFSP, Request for Supplementary Information adopted on 22.06.2017.</td>
</tr>
<tr>
<td>bevacizumab -</td>
<td>EMEA/H/C/004360</td>
<td>Pharma Mar, S.A.,</td>
<td>treatment of breast cancer, non-small cell lung cancer, renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian,</td>
</tr>
</tbody>
</table>
- velmanase alfa - EMEA/H/C/003922, Orphan
Applicant: Chiesi Farmaceutici S.p.A., indicated for long-term enzyme replacement therapy in patients with alpha-mannosidosis

- bevacizumab - EMEA/H/C/004728, treatment of metastatic breast cancer, unresectable advanced, metastatic or recurrent non-small cell lung cancer, unresectable advanced metastatic or recurrent non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell cancer, advanced epithelial ovarian, fallopian tube, or primary peritoneal cancer, platinum-sensitive epithelial ovarian, fallopian tube or primary peritoneal cancer,

- semaglutide - EMEA/H/C/004174, to improve glycaemic control in adults with type 2 diabetes and to prevent cardiovascular events

- d-biotin - EMEA/H/C/004153, treatment of progressive multiple sclerosis (primary or secondary)

- ciclosporin - EMEA/H/C/004229, for the treatment of moderate dry eye disease in adults
List of Questions adopted on 23.03.2017.

- rucaparib - EMEA/H/C/004272, Orphan
Applicant: Clovis Oncology UK Ltd, treatment of ovarian cancer
List of Questions adopted on 23.03.2017.

- human herpesvirus 3 - EMEA/H/C/004336, prevention of herpes zoster (HZ) and HZ-related complications

- human fibrinogen / human thrombin - EMEA/H/C/004446, treatment of haemostasis
### B.6.4. Annual Re-assessments: timetables for adoption

### B.6.5. Renewals of Marketing Authorisations: timetables for adoption provided only if the validation has been completed

<table>
<thead>
<tr>
<th>Product Name</th>
<th>Description</th>
<th>Referral</th>
<th>Reviewer</th>
</tr>
</thead>
<tbody>
<tr>
<td>Actelsar HCT - telmisartan / hydrochlorothiazide</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hexacima - diphtheria, tetanus, pertussis (acellular, component), hepatitis B (rDNA), poliomyelitis (inact.) and Haemophilus type B conjugate vaccine (adsorbed)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hexyon - diphtheria (D), tetanus (T), pertussis (acellular, component) (Pa), hepatitis B (rDNA) (HBV), poliomyelitis (inactivated) (IPV) and Haemophilus influenzae type b (Hib) conjugate vaccine (adsorbed)</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>matinib Actavis - imatinib</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Marixino - memantine</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mycamine - micafungin</td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ocaliva - obeticholic acid</td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
**B.6.6. VARIATIONS – START OF THE PROCEDURE**

Timetables for adoption provided that the validation has been completed.

**B.6.7. Type II Variations scope of the Variations: Extension of indication**

Blincyto - blinatumomab -
EMEA/H/C/003731/II/0018, Orphan
MAH: Amgen Europe B.V., Rapporteur:
Alexandre Moreau, PRAC Rapporteur: Eva
Jirsová“Extension of Indication to include the
children 1 month and older to the authorised
population for the treatment of adults with
Philadelphia chromosome-negative relapsed or
refractory B-precursor acute lymphoblastic
leukaemia (ALL) for BLINCYTO;
as a consequence, sections 4.1, 4.2, 4.4, 4.8,
5.1, 5.2 and 6.6 of the SmPC are updated in order to include the new population, updated the posology and update the safety information. The Package Leaflet is updated in accordance. RMP version 6.0 has been submitted”

Briviact - brivaracetam - EMEA/H/C/003898/II/0010/G
Extension of Indication to include adjunctive therapy in the treatment of partial-onset seizures with or without secondary generalisation in patients with epilepsy 4 years of age and older for Briviact. As a consequence, sections 4.1, 4.2, 4.7, 5.1 and 5.2 of the SmPC are updated.
In addition, the Marketing authorisation holder (MAH) submitted a 5ml oral syringe and adaptor for the paediatric population.
The Package Leaflet and Labelling are updated in accordance.
Submission of the final Environmental Risk Assessment for the inclusion of the paediatric population in accordance with the new indication sought.”

B.6.8. CHMP assessed procedures scope: Pharmaceutical aspects

BeneFIX - nonacog alfa - EMEA/H/C/000139/II/0146
MAH: Pfizer Limited, Rapporteur: Jan Mueller-Berghaus,

Beneplali - etanercept - EMEA/H/C/004007/II/0026
MAH: Samsung Bioepis UK Limited (SBUK), Rapporteur: Andrea Laslop

Cosentyx - secukinumab - EMEA/H/C/003729/II/0026
MAH: Novartis Europharm Ltd, Rapporteur: Tuomo Lapveteläinen,

Cystadane - betaine anhydrous - EMEA/H/C/000678/II/0029
MAH: Orphan Europe SARL, Rapporteur: Harald Enzmann

Deltyba - delamanid - EMEA/H/C/002552/II/0020/G, Orphan
<table>
<thead>
<tr>
<th>Product Name</th>
<th>EMEA Ref.</th>
<th>MAH/RA</th>
<th>Rapporteur</th>
</tr>
</thead>
<tbody>
<tr>
<td>Elocta - efmoroctocog alfa</td>
<td>EMEA/H/C/003964/II/0016/G</td>
<td>Otsuka Novel Products GmbH, Greg Markey</td>
<td></td>
</tr>
<tr>
<td>Foscan - temoporfin</td>
<td>EMEA/H/C/000318/II/0042</td>
<td>Swedish Orphan Biovitrum AB (publ), Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td>Hizentra - human normal immunoglobulin</td>
<td>EMEA/H/C/002127/II/0086</td>
<td>CSL Behring GmbH, Jan Mueller-Berghaus</td>
<td></td>
</tr>
<tr>
<td>Intanza - influenza vaccine (split virion, inactivated)</td>
<td>EMEA/H/C/000957/II/0054</td>
<td>Sanofi Pasteur Europe, Jorge Camarero Jiménez</td>
<td></td>
</tr>
<tr>
<td>Opdivo - nivolumab</td>
<td>EMEA/H/C/003985/II/0037/G</td>
<td>Bristol-Myers Squibb Pharma EEIG, Jorge Camarero Jiménez</td>
<td></td>
</tr>
<tr>
<td>ergoveris - follitropin alfa / lutropin alfa</td>
<td>EMEA/H/C/000714/II/0052/G</td>
<td>Merck Serono Europe Limited, Nithyanandan Nagercoil</td>
<td></td>
</tr>
<tr>
<td>Soliris - eculizumab</td>
<td>EMEA/H/C/000791/II/0100, Orphan</td>
<td>Alexion Europe SAS, Jorge Camarero Jiménez</td>
<td></td>
</tr>
<tr>
<td>Suliqua - insulin glargine / lixisenatide</td>
<td>EMEA/H/C/004243/II/0003/G</td>
<td>sanofi-aventis groupe, Kristina Dunder</td>
<td></td>
</tr>
<tr>
<td>Uptravi - selexipag</td>
<td>EMEA/H/C/003774/II/0010</td>
<td>Actelion Registration Limited, Martina Weise</td>
<td></td>
</tr>
<tr>
<td>Voncento - human coagulation factor VIII / human von willebrand factor</td>
<td>EMEA/H/C/002493/II/0030/G</td>
<td>CSL Behring GmbH, Paula Boudewina van Hennik</td>
<td></td>
</tr>
<tr>
<td>WS1084/G</td>
<td>EMEA/H/C/000668/WS1084/002</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
B.6.9. CHMP assessed procedures scope: Non-Clinical and Clinical aspects

Ameluz - 5-aminolevulinic acid - EMEA/H/C/002204/II/0027/G
Update of sections 4.2, 4.4, 4.8 and 5.1 of the SmPC in order to update the posology and method of administration of Ameluz for the treatment of actinic keratosis (AK) and field cancerization in combination with daylight and to update the safety information, based on the clinical study results from ALA-AK-CT009; this is a phase III, randomised, interventional, observer-blinded study aimed to compare the efficacy and safety of Ameluz in the treatment of mild to moderate AK with Metvix in combination with daylight photodynamic therapy. Section 5.2 of the SmPC has included a minor editorial change. The Package Leaflet is updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to update the list of local representatives in the Package Leaflet.

C.I.5.b
Change in the legal status of Ameluz from "medicinal product subject to restricted medical prescription" to "medicinal product subject to
Annex to July 2017 CHMP Minutes

Aranesp - darbepoetin alfa -
EMEA/H/C/000332/II/0143
MAH: Amgen Europe B.V., Rapporteur: Martina Weise
"Update of section of section 4.8 the SmPC in order to add a warning on injection site bruise and haemorrhage with frequency unknown and to provide additional instructions on the use of the device in the PL following signal procedure EMEA/H/C000332/SDA/090 on cases of incorrect device use / device malfunction"

Dellyba - delamanid -
EMEA/H/C/002552/II/0021, Orphan
MAH: Otsuka Novel Products GmbH, Rapporteur: Greg Markey
"Update of sections 4.2, 4.4, 4.8, 4.9, 5.1 and 5.2 of the SmPC to reflect the results of the final study report of 242-09-213 (A Phase 3, Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel Group Trial to Evaluate the Safety and Efficacy of Delamanid (OPC-67683) Administered Orally as 200 mg Total Daily Dose for Six Months in Patients With Pulmonary Sputum Culture-positive, Multidrug-resistant Tuberculosis), submitted to fulfill SOB-01. The Package leaflet is updated accordingly."

Epclusa - sofosbuvir / velpatasvir -
EMEA/H/C/004210/II/0012
MAH: Gilead Sciences International Ltd, Rapporteur: Filip Josephson
"Update of section 5.3 of the SmPC in order to add non-clinical safety findings based on a 6-month carcinogenicity study conducted with velpatasvir in transgenic mice"

ReFacto AF - moroctocog alfa -
EMEA/H/C/000232/II/0140
MAH: Pfizer Limited, Rapporteur: Hanne Lomholt Larsen
"Submission of the report ‘The Immunogenicity of ReFacto AF in UK PUPs Who Started Treatment from 2010’ prepared by the United Kingdom Haemophilia Centre Doctors’ Organisation (UKHDCO). This report is being submitted in the context of a post-approval commitment, MEA 115.1 (‘The MAH commits to submit the CSR for ‘A Postauthorization Safety Surveillance Registry or ReFacto AF in Previously Untreated Patients (PUPs) in Usual Care Settings – study number 4435” and to initiate the registry’), as supporting..."
evidence of the ongoing safety evaluation of ReFacto AF in PUPs with haemophilia A and with a specific focus on the development of inhibitors.”

**Revatio - sildenafil -**
**EMEA/H/C/000638/II/0077**
MAH: Pfizer Limited, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.6 of the SmPC in order to revise the statement concerning the detection of sildenafil and its active metabolite in human milk and the potential for impact on the breastfed infant.

The Package Leaflet and Labelling are updated accordingly.

In addition, the Marketing authorisation holder (MAH) took the opportunity to bring the PI in line with the latest QRD template version 10.0.”

**Stelara - ustekinumab -**
**EMEA/H/C/000958/II/0058**
MAH: Janssen-Cilag International NV, Rapporteur: Greg Markey,”Update of section 4.8 of the SmPC in order to include Lower Respiratory Tract Infection as an Adverse Drug Reaction based on a comprehensive evaluation of safety information from the STELARA clinical studies database and post-marketing database, as well as available literature.

The Package Leaflet is updated accordingly.”

**trensiq - asfotase alfa -**
**EMEA/H/C/003794/II/0019/G, Orphan**
MAH: Alexion Europe SAS, Rapporteur: Greg Markey,”Update of section 5.1 of the SmPC in order to update information following final results from studies ENB-006-09 [A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Historical Control Study of the Safety, Efficacy, Pharmacokinetics, and Pharmacodynamics of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hypophosphatasia (HPP)] (and its extension ENB-008-10 [Extension Study of Protocol ENB-006-09 Evaluating the Long-Term Safety and Efficacy of Asfotase Alfa (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Children with Hypophosphatasia (HPP)]) and ENB-009-10 [A Randomized, Open-Label, Multicenter, Multinational, Dose-Ranging, Concurrent Control...
Study of the Safety, Efficacy, and Pharmacokinetics of ENB-0040 (Human Recombinant Tissue-Nonspecific Alkaline Phosphatase Fusion Protein) in Adolescents and Adults with Hypophosphatasia (HPP)] listed as an obligation in the Annex II (ANX002). In addition, the Marketing authorisation holder (MAH) took the opportunity to propose editorial changes for section 4.5 to better clarify the information provided."

**Stribil - elvitegravir / cobicistat / emtricitabine / tenofovir disoproxil**

EMEA/H/C/002574/II/0083  
MAH: Gilead Sciences International Ltd, Rapporteur: Robert James Hemmings,"Update of sections 4.5 of the SmPC in order to add drug-drug interaction data from Study GS-US-292-1316; this is a Phase 1, Open-Label, Fixed Sequence Study Evaluating the Pharmacokinetics and Drug Interaction Potential Between Elvitegravir/Cobicistat/Emtricitabine/Tenofovir Alafenamide Single-Table Regimen and Sertraline in Healthy Subjects.

In addition, the Marketing authorisation holder (MAH) took the opportunity to make administrative amendments to section 4.8 of the SmPC."

**ecfidera - dimethyl fumarate**

EMEA/H/C/002601/II/0041  
MAH: Biogen Idec Ltd, Rapporteur: Martina Weise,"Update of sections 4.4 and 4.8 of the SmPC in order to add anaphylactic reaction as a warning and as an adverse reaction with unknown frequency, based on post-marketing experience. The Package Leaflet is updated accordingly.

In addition, the Biogen Idec Ltd took the opportunity to bring the PI in line with the latest QRD template version 10."

**Tecfidera - dimethyl fumarate**

EMEA/H/C/002601/II/0042  
MAH: Biogen Idec Ltd, Rapporteur: Martina Weise,"Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC in order to update the safety and efficacy information in the paediatric population based on the clinical study results from study 109MS202, listed as a category 3 study in the RMP; this is an open-label, multicentre,
multidose study designed to assess the effect of Tecfidera on magnetic resonance imaging lesions and pharmacokinetics, safety and tolerability in paediatric population with relapsing-remitting multiple sclerosis.

There are no updates proposed in the package leaflet or RMP.

**Tecfidera - dimethyl fumarate -**
**EMEA/H/C/002601/II/0043/G**
MAH: Biogen Idec Ltd, Rapporteur: Martina Weise, "C.I.13 Submission of non-clinical study report for study PD-15-73: a haemotoxicity study of two test compounds (BIO 0022819 and BIO 0022817) on T-CFC progenitor stem cells and T-cells derived from both human and non-human primate bone marrow and peripheral blood mononuclear cells (MNCs). This submission is linked to a category 3 study in the RMP.

C.I.13 Submission of non-clinical study report for study P00012-15-05: a preclinical study to evaluate the toxicity potential and toxicokinetic profile of dimethyl fumarate and hydroxyurea, when co-administered once daily via nasogastric intubation to cynomolgus monkeys for a minimum of 91 days. This submission is linked to a category 3 study in the RMP."

**Tecfidera - dimethyl fumarate -**
**EMEA/H/C/002601/II/0044**

**Toviaz - fesoterodine -**
**EMEA/H/C/000723/II/0049**
MAH: Pfizer Limited, Rapporteur: Concepcion Prieto Yerro"Update of the SmPC sections 4.6 and 5.3 with revised information from reproductive toxicity studies in mice. In addition, the MAH took the opportunity to bring the PI in line with the latest QRD template version 10.0."

**Translarna - ataluren -**
**EMEA/H/C/002720/II/0036, Orphan**
MAH: PTC Therapeutics International Limited, Rapporteur: Johann Lodewijk Hillege, “Update of section 4.5 of the SmPC in order to include information regarding the effects of ataluren on the pharmacokinetics of sensitive probe substrate of organic anion transporter 3 (OAT3)) following results from study PTC124-GD-037-HV (MEA015). In addition, the Marketing authorisation holder (MAH) took the opportunity to introduce some editorial changes in the PI.”

**Trevicta - paliperidone -**
**EMEA/H/C/004066/II/0011**
MAH: Janssen-Cilag International NV, Informed Consent of Xeplion, Rapporteur: Kristina Dunder “Update of section 4.8 of the SmPC in order to update the safety information after assessment of study R092670-SCA-3004 (A Randomized, Double-Blind, Placebo-Controlled, Parallel-Group Study of Paliperidone Palmitate Evaluating Time to Relapse in Subjects With Schizoaffective Disorder). The Package Leaflet has been updated accordingly”

**Vargatef - nintedanib -**
**EMEA/H/C/002569/II/0017**
MAH: Boehringer Ingelheim International GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.8 of the SmPC in order to add ‘weight decreased’ as a new adverse drug reaction based on a safety review of clinical trials and post-marketing data. The Package Leaflet is updated accordingly. In addition, the Marketing authorisation holder (MAH) took the opportunity to implement a minor correction in the English product information, minor corrections to the Croatian, Danish, Dutch and Finnish translations and to bring section 4 of the Package Leaflet in line with QRD template version 10.”

**Vargatef - nintedanib -**
**EMEA/H/C/002569/II/0018**
MAH: Boehringer Ingelheim International GmbH, Rapporteur: Sinan B. Sarac, “Update of section 4.4 of the SmPC to amend the current warning on hepatic function to include that drug liver induced injury was associated with nintendanib administration, to include female sex as a factor of increased risk of liver enzyme elevations, update of section 4.8 of the SmPC to add ‘drug-induced liver injury’ (DILI) as new ADR and update of section 5.2 of the SmPC to amend the
current information related to the mean exposure to nintedanib by race, based on a review of clinical trials and post-marketing data on DILI and on the exposure safety relationship between nintedanib plasma exposure and liver enzyme elevations, as requested by the PRAC as part of PSUSA/00010318/201611. The Package Leaflet is updated accordingly. In addition, the MAH took the opportunity to make some minor changes to section 4.4 and 4.8 of the SmPC.”

**Xeljanz - tofacitinib -**
**EMEA/H/C/004214/II/0003**
MAH: Pfizer Limited, Rapporteur: Robert James Hemmings,”Submission of 2 transported inhibition studies evaluating tofacitinib for its potential to inhibit organic anion transporter (OAT) 1, OAT3 and to interact with Human MRP2 Efflux (ABC) Transporter in fulfilment of the Recommendation dated 26 January 2017.”

**Xultophy - insulin degludec / liraglutide -**
**EMEA/H/C/002647/II/0021**
MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder,”Update of section 5.1 of the SmPC in order to reflect data for transfer from insulin glargine U100 to Xultophy as compared to a basal-bolus regimen. The update is based on data from the clinical trial NN9068-4185: “A clinical trial comparing efficacy and safety of insulin degludec/liraglutide (IDegLira) versus basal-bolus therapy in subjects with type 2 diabetes mellitus”.

The MAH has taken the opportunity to make minor editorial and formatting changes throughout the Annexes.”

**Xyrem - sodium oxybate -**
**EMEA/H/C/000593/II/0067/G**
MAH: UCB Pharma Limited, Rapporteur: Bruno Sepodes,”Update of section 4.8 of the SmPC in order to add the adverse reactions “increased libido” and “seborrhea” with an unknown frequency. Update of section 4.6 of the SmPC in order to amend the information about breast-feeding. The Package Leaflet is updated accordingly.”

**Zykadia - ceritinib -**
**EMEA/H/C/003819/II/0016**
MAH: Novartis Europharm Ltd, Rapporteur: Jorge Camarero Jiménez "Update of sections 4.2, 4.4,
4.8 and 5.2 of the SmPC in order to include amendments to the posology in hepatically impaired patients and update the safety information, respectively. The updates are based on the results from the hepatic function Study CLDK378A2110 which evaluated the PK, safety and tolerability of a single oral dose of ceritinib in subjects with varying degrees of impaired hepatic function and results from physiology-based pharmacokinetic (PBPK) modeling at steady-state.

Submission of the Report for Study A2110 fulfils MEA 001 for Zykadia."

---

**WS1203/G**

**Docetaxel**

Winthrop-EMEA/H/C/000808/WS1203/0053/G

Taxotere-EMEA/H/C/000073/WS1203/0128/G

MAH: Aventis Pharma S.A., Lead Rapporteur: Alexandre Moreau"1) C.I.4 (type II)

Update of sections 4.4 and 4.8 of the SmPC to add information about ventricular arrhythmia including ventricular tachycardia based on review of the MAH's global pharmacovigilance database and scientific literature. The Package Leaflet is updated accordingly.

2) C.I.4 (type II)

Update of section 4.8 of the SmPC on the 10-year follow-up data for studies TAX316 and GEICAM 9805 studies in order to clarify the persisting events in the follow-up periods."
Management Plans (RMPs) as an additional pharmacovigilance activity (Category 3) (Genvoya: MEA 006; Descovy: MEA 004; Odefsey: MEA 007).

The requested worksharing procedure proposed amendments to the Summary of Product Characteristics.”

**WS1218**
**Brîmica**
**Genuair-EMEA/H/C/003969/WS1218/001**

**5**

**Duaklir**
**Genuair-EMEA/H/C/003745/WS1218/001**

**5**

MAH: AstraZeneca AB, Lead Rapporteur: Nithyanandan Nagercoil"Update of section 5.1 of the SmPC in order to update information following results from study M-40464-33 (A Multiple Dose, Randomised, Double-Blind, Placebo Controlled, Parallel Clinical Trial to Assess the Effect of Acclidinium Bromide/Formoterol Fumarate Fixed-Dose Combination on Lung Hyperinflation, Exercise Capacity and Physical Activity in Patients with Moderate to Severe Chronic Obstructive Pulmonary Disease (COPD))"

**WS1219**
**Brîmica**
**Genuair-EMEA/H/C/003969/WS1219/001**

**4**

**Duaklir**
**Genuair-EMEA/H/C/003745/WS1219/001**

**4**

MAH: AstraZeneca AB, Lead Rapporteur: Nithyanandan Nagercoil"Update of section 5.2 of the SmPC in order to update information based on results from study KRP-AB1102F-302 [KRP-AB1102F Phase II Clinical Pharmacology Study - An Investigation into the Pharmacokinetics upon Repeated Administration of KRP-AB1102F to COPD Patients as Subjects]. In addition, the Worksharing applicant (WSA) took the opportunity to update footnotes of the table in section 4.8 as requested during PSUR procedure EMEA/H/C/PSUSA/00010307/201511 and to amend annex II following request from procedure EMEA/H/C/PSA/S/0017.”

**WS1225/G**
**Exviera-EMEA/H/C/003837/WS1225/0031**
Submission of the final reports for two phase IIIb studies (studies M14-226 and M15-461) listed as category 3 studies in the RMP. These are open-label studies evaluating the safety and efficacy of ombitasvir/paritaprevir/ritonavir and dasabuvir with or without ribavirin in hepatitis C virus infected patients with several renal impairment or end-stage renal disease with or without compensated cirrhosis.”

Update of sections 4.4 and 4.5 of the SmPC based on data from the following Pharmacology Studies (GS-US-216-1008 and GS-US-216-4032).

- Study GS-US-216-1008 is a Phase 1, randomized, fixed-sequence, open-label, single and multiple-dose, multiple-cohort, single-center study that evaluated the drug interaction potential between darunavir (DRV)+COBI, atazanavir (ATV)+COBI, or Genvoya and the 3 hydroxy-3-methylglutaryl-coenzyme A (HMG CoA) reductase inhibitors rosuvastatin and/or atorvastatin.

- Study GS-US-216-4032 is an open-label, single-center, multiple-cohort, fixed-sequence, Phase 1 study that evaluated the effect of DRV+COBI or ATV+COBI on the pharmacokinetic (PK) of a representative hormonal contraceptive medication, drospirenone/ethinyl estradiol.

The Package Leaflet is updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to make administrative changes to the PI of all three products and update the list of local representatives for Estonia, Latvia and Lithuania for Tybost and
Stribild.

Minor linguistic amendments were made to the Product Information.”

B.6.10. CHMP-PRAC assessed procedures

**Adcetris - brentuximab vedotin -**
**EMEA/H/C/002455/II/0049, Orphan**
MAH: Takeda Pharma A/S, Rapporteur: Paula Boudewina van Hennik, PRAC Rapporteur: Sabine Straus, "Update of sections 4.2, 4.8, 5.1 and 5.2 of the SmPC with data from study C25002; a phase 1/2 study of brentuximab vedotin (SGN-35) in paediatric patients with relapsed or refractory systemic anaplastic large cell lymphoma or hodgkin lymphoma (listed in the agreed PIP covering the conditions of Hodgkin lymphoma and anaplastic large cell lymphoma for ADCETRIS (EMEA-000980-PIP01-10-M04)). An updated RMP version 11.0 was provided as part of the application.”

**Adenuric - febuxostat -**
**EMEA/H/C/000777/II/0047**
MAH: Menarini International Operations Luxembourg S.A., Rapporteur: Andrea Laslop, PRAC Rapporteur: Jan Neuhauser,"Update of sections 4.4 and 4.5 of the SmPC in order to reflect the results of preclinical study MRPO-2015-PKM-005 “Pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral administration of febuxostat or allopurinol” and clinical study REP-POPPK-MRP-2015-PKM-005 "Population Pharmacokinetic analysis from study titled Pharmacokinetic of azathioprine in the rat after one-week daily oral treatment at three different dosages and with the concomitant oral administration of febuxostat or allopurinol”, investigating the drug-drug interaction with azathioprine when co-administered with febuxostat.

The RMP version 6.0 has also been submitted.

In addition, the MAH took the opportunity to correct the typing errors and to bring the PI in line with the latest QRD template version 10.”

**Cabometyx - cabozantinib -**
**EMEA/H/C/004163/II/0002/G**
MAH: Ipsen Pharma, Rapporteur: Robert James Hemmings, PRAC Rapporteur: Sabine Straus, "1) C.I.4 (type II)
Update of section 5.1 of the SmPC to reflect the final study results from clinical study XL184-308: A Phase 3, Randomized, Controlled Study of Cabozantinib (XL184) vs Everolimus in Subjects with Metastatic Renal Cell Carcinoma that has Progressed after Prior VEGFR Tyrosine Kinase Inhibitor Therapy, to fulfil the condition to the marketing authorisation listed as a PAES in the Annex II. The RMP version 2.0 has also been submitted.
2) C.I.4 (type II)
Update of section 5.3 of the SmPC to reflect the final study results from non-clinical study XL184-NC-036: 104-Week Oral Gavage Carcinogenicity and Toxicokinetic Study with Cabozantinib (XL184) in Rats. The RMP version 2.0 has also been submitted.
3) C.I.3.z (type IB)
Update of section 4.5 of the SmPC to implement the wording agreed by the PRAC following the outcome of the PSUR procedure EMEA/H/C/PSUSA/10180/201603."

Cerdelga - eliglustat -
EMEA/H/C/003724/II/0013, Orphan
MAH: Genzyme Europe BV, Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Dolores Montero Corominas, "Update of section 4.8. of the SmPC in order to amend the safety information based on the analysis of Adverse Events from the following clinical trials: GZGD00304 (Phase 2), GZGD02507 (ENGAGE), GZGD02607 (ENCORE) and GZGD03109 (EDGE) to address post-authorisation MEA011.1 which is included in the current approved Risk Management Plan.

Update of the labelling in order to reflect the instructions on use for the sleeve of the intermediate packaging of the single blister.

The RMP version 4.0 has also been submitted."

Eperzan - albiglutide -
EMEA/H/C/002735/II/0033
MAH: GlaxoSmithKline Trading Services Limited, Rapporteur: Kristina Dunder, PRAC Rapporteur: Julie Williams"Update of the Package Leaflet in order to amend the layout and content of the Instructions for Use (IFU). In addition, the RMP
version 8 has also been submitted to implement additional pharmacovigilance and risk minimisation activities addressing the safety concern of "medication errors/device issue potentially leading to lack of efficacy or inadequate diabetes control" and to add a PASS study to investigate the effectiveness of the new IFU.”

**Ibrance - palbociclib -**
**EMEA/H/C/003853/II/0007**
MAH: Pfizer Limited, Rapporteur: Filip Josephson, PRAC Rapporteur: Torbjorn Callreus, "Update of sections 4.2, 4.4 and 5.2 of the SmPC to reflect the results of studies A5481013 and A5481014. The mentioned studies provide information of the impact of hepatic impairment (Study A5481013) on the PK of a single oral dose of 75 mg palbociclib and the impact of renal impairment (Study A5481014) on the PK of a single oral dose of 125 mg palbociclib both administered under fed conditions to subjects with varying degrees of hepatic function or renal function. The RMP (version 1.4) is proposed to be amended to reflect the completion of these studies.”

**Nulojix - belatacept -**
**EMEA/H/C/002098/II/0045**
MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Filip Josephson, PRAC Rapporteur: Ulla Wändel Liminga "Update of sections 4.4 and 4.8 of the SmPC in order to add a warning and update the safety information on the risk of venous thrombosis of the renal allograft when anti-thymocyte globulin (ATG) and belatacept are coadministered (at the same or nearly the same time) in patients with other predisposing risk factors for thrombosis.

The update is based on a review of the potential increased risk for allograft thrombosis with belatacept given in close temporal relation to Thymoglobulin, as requested during assessment of PSUR 8 (EMEA/H/C/PSUSA/00000311/201606).

In addition, the MAH took the opportunity update section 6.6 "Special precautions for disposal and other handling" of the SmPC and the "Information for healthcare professionals (HCPs)" in the Package Leaflet (PL) with additional safety instructions for the
co-administration of Belatacept.

Submission of this variation application fulfils LEG 021 for Nulojix.

Consistently with the above, RMP version 14 has also been submitted, including addition of the potential risk of venous thrombosis of the allograft when ATG and belatacept are coadministered in patients with other predisposing risk factors for thrombosis and a number of administrative changes.”

**Olumiant - baricitinib -**

EMEA/H/C/004085/II/0002

MAH: Eli Lilly Nederland B.V., Rapporteur: Johann Lodewijk Hillege, PRAC Rapporteur: Patrick Batty, "Update of sections 4.5 and 5.2 of the SmPC, based on the final study report of in vitro study to investigate the inhibitory effect of baricitinib on the organic anion transporter 2 (OAT2) in fulfilment of PAM (MEA 001). The updated RMP version 3.0 has been submitted as part of this application.”

**Opdivo - nivolumab -**

EMEA/H/C/003985/II/0038

MAH: Bristol-Myers Squibb Pharma EEIG, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Brigitte Keller-Stanislawski, "Update of section 4.8 of the SmPC with longer follow-up for subjects proceeding to allogeneic transplant following nivolumab treatment, of section 5.1 of the SmPC with efficacy data from longer follow-up based on final results from study CA209205 listed as a PAES in the Annex II; this is a Phase 2, non-comparative, multi-cohort, single-arm, open-label study of nivolumab (BMS-936558) in cHL subjects after failure of ASCT
Annex II is updated to remove the commitment. Version 7.5 of the RMP has been submitted.”

**Soliris - eculizumab -**

EMEA/H/C/000791/II/0098, Orphan

MAH: Alexion Europe SAS, Rapporteur: Jorge Camarero Jiménez, PRAC Rapporteur: Eva A. Segovia, "Update of sections 4.6 and 5.3 of the SmPC in order to update the safety information related to pregnancy, lactation and fertility following the review of data in PSUR 13 and 14. Annex II and the Package Leaflet are updated accordingly.
The RMP version 17 has also been submitted with updated information on pregnancy and lactation and fertility.

**Spedra - avanafil -**

**EMEA/H/C/002581/II/0027/G**

MAH: Menarini International Operations Luxembourg S.A., Rapporteur: Concepcion Prieto Yerro, PRAC Rapporteur: Dolores Montero Corominas

Update of section 4.4. to reflect the results of clinical study TA-402 "A Double-Blind, Randomized, Placebo-Controlled, Single-Dose, Parallel Study to Assess the Effects of Avanafil on Multiple Parameters of Vision, including, but Not Limited to Visual Acuity, Intraocular Pressure, Pupillometry, and Color Vision Discrimination, in Healthy Male Subjects)."

Update of section 4.6. of the SmPC in order to reflect the results of clinical study TA-401 "A Randomized, Double-Blind, Placebo-Controlled, Parallel Group, Multicenter Clinical Trial of the Effect of Avanafil on Spermatogenesis in Healthy Adult Males and Adult Males with Mild Erectile Dysfunction". The Package Leaflet is updated accordingly.

The RMP version 5.1 has also been submitted.

In addition, the MAH took the opportunity to make an editorial correction on the approved SmPC by adding the missing adverse reaction epistaxis from the tabulated list of adverse reactions reported in section 4.8. Additionally, the MAH took the opportunity of this variation to align the information included in Section 3 "How to take Spedra" in the Package Leaflet to section 4.2 "Posology" in the SmPC.

Some additional minor amendments, due to translation mistakes are proposed for the French Product Information.

**Tresiba - insulin degludec -**

**EMEA/H/C/002498/II/0028**

MAH: Novo Nordisk A/S, Rapporteur: Kristina Dunder, PRAC Rapporteur: Qun-Ying Yue,

"Update of section 5.1 of the SmPC based on new clinical data from a cardiovascular outcome trial EX1250-4080 (DEVOTE) conducted for Tresiba. DEVOTE was a randomised, double-blind and event-driven clinical trial with a median duration of 2 years comparing the cardiovascular safety of Tresiba versus insulin glargine (100 units/mL) in
patients with type 2 diabetes mellitus at high risk of cardiovascular events.

The RMP version 8 has also been submitted, with updates consequent to the data in support of the application."

**WS1168**  
**AZILECT-EMEA/H/C/000574/WS1168/007**  
**Rasagiline**  
**ratiopharm-EMEA/H/C/003957/WS1168/0010**  
MAH: Teva B.V., Lead Rapporteur: Bruno Sepodes, Lead PRAC Rapporteur: Ana Sofia Diniz Martins, "Update of sections 4.4, 4.7 and 4.8 to include a new warning on excessive daytime sleepiness and sudden sleep onset episodes and sudden sleep onset episodes, update of section 4.9 to remove 'dysphoria' as a symptom reported following overdose of rasagiline based on a CCDS update. The Package Leaflet is updated accordingly. The RMP version 2.0 has also been submitted. In addition, the Worksharing applicant (WSA) took the opportunity to make editorial changes throughout the PI, to correct the invented name for Rasagiline Ratiopharm in the Czech annexes and to bring the PI in line with the latest QRD template version 10."

**WS1180**  
**Corlentor-EMEA/H/C/000598/WS1180/0047**  
**Ivabradine**  
**Anpharm-EMEA/H/C/004187/WS1180/0006**  
**Procoralan-EMEA/H/C/000597/WS1180/0046**  
MAH: Les Laboratoires Servier, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst,"Update to the section 4.8 of the SmPC with new ADRs: Ventricular tachycardia, Ventricular fibrillation and Torsade de pointes. The PL is updated accordingly. The RMP version 6 has also been submitted. In addition the MAH took the opportunity to align the PI with the latest QRD template 10.0."

**WS1211**  
**Januvia-EMEA/H/C/000722/WS1211/0059**  
**Ristaben-EMEA/H/C/001234/WS1211/0051**
TESAVEL-EMEA/H/C/000910/WS1211/00

Xelevia-EMEA/H/C/000762/WS1211/0063

AH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst, “Update of sections 4.2, 4.4 and 5.2 of the SmPC in order to modify the information on dosing, an existing warning and administration instructions, respectively for use of sitagliptin in patients with type 2 diabetes mellitus and renal impairment. Consequently, the RMP version 8 has also been updated accordingly.

In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflet for Tesavel and to bring the PI in line with the latest QRD template version 10. Minor editorial changes are also introduced in the Product Information.”

WS1212/G

Efficib-EMEA/H/C/000896/WS1212/0085/G

Janumet-EMEA/H/C/000861/WS1212/0085/G

Ristfor-EMEA/H/C/001235/WS1212/0072/G

Velmetia-EMEA/H/C/000862/WS1212/0088/G

MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege, Lead PRAC Rapporteur: Menno van der Elst “Update of sections 4.2, and 5.2 of the SmPC in order to modify the information on dosing, and administration instructions respectively for use of sitagliptin/metformin in patients with type 2 diabetes mellitus and moderate renal impairment. Consequently, the RMP version 8 has also been updated accordingly.

Section 4.5 of the SmPC is also updated to include information on the concomitant use of ranolazine, vandetanib, dolutegravir and cimetidine.

In addition, the Worksharing applicant (WSA) took the opportunity to update the list of local representatives in the Package Leaflet for Efficib and to bring the PI in line with the latest QRD template version 10. Minor editorial changes are also introduced in the Product Information.”
B.6.11. PRAC assessed procedures

PRAC Led

**Eliquis - apixaban -**

**EMEA/H/C/002148/II/0043**

MAH: Bristol-Myers Squibb / Pfizer EEIG,

Rapporteur: Johann Lodewijk Hillege, PRAC

Rapporteur: Menno van der Elst, PRAC-CHMP

liaison: Johann Lodewijk Hillege

"Submission of the final report from study (CV185-365) listed as a category 3 study in the RMP. This is a post authorisation safety study which evaluates the effectiveness of Eliquis (apixaban) risk minimisation tools in the European Economic Area countries. A RMP (version 17.0) has also been submitted to reflect the completion of the study CV185-365."

---

PRAC Led

**Invokana - canagliflozin -**

**EMEA/H/C/002649/II/0030**

MAH: Janssen-Cilag International NV,

Rapporteur: Martina Weise, PRAC Rapporteur:

Valerie Strassmann, PRAC-CHMP liaison: Martina Weise

"Submission of an updated RMP version 7.0 in order to include prior commitments made to PRAC during the PSUR/LEG procedural review of pancreatitis cases and the Article 20 referral procedure reviewing lower limb amputation in relation to the use of SGLT-2 inhibitors. In addition, the updated RMP reflects labelling changes that resulted from a variation to add information regarding fatal DKA cases to the existing DKA warning and the Article 31 procedure reviewing metformin-containing medicines."

---

PRAC Led

**Viread - tenofovir disoproxil -**

**EMEA/H/C/000419/II/0182**

MAH: Gilead Sciences International Ltd,

Rapporteur: Joseph Emmerich, PRAC

Rapporteur: Caroline Laborde, PRAC-CHMP

liaison: Joseph Emmerich

"Submission of the final report from Study GX-US-174-0172, listed as a category 3 study in the RMP. This is a 5-year observational (non-interventional) renal safety registry conducted to provide further safety data in HBV-infected patients with decompensated liver disease."

---

PRAC Led
Vokanamet - canagliflozin / metformin - EMEA/H/C/002656/II/0031
MAH: Janssen-Cilag International NV,
Rapporteur: Martina Weise, PRAC Rapporteur: Menno van der Elst, PRAC-CHMP liaison: Johann Lodewijk HillegesSubmission of an updated RMP version 7.0 in order to include prior commitments made to PRAC during the PSUR/LEG procedural review of pancreatitis cases and the Article 20 referral procedure reviewing lower limb amputation in relation to the use of SGLT-2 inhibitors. In addition, the updated RMP reflects labelling changes that resulted from a variation to add information regarding fatal DKA cases to the existing DKA warning and the Article 31 procedure reviewing metformin-containing medicines.”

PRAC Led WS1197
Actraphane-EMEA/H/C/000427/WS1197/0072
Actrapid-EMEA/H/C/000424/WS1197/0066
Insulatard-EMEA/H/C/000441/WS1197/0069
Mixtard-EMEA/H/C/000428/WS1197/0073
Protaphane-EMEA/H/C/000442/WS1197/0068
MAH: Novo Nordisk A/S, Lead Rapporteur: Hanne Lomholt Larsen, Lead PRAC Rapporteur: Doris Stenver, PRAC-CHMP liaison: Sinan B. SaracSubmission of an updated RMP version 3.0 according to GVP Module V, in order to remove three important potential risks (immunogenicity, allergic reactions and lack of efficacy) related to the new NN729 manufacturing process from the RMP, remove hypoglycaemia and anaphylactic reactions, remove peripheral neuropathy, refraction disorders, lipodystrophy, urticaria, rash, oedema and diabetic retinopathy and remove missing information concerning special populations. No changes are proposed to the product information.”
B.6.12. CHMP-CAT assessed procedures

B.6.13. CHMP-PRAC-CAT assessed procedures

B.6.14. PRAC assessed ATMP procedures

B.6.15. Unclassified procedures and worksharing procedures of type I variations

| WS0935/G | Filgrastim |
| Hexal-EMEA/H/C/000918/WS0935/0035/G |
| Zarzio-EMEA/H/C/000917/WS0935/0036/G |
| MAH: Sandoz GmbH, Lead Rapporteur: Greg Markey |

| WS1172 | Infanrix hexa-EMEA/H/C/000296/WS1172/0221 |
| MAH: GlaxoSmithkline Biologicals SA, Lead Rapporteur: Bart Van der Schueren |

| WS1184 | Eucreas-EMEA/H/C/000807/WS1184/0063 |
| Icandra-EMEA/H/C/001050/WS1184/0064 |
| Zomarist-EMEA/H/C/001049/WS1184/0064 |
| MAH: Novartis Europharm Ltd, Lead Rapporteur: Kristina Dunder |

| WS1185/G | Hexacima-EMEA/H/C/002702/WS1185/0065/G |
| Hexaxim-EMEA/H/W/002495/WS1185/0071/G |
| Hexyon-EMEA/H/C/002796/WS1185/0069/G |
| MAH: Sanofi Pasteur Europe, Duplicate, Duplicate of Hexacima, Lead Rapporteur: Jan Mueller-Berghaus |

| WS1187/G | Kalydeco-EMEA/H/C/002494/WS1187/0061/G |
| Orkambi-EMEA/H/C/003954/WS1187/0022/G |
| MAH: Vertex Pharmaceuticals (Europe) Ltd, Lead Rapporteur: Nithyanandan Nagercoil |
**WS1194**
Infanrix hexa-EMEA/H/C/000296/WS1194/0222
MAH: GlaxoSmithkline Biologicals SA, Lead Rapporteur: Bart Van der Schueren

**WS1196/G**
Ebymect-EMEA/H/C/004162/WS1196/0023/G
Xigduo-EMEA/H/C/002672/WS1196/0034/G
MAH: AstraZeneca AB, Lead Rapporteur: Kristina Dunder

**WS1201/G**
Glyxambi-EMEA/H/C/003833/WS1201/009/G
Jentadueto-EMEA/H/C/002279/WS1201/0041/G
Trajenta-EMEA/H/C/002110/WS1201/0031/G
MAH: Boehringer Ingelheim International GmbH, Lead Rapporteur: Johann Lodewijk Hillege

**WS1202/G**
Efficib-EMEA/H/C/000896/WS1202/0084/G
Janumet-EMEA/H/C/000861/WS1202/0084/G
Januvia-EMEA/H/C/000722/WS1202/0058/G
Ristaben-EMEA/H/C/001234/WS1202/0050/G
Ristfor-EMEA/H/C/001235/WS1202/0071/G
TESAVEL-EMEA/H/C/000910/WS1202/0058/G
Velmetia-EMEA/H/C/000862/WS1202/0087/G
Xellevia-EMEA/H/C/000762/WS1202/0062/G
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Johann Lodewijk Hillege

**WS1204/G**
Herceptin-EMEA/H/C/000278/WS1204/0134/G
Kadcyla-EMEA/H/C/002389/WS1204/0037/G
MAH: Roche Registration Limited, Lead Rapporteur: Jan Mueller-Berghaus

**WS1213**
Lyrica-EMEA/H/C/000546/WS1213/0090
Pregabalin
Pfizer-EMEA/H/C/003880/WS1213/0020
MAH: Pfizer Limited, Lead Rapporteur: Johann Lodewijk Hiliege

WS1214
Aflunov-EMEA/H/C/002094/WS1214/0039
Foclivia-EMEA/H/C/001208/WS1214/0033
MAH: Seqirus S.r.l, Lead Rapporteur: Daniela Melchiorri

WS1216
IntronA-EMEA/H/C/000281/WS1216/0112
PegIntron-EMEA/H/C/000280/WS1216/0131
ViraferonPeg-EMEA/H/C/000329/WS1216/0124
MAH: Merck Sharp & Dohme Limited, Lead Rapporteur: Koenraad Norga

WS1224
Relvar
Ellipta-EMEA/H/C/002673/WS1224/0031
Revinty
Ellipta-EMEA/H/C/002745/WS1224/0027
MAH: Glaxo Group Ltd, Lead Rapporteur: Concepcion Prieto Yerro

WS1235/G
Incresync-EMEA/H/C/002178/WS1235/0020/G
Vipdomet-EMEA/H/C/002654/WS1235/0022/G
Vipidia-EMEA/H/C/002182/WS1235/0017/G
MAH: Takeda Pharma A/S, Lead Rapporteur: Johann Lodewijk Hiliege

B.7. DOCUMENTS TABLED IN MMD AFTER THE CHMP PLENARY

B.7.1. Yearly Line listing for Type I and II variations

B.7.2. Monthly Line listing for Type I variations

B.7.3. Opinion on Marketing Authorisation transfer (MMD only)

B.7.5. Request for supplementary information relating to Notification of Type I variation (MMD only)

B.7.6. Notifications of Type I Variations (MMD only)

C. Annex C - Post-Authorisation Measures (PAMs), (Line listing of Post authorisation measures with a description of the PAM. Procedures starting in that given month with assessment timetabled)

D. Annex D - Post-Authorisation Measures (PAMs), (Details on PAMs including description and conclusion, for adoption by CHMP in that given month, or finalised ones with PRAC recommendation and no adoption by CHMP needed)

E. Annex E - EMEA CERTIFICATION OF PLASMA MASTER FILES

Information related to plasma master files cannot be released at the present time as these contain commercially confidential information.

E.1. PMF Certification Dossiers:

E.1.1. Annual Update

E.1.2. Variations

E.1.3. Initial PMF Certification

E.2. Time Tables – starting & ongoing procedures: For information

F. ANNEX F - Decision of the Granting of a Fee Reduction/Fee Waiver


F.2. Request for scientific opinion on justification of exceptional circumstance and for imperative grounds of public health

G. ANNEX G

G.1. Final Scientific Advice (Reports and Scientific Advice letters):

Information related to Scientific Advice cannot be released at the present time as these contain commercially confidential information.
Qualification of Biomarkers:

HTA:

G.2. Ongoing procedures

G.3. PRIME

Some information related to PRIME cannot be released at the present time as these contain commercially confidential information.

G.3.1. List of procedures concluding at 17-20 July 2017 CHMP plenary:

<table>
<thead>
<tr>
<th>Oncology</th>
</tr>
</thead>
<tbody>
<tr>
<td>1. Treatment of fully resectable metastatic melanoma</td>
</tr>
<tr>
<td>2. Vocimagene amiretrorepvec, (SME) ATMP, Treatment of high grade glioma</td>
</tr>
<tr>
<td>3. (SME) Treatment of cholangiocarcinoma</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Dermatology</th>
</tr>
</thead>
<tbody>
<tr>
<td>4. Treatment of Chronic Hand Eczema</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Oto-rhino-laryngology</th>
</tr>
</thead>
<tbody>
<tr>
<td>5. ATMP Treatment of Muscular Disorder</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Neurology</th>
</tr>
</thead>
<tbody>
<tr>
<td>6. (SME) ATMP, Treatment of ischaemic stroke</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Ophtalmology</th>
</tr>
</thead>
<tbody>
<tr>
<td>7. (SME) Treatment of Neurotrophic Keratitis</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Other</th>
</tr>
</thead>
<tbody>
<tr>
<td>8. Treatment of Light Chain (AL) Amyloidosis</td>
</tr>
</tbody>
</table>

G.3.2. List of procedures starting in July 2017 for August 2017 CHMP adoption of outcomes

H. ANNEX H - Product Shared Mailboxes – e-mail address